18. Literaturverzeichnis – Endometriumkarzinom
1. ICD-10-GM 2018 Systematisches Verzeichnis : Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 2017.
2. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) - Ständige Kommission Leitlinien, AWMF-Regelwerk „Leitlinien“, Auflage 2.1 2023.
3. Atkins, D., Best, D., Briss, P. A., Eccles, M., Falck-Ytter, Y., Flottorp, S., et.al. Grading quality of evidence and strength of recommendations, BMJ, 2004. 328: p. 1490., https://www.ncbi.nlm.nih.gov/pubmed/15205295
4. Robert, Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e, V., Krebs in Deutschland 2015/2016, 2019.
5. Tempfer, CB, Hilal, Z, Kern, P, Juhasz-Boess, I, Rezniczek, GA, Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review., Cancers (Basel), 2020. 12 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/32781573/
6. Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., Lee, J., Long-term hormone therapy for perimenopausal and postmenopausal women, Cochrane Database Syst Rev, 2017. 1(1): p. Cd004143.
7. Beral, V., Bull, D., Reeves, G., Endometrial cancer and hormone-replacement therapy in the Million Women Study, Lancet, 2005. 365: p. 1543-51., https://www.ncbi.nlm.nih.gov/pubmed/15866308
8. Lacey, J. V., Jr., Brinton, L. A., Lubin, J. H., Sherman, M. E., Schatzkin, A., Schairer, C., Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women, Cancer Epidemiol Biomarkers Prev, 2005. 14: p. 1724-31., https://www.ncbi.nlm.nih.gov/pubmed/16030108
9. Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., Allan, J. D., Postmenopausal hormone replacement therapy: scientific review, JAMA, 2002. 288: p. 872-81., https://www.ncbi.nlm.nih.gov/pubmed/12186605
10. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., Petitti, D., Hormone replacement therapy and endometrial cancer risk: a meta-analysis (Structured abstract), Obstetrics and Gynecology, 1995. 85: p. 304-313., https://www.ncbi.nlm.nih.gov/pubmed/7824251
11. Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E., et.al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition, Am J Epidemiol, 2010. 172: p. 1394-403., https://www.ncbi.nlm.nih.gov/pubmed/20961969
12. Chlebowski, R. T., Anderson, G. L., Sarto, G. E., Haque, R., Runowicz, C. D., Aragaki, A. K., et.al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial, J Natl Cancer Inst, 2015. 108:, https://www.ncbi.nlm.nih.gov/pubmed/26668177
13. Mørch, LS, Kjaer, SK, Keiding, N, Løkkegaard, E, Lidegaard, Ø, The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study., Int J Cancer, 2016. 138 (6)(6): p. 1506-15., https://pubmed.ncbi.nlm.nih.gov/26421912/
14. Doherty, J. A., Cushing-Haugen, K. L., Saltzman, B. S., Voigt, L. F., Hill, D. A., Beresford, S. A., et.al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer, Am J Obstet Gynecol, 2007. 197: p. 139 e1-7., https://www.ncbi.nlm.nih.gov/pubmed/17689625
15. Sjögren, L. L., Mørch, L. S., Løkkegaard, E., Hormone replacement therapy and the risk of endometrial cancer: A systematic review, Maturitas, 2016. 91: p. 25-35.
16. Fournier, A., Dossus, L., Mesrine, S., Vilier, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., et.al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008, Am J Epidemiol, 2014. 180: p. 508-17., https://www.ncbi.nlm.nih.gov/pubmed/25008104
17. Razavi, P., Pike, M. C., Horn-Ross, P. L., Templeman, C., Bernstein, L., Ursin, G., Long-term postmenopausal hormone therapy and endometrial cancer, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 475-83., https://www.ncbi.nlm.nih.gov/pubmed/20086105
18. Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., Renehan, A. G., Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 3119-30., https://www.ncbi.nlm.nih.gov/pubmed/21030602
19. Judd, H.L., Mebane-Sims, I., Legault, C., Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA, 1996. 275: p. 370-5., https://www.ncbi.nlm.nih.gov/pubmed/8569016
20. Phipps, A. I., Doherty, J. A., Voigt, L. F., Hill, D. A., Beresford, S. A., Rossing, M. A., et.al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer, Cancer Causes Control, 2011. 22: p. 1639-46., https://link.springer.com/article/10.1007%2Fs10552-011-9840-6
21. Al-Mubarak, M., Tibau, A., Templeton, A. J., Cescon, D. W., Ocana, A., Seruga, B., et.al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis, PLoS One, 2014. 9: p. e88238., https://www.ncbi.nlm.nih.gov/pubmed/24586311
22. Emons, G., Mustea, A., Tempfer, C., Tamoxifen and Endometrial Cancer: A Janus-Headed Drug, Cancers (Basel), 2020. 12(9):, https://pubmed.ncbi.nlm.nih.gov/32906618/
23. Clarke, M. J, WITHDRAWN: Tamoxifen for early breast cancer, Cochrane Database Syst Rev, 2008. p. Cd000486., https://www.ncbi.nlm.nih.gov/pubmed/18843611
24. Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., Col, N. F., Meta-analysis of vascular and neoplastic events associated with tamoxifen, J Gen Intern Med, 2003. 18: p. 937-47., https://www.ncbi.nlm.nih.gov/pubmed/14687281
25. Nelson, H. D., Smith, M. E., Griffin, J. C., Fu, R., Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, 2013. 158: p. 604-14., https://www.ncbi.nlm.nih.gov/pubmed/23588749
26. DeMichele, A., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., et.al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study, J Clin Oncol, 2008. 26: p. 4151-9., https://www.ncbi.nlm.nih.gov/pubmed/18757329
27. Ignatov, A, Ortmann, O, Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen., Cancers (Basel), 2020. 12 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/32630728/
28. Dossus, L., Allen, N., Kaaks, R., Bakken, K., Lund, E., Tjonneland, A., et.al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition, Int J Cancer, 2009. 127: p. 442-51., https://www.ncbi.nlm.nih.gov/pubmed/19924816
29. Gorenoi, V., Schonermark, M. P., Hagen, A., Benefits and risks of hormonal contraception for women, GMS Health Technol Assess, 2007. 3: p. Doc06., https://www.ncbi.nlm.nih.gov/pubmed/21289940
30. Schlesselman, J. J., Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis, Hum Reprod, 1997. 12: p. 1851-63., https://www.ncbi.nlm.nih.gov/pubmed/9363696
31. Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Havrilesky, L. J., Moorman, P. G., Lowery, W. J., et.al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review, Cancer Epidemiol Biomarkers Prev, 2013. 22: p. 1931-43., https://www.ncbi.nlm.nih.gov/pubmed/24014598
32. Collaborative Group on Epidemiological Studies on Endometrial Cancer, Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies, Lancet Oncol, 2015. 16: p. 1061-1070., https://www.ncbi.nlm.nih.gov/pubmed/26254030
33. Skalkidou, A., Sergentanis, T. N., Gialamas, S. P., Georgakis, M. K., Psaltopoulou, T., Trivella, M., et.al. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility, Cochrane Database Syst Rev, 2017. 3(3): p. Cd010931.
34. Barcroft, JF, Galazis, N, Jones, BP, Getreu, N, Bracewell-Milnes, T, Grewal, KJ, et.al. Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis., Hum Reprod, 2021. 36 (4)(4): p. 1093-1107., https://pubmed.ncbi.nlm.nih.gov/33586777/
35. Parazzini, F., Pelucchi, C., Talamini, R., Montella, M., La Vecchia, C., Use of fertility drugs and risk of endometrial cancer in an Italian case-control study, Eur J Cancer Prev, 2010. 19: p. 428-30., https://www.ncbi.nlm.nih.gov/pubmed/20634699
36. Siristatidis, C., Sergentanis, T. N., Kanavidis, P., Trivella, M., Sotiraki, M., Mavromatis, I., et.al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis, Human Reproduction Update, 2013. 19: p. 105-123., https://www.ncbi.nlm.nih.gov/pubmed/23255514
37. Formoso, G., Perrone, E., Maltoni, S., Balduzzi, S., D'Amico, R., Bassi, C., et.al. Short and long term effects of tibolone in postmenopausal women, Cochrane Database Syst Rev, 2012. 2: p. Cd008536.
38. Ettinger, B., Kenemans, P., Johnson, S. R., Mol-Arts, M., Van Os, S., Seifert, W., et.al. Endometrial effects of tibolone in elderly, osteoporotic women, Obstet Gynecol, 2008. 112: p. 653-9., https://www.ncbi.nlm.nih.gov/pubmed/18757665
39. Dörk, T, Hillemanns, P, Tempfer, C, Breu, J, Fleisch, MC, Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management., Cancers (Basel), 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32854222/
40. Setiawan, V. W., Pike, M. C., Karageorgi, S., Deming, S. L., Anderson, K., Bernstein, L., et.al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium, Am J Epidemiol, 2012. 176: p. 269-78., https://www.ncbi.nlm.nih.gov/pubmed/22831825
41. Karageorgi, S., Hankinson, S. E., Kraft, P., De Vivo, I., Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004, Int J Cancer, 2009. 126: p. 208-16., https://www.ncbi.nlm.nih.gov/pubmed/19551854
42. Friberg, E., Orsini, N., Mantzoros, C. S., Wolk, A., Diabetes mellitus and risk of endometrial cancer: a meta-analysis, Diabetologia, 2007. 50: p. 1365-74., https://www.ncbi.nlm.nih.gov/pubmed/17476474
43. Barone, B. B., Yeh, H. C., Snyder, C. F., Peairs, K. S., Stein, K. B., Derr, R. L., et.al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis, Jama, 2008. 300: p. 2754-64., https://www.ncbi.nlm.nih.gov/pubmed/19088353
44. Huang, Y., Cai, X., Qiu, M., Chen, P., Tang, H., Hu, Y., et.al. Prediabetes and the risk of cancer: a meta-analysis, Diabetologia, 2014. 57: p. 2261-9., https://www.ncbi.nlm.nih.gov/pubmed/25208757
45. Zhang, Z. H., Su, P. Y., Hao, J. H., Sun, Y. H., The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies, Int J Gynecol Cancer, 2013. 23: p. 294-303., https://www.ncbi.nlm.nih.gov/pubmed/23287960
46. Liao, C, Zhang, D, Mungo, C, Tompkins, DA, Zeidan, AM, Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies., Gynecol Oncol, 2014. 135 (1)(1): p. 163-71., https://pubmed.ncbi.nlm.nih.gov/25072931/
47. Luo, J, Beresford, S, Chen, C, Chlebowski, R, Garcia, L, Kuller, L, et.al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer., Br J Cancer, 2014. 111 (7)(7): p. 1432-9., https://pubmed.ncbi.nlm.nih.gov/25051408/
48. McVicker, L, Cardwell, CR, Edge, L, McCluggage, WG, Quinn, D, Wylie, J, et.al. Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis., BMC Cancer, 2022. 22 (1)(1): p. 427., https://pubmed.ncbi.nlm.nih.gov/35439978/
49. Gnagnarella, P., Gandini, S., La Vecchia, C., Maisonneuve, P., Glycemic index, glycemic load, and cancer risk: a meta-analysis, Am J Clin Nutr, 2008. 87: p. 1793-801., https://www.ncbi.nlm.nih.gov/pubmed/18541570
50. Mulholland, H. G., Murray, L. J., Cardwell, C. R., Cantwell, M. M., Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis, Br J Cancer, 2008. 99: p. 434-41., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527795/
51. Choi, Y., Giovannucci, E., Lee, J. E., Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis, Br J Nutr, 2012. 108: p. 1934-47., https://www.ncbi.nlm.nih.gov/pubmed/23167978
52. Nagle, C. M., Olsen, C. M., Ibiebele, T. I., Spurdle, A. B., Webb, P. M., Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis, Eur J Nutr, 2012. 52: p. 705-15., https://www.ncbi.nlm.nih.gov/pubmed/22648201
53. Bjorge, T., Stocks, T., Lukanova, A., Tretli, S., Selmer, R., Manjer, J., et.al. Metabolic syndrome and endometrial carcinoma, Am J Epidemiol, 2010. 171: p. 892-902., https://www.ncbi.nlm.nih.gov/pubmed/20219764
54. Esposito, K., Chiodini, P., Colao, A., Lenzi, A., Giugliano, D., Metabolic syndrome and risk of cancer: a systematic review and meta-analysis, Diabetes Care, 2012. 35: p. 2402-11., https://www.ncbi.nlm.nih.gov/pubmed/23093685
55. Baptiste, C. G., Battista, M. C., Trottier, A., Baillargeon, J. P., Insulin and hyperandrogenism in women with polycystic ovary syndrome, J Steroid Biochem Mol Biol, 2009. 122: p. 42-52., https://www.ncbi.nlm.nih.gov/pubmed/20036327
56. Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P., La Sala, G. B., Fauser, B. C., Pregnancy complications in women with polycystic ovary syndrome, Hum Reprod Update, 2015. 21: p. 575-92., https://www.ncbi.nlm.nih.gov/pubmed/26117684
57. Fearnley, E. J., Marquart, L., Spurdle, A. B., Weinstein, P., Webb, P. M., Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study, Cancer Causes Control, 2010. 21: p. 2303-8., https://www.ncbi.nlm.nih.gov/pubmed/20953904
58. Gottschau, M., Kjaer, S. K., Jensen, A., Munk, C., Mellemkjaer, L., Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study, Gynecol Oncol, 2014. 136: p. 99-103., https://www.ncbi.nlm.nih.gov/pubmed/25451694
59. Chittenden, B. G., Fullerton, G., Maheshwari, A., Bhattacharya, S., Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review, Reprod Biomed Online, 2009. 19: p. 398-405., https://www.ncbi.nlm.nih.gov/pubmed/19778486
60. Haoula, Z., Salman, M., Atiomo, W., Evaluating the association between endometrial cancer and polycystic ovary syndrome, Hum Reprod, 2012. 27: p. 1327-31., https://www.ncbi.nlm.nih.gov/pubmed/22367984
61. Barry, J. A., Azizia, M. M., Hardiman, P. J., Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 2014. 20: p. 748-58., https://www.ncbi.nlm.nih.gov/pubmed/24688118
62. Li, Z, Wang, YH, Wang, LL, Hu, DT, Teng, Y, Zhang, TY, et.al. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: An updated meta-analysis., Scott Med J, 2022. 67 (3)(3): p. 109-120., https://pubmed.ncbi.nlm.nih.gov/35686317/
63. Ward, K. K., Roncancio, A. M., Shah, N. R., Davis, M. A., Saenz, C. C., McHale, M. T., et.al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women, Am J Obstet Gynecol, 2013. 209: p. 579 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/23938608
64. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008. 371: p. 569-78., https://www.ncbi.nlm.nih.gov/pubmed/18280327
65. Dobbins, M., Decorby, K., Choi, B. C., The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011, ISRN Prev Med, 2013. 2013: p. 680536., https://www.ncbi.nlm.nih.gov/pubmed/24977095
66. Bergstrom, A., Pisani, P., Tenet, V., Wolk, A., Adami, H. O., Overweight as an avoidable cause of cancer in Europe, Int J Cancer, 2001. 91: p. 421-30., https://www.ncbi.nlm.nih.gov/pubmed/11169969
67. Reeves, K. W., Carter, G. C., Rodabough, R. J., Lane, D., McNeeley, S. G., Stefanick, M. L., et.al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative, Gynecol Oncol, 2011. 121: p. 376-82., https://www.ncbi.nlm.nih.gov/pubmed/21324514
68. Byun, D, Hong, S, Ryu, S, Nam, Y, Jang, H, Cho, Y, et.al. Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies., Br J Cancer, 2022. 126 (4)(4): p. 664-672., https://pubmed.ncbi.nlm.nih.gov/34773099/
69. Cote, M. L., Alhajj, T., Ruterbusch, J. J., Bernstein, L., Brinton, L. A., Blot, W. J., et.al. Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2), Cancer Causes Control, 2014. 26: p. 287-96., https://www.ncbi.nlm.nih.gov/pubmed/25534916
70. Win, A. K., Reece, J. C., Ryan, S., Family history and risk of endometrial cancer: a systematic review and meta-analysis, Obstet Gynecol, 2015. 125: p. 89-98., https://www.ncbi.nlm.nih.gov/pubmed/25560109
71. Liu, J., Jiang, W., Mao, K., An, Y., Su, F., Kim, B. Y., et.al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis, Breast Cancer Res Treat, 2015. 150: p. 439-45., https://www.ncbi.nlm.nih.gov/pubmed/25764167
72. Bandera, E. V., Kushi, L. H., Moore, D. F., Gifkins, D. M., McCullough, M. L., Association between dietary fiber and endometrial cancer: a dose-response meta-analysis, Am J Clin Nutr, 2007. 86: p. 1730-7., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214669/
73. Myung, S. K., Ju, W., Choi, H. J., Kim, S. C., Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis, BJOG, 2009. 116: p. 1697-705., https://www.ncbi.nlm.nih.gov/pubmed/19775307
74. Ollberding, N. J., Lim, U., Wilkens, L. R., Setiawan, V. W., Shvetsov, Y. B., Henderson, B. E., et.al. Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study, J Natl Cancer Inst, 2011. 104: p. 67-76., https://www.ncbi.nlm.nih.gov/pubmed/22158125
75. Bandera, E. V., Gifkins, D. M., Moore, D. F., McCullough, M. L., Kushi, L. H., Antioxidant vitamins and the risk of endometrial cancer: a dose-response meta-analysis, Cancer Causes Control, 2009. 20: p. 699-711., https://www.ncbi.nlm.nih.gov/pubmed/19083131
76. Inoue-Choi, M., Robien, K., Mariani, A., Cerhan, J. R., Anderson, K. E., Sugar-sweetened beverage intake and the risk of type I and type II endometrial cancer among postmenopausal women, Cancer Epidemiol Biomarkers Prev, 2013. 22: p. 2384-94., https://www.ncbi.nlm.nih.gov/pubmed/24273064
77. Yu, X., Bao, Z., Zou, J., Dong, J., Coffee consumption and risk of cancers: a meta-analysis of cohort studies, BMC Cancer, 2011. 11: p. 96., https://www.ncbi.nlm.nih.gov/pubmed/21406107
78. Je, Y., Hankinson, S. E., Tworoger, S. S., De Vivo, I., Giovannucci, E., A prospective cohort study of coffee consumption and risk of endometrial cancer over a 26-year follow-up, Cancer Epidemiol Biomarkers Prev, 2011. 20: p. 2487-95., https://www.ncbi.nlm.nih.gov/pubmed/22109346
79. Bravi, F., Scotti, L., Bosetti, C., Gallus, S., Negri, E., La Vecchia, C., et.al. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies, Am J Obstet Gynecol, 2009. 200: p. 130-5., https://www.ncbi.nlm.nih.gov/pubmed/19110217
80. Uccella, S., Mariani, A., Wang, A. H., Vierkant, R. A., Cliby, W. A., Robien, K., et.al. Intake of coffee, caffeine and other methylxanthines and risk of Type I vs Type II endometrial cancer, Br J Cancer, 2013. 109: p. 1908-13., https://www.ncbi.nlm.nih.gov/pubmed/24022184
81. Tang, N. P., Li, H., Qiu, Y. L., Zhou, G. M., Ma, J., Tea consumption and risk of endometrial cancer: a metaanalysis, Am J Obstet Gynecol, 2009. 201: p. 605.e1-8., https://www.ncbi.nlm.nih.gov/pubmed/19766982
82. Ma, X, Zhao, LG, Sun, JW, Yang, Y, Zheng, JL, Gao, J, et.al. Association between breastfeeding and risk of endometrial cancer: a meta-analysis of epidemiological studies., Eur J Cancer Prev, 2018. 27 (2)(2): p. 144-151., https://pubmed.ncbi.nlm.nih.gov/26258808/
83. McCullough, M. L., Bandera, E. V., Moore, D. F., Kushi, L. H., Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature, Prev Med, 2007. 46: p. 298-302., https://www.ncbi.nlm.nih.gov/pubmed/18155758
84. Neill, A. S., Nagle, C. M., Protani, M. M., Obermair, A., Spurdle, A. B., Webb, P. M., Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis, Int J Cancer, 2012. 132: p. 1146-55., https://www.ncbi.nlm.nih.gov/pubmed/22777678
85. Zhou, B., Yang, L., Sun, Q., Cong, R., Gu, H., Tang, N., et.al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis, Am J Med, 2008. 121: p. 501-508.e3., https://www.ncbi.nlm.nih.gov/pubmed/18501231
86. Viswanathan, A. N., Hankinson, S. E., Schernhammer, E. S., Night shift work and the risk of endometrial cancer, Cancer Res, 2007. 67: p. 10618-22., https://www.ncbi.nlm.nih.gov/pubmed/17975006
87. Raglan, Olivia, Kalliala, Ilkka, Markozannes, Georgios, Cividini, Sofia, Gunter, Marc J., Nautiyal, Jaya, et.al. Risk factors for endometrial cancer: An umbrella review of the literature, International journal of cancer, 2019. 145(7): p. 1719-1730., http://europepmc.org/abstract/MED/30387875, https://doi.org/10.1002/ijc.31961
88. Kohler, LN, Garcia, DO, Harris, RB, Oren, E, Roe, DJ, Jacobs, ET, Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review., Cancer Epidemiol Biomarkers Prev, 2016. 25 (7)(7): p. 1018-28., https://pubmed.ncbi.nlm.nih.gov/27340121/
89. Zhang, X, Rhoades, J, Caan, BJ, Cohn, DE, Salani, R, Noria, S, et.al. Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis., Int J Gynecol Cancer, 2019. 29 (9)(9): p. 1361-1371., https://pubmed.ncbi.nlm.nih.gov/31451560/
90. Oderkerk, TJ, van de Kar, MRD, Cornel, KMC, Bongers, MY, Geomini, PMAJ, Endometrial cancer after endometrial ablation: a systematic review., Int J Gynecol Cancer, 2022. 32 (12)(12): p. 1555-1560., https://pubmed.ncbi.nlm.nih.gov/36375895/
91. AlHilli, MM, Hopkins, MR, Famuyide, AO, Endometrial cancer after endometrial ablation: systematic review of medical literature., J Minim Invasive Gynecol, 2011. 18 (3)(3): p. 393-400., https://pubmed.ncbi.nlm.nih.gov/21545966/
92. Kalampokas, E, McRobbie, S, Payne, F, Parkin, DE, Endometrial cancer after endometrial ablation or resection for menorrhagia., Int J Gynaecol Obstet, 2018. 142 (1)(1): p. 84-90., https://pubmed.ncbi.nlm.nih.gov/29637560/
93. Flöter Rådestad, A, Dahm-Kähler, P, Holmberg, E, Bjurberg, M, Hellman, K, Högberg, T, et.al. Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) study., Acta Obstet Gynecol Scand, 2022. 101 (8)(8): p. 923-930., https://pubmed.ncbi.nlm.nih.gov/35624547/
94. Keum, N., Ju, W., Lee, D. H., Ding, E. L., Hsieh, C. C., Goodman, J. E., et.al. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies, Int J Cancer, 2014. 135: p. 682-94., https://www.ncbi.nlm.nih.gov/pubmed/24375149
95. Gierach, G. L., Chang, S. C., Brinton, L. A., Lacey, J. V., Jr., Hollenbeck, A. R., Schatzkin, A., et.al. Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study, Int J Cancer, 2009. 124: p. 2139-47., https://www.ncbi.nlm.nih.gov/pubmed/19123463
96. Moore, S. C., Gierach, G. L., Schatzkin, A., Matthews, C. E., Physical activity, sedentary behaviours, and the prevention of endometrial cancer, Br J Cancer, 2010. 103: p. 933-8., https://www.ncbi.nlm.nih.gov/pubmed/20877336
97. Voskuil, D. W., Monninkhof, E. M., Elias, S. G., Vlems, F. A., van Leeuwen, F. E., Physical activity and endometrial cancer risk, a systematic review of current evidence, Cancer Epidemiol Biomarkers Prev, 2007. 16: p. 639-48., https://www.ncbi.nlm.nih.gov/pubmed/17416752
98. Kokts-Porietis, RL, Elmrayed, S, Brenner, DR, Friedenreich, CM, Obesity and mortality among endometrial cancer survivors: A systematic review and meta-analysis., Obes Rev, 2021. 22 (12)(12): p. e13337., https://pubmed.ncbi.nlm.nih.gov/34476900/
99. Schmid, D., Leitzmann, M. F., Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis, J Natl Cancer Inst, 2014. 106:, https://www.ncbi.nlm.nih.gov/pubmed/24935969
100. Soini, T., Hurskainen, R., Grenman, S., Maenpaa, J., Paavonen, J., Pukkala, E., Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland, Obstet Gynecol, 2014. 124: p. 292-9., https://www.ncbi.nlm.nih.gov/pubmed/25004338
101. Felix, A. S., Gaudet, M. M., La Vecchia, C., Nagle, C. M., Shu, X. O., Weiderpass, E., et.al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium, Int J Cancer, 2014. 136: p. E410-22., https://www.ncbi.nlm.nih.gov/pubmed/25242594
102. Ward, K. K., Roncancio, A. M., Shah, N. R., Davis, M. A., Saenz, C. C., McHale, M. T., et.al. Bariatric surgery decreases the risk of uterine malignancy, Gynecol Oncol, 2014. 133: p. 63-6., https://www.ncbi.nlm.nih.gov/pubmed/24680593
103. Neff, R., Havrilesky, L. J., Chino, J., O'Malley, D. M., Cohn, D. E., Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome, Gynecol Oncol, 2015. 138: p. 597-602., https://www.ncbi.nlm.nih.gov/pubmed/26232518
104. Ishihara, BP, Farah, D, Fonseca, MCM, Nazario, A, The risk of developing breast, ovarian, and endometrial cancer in obese women submitted to bariatric surgery: a meta-analysis., Surg Obes Relat Dis, 2020. 16 (10)(10): p. 1596-1602., https://pubmed.ncbi.nlm.nih.gov/32690459/
105. Li, YY, Gao, LJ, Zhang, YX, Liu, SJ, Cheng, S, Liu, YP, et.al. Bisphosphonates and risk of cancers: a systematic review and meta-analysis., Br J Cancer, 2020. 123 (10)(10): p. 1570-1581., https://pubmed.ncbi.nlm.nih.gov/32901134/
106. Chen, Y, Han, L, Zheng, A, Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis., Eur J Obstet Gynecol Reprod Biol, 2022. 268 (): p. 74-81., https://pubmed.ncbi.nlm.nih.gov/34875557/
107. Raatz, H., Glinz, Dominik, Systematische Reviews und Bewertung der Qualität der Evidenz im Rahmen der S3-Leitlinie EndometriumkarzinomCEB, 2015. p. 1-45., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Evidenzbericht_Screening_CEB_Basel.pdf
108. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, AWMF, S3-Leitlinie Hormontherapie in der Peri- und Postmenopause (HT), AWMF-Registernummer: 015/062, wird aktuell überarbeitet, 2009., http://www.awmf.org/leitlinien/detail/ll/015-062.html
109. Woolas, R., Talaat, A., Anderson, M., Brinkmann, D., Gardner, F., Gentry-Maharaj, A., et.al. Significant endometrial pathology detected during a transvaginal ultrasound screening trial for ovarian cancer, Gynecologic Oncology, 2011. 120, Supplement 1: p. S39.
110. Jacobs, I., Gentry-Maharaj, A., Burnell, M., Manchanda, R., Singh, N., Sharma, A., et.al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort, Lancet Oncol, 2010. 12: p. 38-48., https://www.ncbi.nlm.nih.gov/pubmed/21147030
111. Breijer, M. C., Peeters, J. A., Opmeer, B. C., Clark, T. J., Verheijen, R. H., Mol, B. W., et.al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis, Ultrasound Obstet Gynecol, 2012. 40: p. 621-9., https://www.ncbi.nlm.nih.gov/pubmed/23001905
112. Alcázar, JL, Bonilla, L, Marucco, J, Padilla, AI, Chacón, E, Manzour, N, et.al. Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis., J Clin Ultrasound, 2018. 46 (9)(9): p. 565-570., https://pubmed.ncbi.nlm.nih.gov/30113073/
113. Smith-Bindman, R, Weiss, E, Feldstein, V, How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding., Ultrasound Obstet Gynecol, 2004. 24 (5)(5): p. 558-65., https://pubmed.ncbi.nlm.nih.gov/15386607/
114. Manchanda, R., Saridogan, E., Abdelraheim, A., Johnson, M., Rosenthal, A. N., Benjamin, E., et.al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS), Arch Gynecol Obstet, 2012. 286: p. 1555-62., https://www.ncbi.nlm.nih.gov/pubmed/22865035
115. Helder-Woolderink, J. M., De Bock, G. H., Sijmons, R. H., Hollema, H., Mourits, M. J., The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome, Gynecol Oncol, 2013. 131: p. 304-8., https://www.ncbi.nlm.nih.gov/pubmed/23769810
116. Vasen, H. F., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., et.al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts, Gut, 2013. 62: p. 812-23., https://www.ncbi.nlm.nih.gov/pubmed/23408351
117. Fleming, CA, Heneghan, HM, O'Brien, D, McCartan, DP, McDermott, EW, Prichard, RS, Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy., Br J Surg, 2018. 105 (9)(9): p. 1098-1106., https://pubmed.ncbi.nlm.nih.gov/29974455/
118. Gao, W. L., Zhang, L. P., Feng, L. M., Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen, Chin Med J (Engl), 2011. 124: p. 2335-9., https://www.ncbi.nlm.nih.gov/pubmed/21933565
119. Bertelli, G., Valenzano, M., Costantini, S., Rissone, R., Angiolini, C., Signorini, A., et.al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen, Gynecol Oncol, 2000. 78: p. 275-7., https://www.ncbi.nlm.nih.gov/pubmed/10985880
120. Gerber, B., Krause, A., Muller, H., Reimer, T., Kulz, T., Makovitzky, J., et.al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound, J Clin Oncol, 2000. 18: p. 3464-70., https://www.ncbi.nlm.nih.gov/pubmed/11032586
121. Fung, M. F., Reid, A., Faught, W., Le, T., Chenier, C., Verma, S., et.al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen, Gynecol Oncol, 2003. 91: p. 154-9., https://www.ncbi.nlm.nih.gov/pubmed/14529676
122. Saccardi, C., Gizzo, S., Patrelli, T. S., Ancona, E., Anis, O., Di Gangi, S., et.al. Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study, Endocr Relat Cancer, 2013. 20: p. 455-62., https://www.ncbi.nlm.nih.gov/pubmed/23629476
123. Van den Bosch, T., Van Schoubroeck, D., Ameye, L., De Brabanter, J., Van Huffel, S., Timmerman, D., Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy, Am J Obstet Gynecol, 2003. 188: p. 1249-53., https://www.ncbi.nlm.nih.gov/pubmed/12748493
124. Li, JXL, Chan, F, Johansson, CYM, Can a higher endometrial thickness threshold exclude endometrial cancer and atypical hyperplasia in asymptomatic postmenopausal women? A systematic review., Aust N Z J Obstet Gynaecol, 2022. 62 (2)(2): p. 190-197., https://pubmed.ncbi.nlm.nih.gov/34994399/
125. Bittencourt, CA, Dos Santos Simões, R, Bernardo, WM, Fuchs, LFP, Soares Júnior, JM, Pastore, AR, et.al. Accuracy of saline contrast sonohysterography in detection of endometrial polyps and submucosal leiomyomas in women of reproductive age with abnormal uterine bleeding: systematic review and meta-analysis., Ultrasound Obstet Gynecol, 2017. 50 (1)(1): p. 32-39., https://pubmed.ncbi.nlm.nih.gov/27862503/
126. Nieuwenhuis, LL, Hermans, FJ, Bij de Vaate, AJM, Leeflang, MM, Brölmann, HA, Hehenkamp, WJ, et.al. Three-dimensional saline infusion sonography compared to two-dimensional saline infusion sonography for the diagnosis of focal intracavitary lesions., Cochrane Database Syst Rev, 2017. 5 (): p. CD011126., https://pubmed.ncbi.nlm.nih.gov/28472862/
127. Vroom, AJ, Timmermans, A, Bongers, MY, van den Heuvel, ER, Geomini, PMAJ, van Hanegem, N, Diagnostic accuracy of saline contrast sonohysterography in detecting endometrial polyps in women with postmenopausal bleeding: systematic review and meta-analysis., Ultrasound Obstet Gynecol, 2019. 54 (1)(1): p. 28-34., https://pubmed.ncbi.nlm.nih.gov/30693579/
128. Clarke, MA, Long, BJ, Del Mar Morillo, A, Arbyn, M, Bakkum-Gamez, JN, Wentzensen, N, Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis., JAMA Intern Med, 2018. 178 (9)(9): p. 1210-1222., https://pubmed.ncbi.nlm.nih.gov/30083701/
129. Vitale, SG, Haimovich, S, Laganà, AS, Alonso, L, Di Spiezio Sardo, A, Carugno, J, Endometrial polyps. An evidence-based diagnosis and management guide., Eur J Obstet Gynecol Reprod Biol, 2021. 260 (): p. 70-77., https://pubmed.ncbi.nlm.nih.gov/33756339/
130. Grab, D, Merz, E, Eichhorn, KH, Tutschek, B, Kagan, KO, Heling, KS, et.al. Basic Gynecologic Ultrasound Examination (Level I): DEGUM, ÖGUM, and SGUM Recommendations., Ultraschall Med, 2023. 44 (2)(2): p. 151-161., https://pubmed.ncbi.nlm.nih.gov/35705173/
131. Leone, FP, Timmerman, D, Bourne, T, Valentin, L, Epstein, E, Goldstein, SR, et.al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group., Ultrasound Obstet Gynecol, 2010. 35 (1)(1): p. 103-12., https://pubmed.ncbi.nlm.nih.gov/20014360/
132. Van Den Bosch, T, Verbakel, JY, Valentin, L, Wynants, L, De Cock, B, Pascual, MA, et.al. Typical ultrasound features of various endometrial pathologies described using International Endometrial Tumor Analysis (IETA) terminology in women with abnormal uterine bleeding., Ultrasound Obstet Gynecol, 2021. 57 (1)(1): p. 164-172., https://pubmed.ncbi.nlm.nih.gov/32484286/
133. Hefler, L, Lafleur, J, Kickmaier, S, Leipold, H, Siebenhofer, C, Tringler, B, et.al. Risk of endometrial cancer in asymptomatic postmenopausal patients with thickened endometrium: data from the FAME-Endo study: an observational register study., Arch Gynecol Obstet, 2018. 298 (4)(4): p. 813-820., https://pubmed.ncbi.nlm.nih.gov/30182190/
134. Aggarwal, A, Hatti, A, Tirumuru, SS, Nair, SS, Management of Asymptomatic Postmenopausal Women Referred to Outpatient Hysteroscopy Service with Incidental Finding of Thickened Endometrium - A UK District General Hospital Experience., J Minim Invasive Gynecol, 2021. 28 (10)(10): p. 1725-1729., https://pubmed.ncbi.nlm.nih.gov/33610754/
135. Ozelci, R, Dilbaz, B, Akpınar, F, Kınay, T, Baser, E, Aldemir, O, et.al. The significance of sonographically thickened endometrium in asymptomatic postmenopausal women., Obstet Gynecol Sci, 2019. 62 (4)(4): p. 273-279., https://pubmed.ncbi.nlm.nih.gov/31338345/
136. Giannella, L, Mfuta, K, Setti, T, Boselli, F, Bergamini, E, Cerami, LB, Diagnostic accuracy of endometrial thickness for the detection of intra-uterine pathologies and appropriateness of performed hysteroscopies among asymptomatic postmenopausal women., Eur J Obstet Gynecol Reprod Biol, 2014. 177 (): p. 29-33., https://pubmed.ncbi.nlm.nih.gov/24766900/
137. Epstein, E, Fischerova, D, Valentin, L, Testa, AC, Franchi, D, Sladkevicius, P, et.al. Ultrasound characteristics of endometrial cancer as defined by International Endometrial Tumor Analysis (IETA) consensus nomenclature: prospective multicenter study., Ultrasound Obstet Gynecol, 2018. 51 (6)(6): p. 818-828., https://pubmed.ncbi.nlm.nih.gov/28944985/
138. Salim, S, Won, H, Nesbitt-Hawes, E, Campbell, N, Abbott, J, Diagnosis and management of endometrial polyps: a critical review of the literature., J Minim Invasive Gynecol, 2011. 18 (5)(5): p. 569-81., https://pubmed.ncbi.nlm.nih.gov/21783430/
139. Dreisler, E, Sorensen, SS, Lose, G, Endometrial polyps and associated factors in Danish women aged 36-74 years., Am J Obstet Gynecol, 2009. 200 (2)(2): p. 147.e1-6., https://pubmed.ncbi.nlm.nih.gov/18992861/
140. Lieng, M, Istre, O, Sandvik, L, Qvigstad, E, Prevalence, 1-year regression rate, and clinical significance of asymptomatic endometrial polyps: cross-sectional study., J Minim Invasive Gynecol, 2009. 16 (4)(4): p. 465-71., https://pubmed.ncbi.nlm.nih.gov/19573823/
141. Uglietti, A, Buggio, L, Farella, M, Chiaffarino, F, Dridi, D, Vercellini, P, et.al. The risk of malignancy in uterine polyps: A systematic review and meta-analysis., Eur J Obstet Gynecol Reprod Biol, 2019. 237 (): p. 48-56., https://pubmed.ncbi.nlm.nih.gov/31009859/
142. McGowan, MA, Davies, JM, Addley, S, Honeyman, LJ, Kolhe, SN, Phillips, AJ, Does the presence of single compared to multiple endometrial polyps alter the risk of cancer in post-menopausal women?, Eur J Obstet Gynecol Reprod Biol, 2022. 279 (): p. 118-121., https://pubmed.ncbi.nlm.nih.gov/36332539/
143. Patrizi, L, Ticconi, C, Borelli, B, Finocchiaro, S, Chiaramonte, C, Sesti, F, et.al. Clinical significance of endometrial abnormalities: an observational study on 1020 women undergoing hysteroscopic surgery., BMC Womens Health, 2022. 22 (1)(1): p. 106., https://pubmed.ncbi.nlm.nih.gov/35392892/
144. Akış, S, Kıran, G, Göçmen, A, The clinical importance of polyp size measurement through two-dimensional saline infusion sonohysterography prior to hysteroscopic resection in predicting premalignant and malignant endometrial lesions., Int J Gynaecol Obstet, 2022. 157 (3)(3): p. 582-587., https://pubmed.ncbi.nlm.nih.gov/34510415/
145. Pennant, M. E., Mehta, R., Moody, P., Hackett, G., Prentice, A., Sharp, S. J., et.al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer, BJOG, 2016. 124: p. 404-411., https://www.ncbi.nlm.nih.gov/pubmed/27766759
146. Clark, T. J., Mann, C. H., Shah, N., Khan, K. S., Song, F., Gupta, J. K., Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review (Structured abstract), BJOG. An International Journal of Obstetrics and Gynaecology, 2002. 109: p. 313-321., https://www.ncbi.nlm.nih.gov/pubmed/11950187
147. Guido, R. S., Kanbour-Shakir, A., Rulin, M. C., Christopherson, W. A., Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer, J Reprod Med, 1995. 40: p. 553-5., https://www.ncbi.nlm.nih.gov/pubmed/7473450
148. Tanriverdi, H. A., Barut, A., Gun, B. D., Kaya, E., Is pipelle biopsy really adequate for diagnosing endometrial disease?, Med Sci Monit, 2004. 10: p. CR271-4., https://www.ncbi.nlm.nih.gov/pubmed/15173672
149. Del Priore, G., Williams, R., Harbatkin, C. B., Wan, L. S., Mittal, K., Yang, G. C., Endometrial brush biopsy for the diagnosis of endometrial cancer, J Reprod Med, 2001. 46: p. 439-43., https://www.ncbi.nlm.nih.gov/pubmed/11396369
150. Fakhar, S., Saeed, G., Khan, A. H., Alam, A. Y., Validity of pipelle endometrial sampling in patients with abnormal uterine bleeding, Ann Saudi Med, 2008. 28: p. 188-91., https://www.ncbi.nlm.nih.gov/pubmed/18500186
151. Abdelazim, I. A., Abdelrazak, K. M., Elbiaa, A. A., Al-Kadi, M., Yehia, A. H., Accuracy of endometrial sampling compared to conventional dilatation and curettage in women with abnormal uterine bleeding, Arch Gynecol Obstet, 2014. 291: p. 1121-6., https://www.ncbi.nlm.nih.gov/pubmed/25367600
152. Sanam, M., Majid, M. M., Comparison the Diagnostic Value of Dilatation and Curettage Versus Endometrial Biopsy by Pipelle--a Clinical Trial, Asian Pac J Cancer Prev, 2015. 16: p. 4971-5., https://www.ncbi.nlm.nih.gov/pubmed/26163624
153. Munro, MG, Critchley, HO, Broder, MS, Fraser, IS, FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age., Int J Gynaecol Obstet, 2011. 113 (1)(1): p. 3-13., https://pubmed.ncbi.nlm.nih.gov/21345435/
154. Wise, M. R., Gill, P., Lensen, S., Thompson, J. M., Farquhar, C. M., Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women, Am J Obstet Gynecol, 2016. 215: p. 598 e1-598 e8., https://www.ncbi.nlm.nih.gov/pubmed/27287687
155. Ge, L, Liu, G, Hu, K, Huang, K, Zhang, M, Zhou, J, et.al. A New Risk Index Combining d-Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge., Technol Cancer Res Treat, 2020. 19 (): p. 1533033819901117., https://pubmed.ncbi.nlm.nih.gov/32167027/
156. Li, J, Wang, X, Qu, W, Wang, J, Jiang, SW, Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis., Clin Chim Acta, 2019. 488 (): p. 215-220., https://pubmed.ncbi.nlm.nih.gov/30414437/
157. Matsuo, K., Opper, N. R., Ciccone, M. A., Garcia, J., Tierney, K. E., Baba, T., et.al. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome, Obstet Gynecol, 2015. 125: p. 424-33., https://www.ncbi.nlm.nih.gov/pubmed/25569000
158. Clark, T. J., Voit, D., Gupta, J. K., Hyde, C., Song, F., Khan, K. S., Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review, JAMA, 2002. 288: p. 1610-21., https://www.ncbi.nlm.nih.gov/pubmed/12350192
159. Svirsky, R., Smorgick, N., Rozowski, U., Sagiv, R., Feingold, M., Halperin, R., et.al. Can we rely on blind endometrial biopsy for detection of focal intrauterine pathology?, Am J Obstet Gynecol, 2008. 199: p. 115 e1-3., https://www.ncbi.nlm.nih.gov/pubmed/18456238
160. Leitao, M. M., Jr., Kehoe, S., Barakat, R. R., Alektiar, K., Gattoc, L. P., Rabbitt, C., et.al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma, Gynecol Oncol, 2008. 111: p. 244-8., https://www.ncbi.nlm.nih.gov/pubmed/18752842
161. Huang, G. S., Gebb, J. S., Einstein, M. H., Shahabi, S., Novetsky, A. P., Goldberg, G. L., Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors, Am J Obstet Gynecol, 2007. 196: p. 243 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/17346538
162. Deckardt, R., Lueken, R. P., Gallinat, A., Möller, C. P., Busche, D., Nugent, W., et.al. Comparison of Transvaginal Ultrasound, Hysteroscopy, and Dilatation and Curettage in the Diagnosis of Abnormal Vaginal Bleeding and Intrauterine Pathology in Perimenopausal and Postmenopausal Women, The Journal of the American Association of Gynecologic Laparoscopists, 2002. 9(3): p. 277-282.
163. Dueholm, M., Hjorth, I. M., Secher, P., Jorgensen, A., Ortoft, G., Structured Hysteroscopic Evaluation of Endometrium in Women With Postmenopausal Bleeding, J Minim Invasive Gynecol, 2015. 22: p. 1215-24., https://www.ncbi.nlm.nih.gov/pubmed/26140830
164. Wu, H. H., Harshbarger, K. E., Berner, H. W., Elsheikh, T. M., Endometrial brush biopsy (Tao brush). Histologic diagnosis of 200 cases with complementary cytology: an accurate sampling technique for the detection of endometrial abnormalities, Am J Clin Pathol, 2000. 114: p. 412-8., https://www.ncbi.nlm.nih.gov/pubmed/10989642
165. Wu, H. H., Casto, B. D., Elsheikh, T. M., Endometrial brush biopsy. An accurate outpatient method of detecting endometrial malignancy, J Reprod Med, 2003. 48: p. 41-5., https://www.ncbi.nlm.nih.gov/pubmed/12611094
166. Williams, A. R., Brechin, S., Porter, A. J., Warner, P., Critchley, H. O., Factors affecting adequacy of Pipelle and Tao Brush endometrial sampling, BJOG, 2008. 115: p. 1028-36., https://www.ncbi.nlm.nih.gov/pubmed/18651884
167. Critchley, H. O., Warner, P., Lee, A. J., Brechin, S., Guise, J., Graham, B., Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status, Health Technol Assess, 2004. 8: p. iii-iv, 1-139., https://www.ncbi.nlm.nih.gov/pubmed/15361316
168. Al-Azemi, M., Labib, N. S., Motawy, M. M., Temmim, L., Moussa, M. A., Omu, A. E., Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait, Med Princ Pract, 2003. 13: p. 30-4., https://www.ncbi.nlm.nih.gov/pubmed/14657616
169. Narice, BF, Delaney, B, Dickson, JM, Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis., BMC Fam Pract, 2018. 19 (1)(1): p. 135., https://pubmed.ncbi.nlm.nih.gov/30060741/
170. Frias-Gomez, J, Benavente, Y, Ponce, J, Brunet, J, Ibáñez, R, Peremiquel-Trillas, P, et.al. Sensitivity of cervico-vaginal cytology in endometrial carcinoma: A systematic review and meta-analysis., Cancer Cytopathol, 2020. 128 (11)(11): p. 792-802., https://pubmed.ncbi.nlm.nih.gov/32202704/
171. Verdoodt, F, Jiang, X, Williams, M, Schnatz, PF, Arbyn, M, High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis., Int J Cancer, 2016. 138 (2)(2): p. 303-10., https://pubmed.ncbi.nlm.nih.gov/25583258/
172. Timmermans, A., Opmeer, B. C., Khan, K. S., Bachmann, L. M., Epstein, E., Clark, T. J., et.al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis, Obstet Gynecol, 2010. 116: p. 160-7., https://www.ncbi.nlm.nih.gov/pubmed/20567183
173. Herzog, C, Marín, F, Jones, A, Evans, I, Reisel, D, Redl, E, et.al. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets., J Clin Oncol, 2022. 40 (33)(33): p. 3828-3838., https://pubmed.ncbi.nlm.nih.gov/36001862/
174. Evans, I, Reisel, D, Jones, A, Bajrami, A, Nijjar, S, Solangon, SA, et.al. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK., Lancet Oncol, 2023. 24 (12)(12): p. 1375-1386., https://pubmed.ncbi.nlm.nih.gov/37944542/
175. Illah, O, Scott, M, Redl, E, Barrett, JE, Schreiberhuber, L, Herzog, C, et.al. High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities., Int J Cancer, 2024. 155 (5)(5): p. 800-806., https://pubmed.ncbi.nlm.nih.gov/38739012/
176. Ken-Amoah, S, Redl, E, Domson, BKS, Barrett, JE, Schreiberhuber, L, Herzog, C, et.al. Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana., Int J Cancer, 2025. 156 (5)(5): p. 1055-1064., https://pubmed.ncbi.nlm.nih.gov/39655721/
177. Nolin, AC, Atkins, SL, Myers, ER, Wentzensen, N, Clarke, MA, Blank, SV, et.al. Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals., Gynecol Oncol, 2025. 194 (): p. 105-111., https://pubmed.ncbi.nlm.nih.gov/39985869/
178. Kiff, JM, Williams-Weisenberger, M, Spellacy, D, Garg, B, Munro, EG, Bruegl, AS, Ultrasonographic evaluation of endometrial stripe thickness is insufficient to rule out uterine serous carcinoma., Cancer Causes Control, 2023. 34 (12)(12): p. 1133-1138., https://pubmed.ncbi.nlm.nih.gov/37505315/
179. Nicholson, BD, Oke, J, Virdee, PS, Harris, DA, O'Doherty, C, Park, JE, et.al. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study., Lancet Oncol, 2023. 24 (7)(7): p. 733-743., https://pubmed.ncbi.nlm.nih.gov/37352875/
180. Endometriumcarcinoom, Endometriumcarcinoom, 2011., https://www.oncoline.nl/endometriumcarcinoom
181. Lalwani, N., Dubinsky, T., Javitt, M. C., Gaffney, D. K., Glanc, P., Elshaikh, M. A., et.al. ACR Appropriateness Criteria(®) pretreatment evaluation and follow-up of endometrial cancer, Ultrasound Q, 2014. 30: p. 21-8., https://www.ncbi.nlm.nih.gov/pubmed/24901775
182. Amkreutz, L. C., Mertens, H. J., Nurseta, T., Engelen, M. J., Bergmans, M., Nolting, E., et.al. The value of imaging of the lungs in the diagnostic workup of patients with endometrial cancer, Gynecol Oncol, 2013. 131: p. 147-50., https://www.ncbi.nlm.nih.gov/pubmed/23838035
183. Alcázar, JL, Pérez, L, Güell, O, Haro, N, Manzour, N, Chacon, E, et.al. Diagnostic Performance of Transvaginal Ultrasound for Detecting Cervical Invasion In Women With Endometrial Carcinoma: A Systematic Review and Meta-analysis., J Ultrasound Med, 2019. 38 (1)(1): p. 179-189., https://pubmed.ncbi.nlm.nih.gov/29732585/
184. Savelli, L., Ceccarini, M., Ludovisi, M., Fruscella, E., De Iaco, P. A., Salizzoni, E., et.al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging, Ultrasound Obstet Gynecol, 2008. 31: p. 560-6., https://www.ncbi.nlm.nih.gov/pubmed/18398926
185. Haldorsen, I. S., Gruner, R., Husby, J. A., Magnussen, I. J., Werner, H. M., Salvesen, O. O., et.al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence, Eur Radiol, 2013. 23: p. 2916-25., https://www.ncbi.nlm.nih.gov/pubmed/23732687
186. Antonsen, S. L., Jensen, L. N., Loft, A., Berthelsen, A. K., Costa, J., Tabor, A., et.al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study, Gynecol Oncol, 2012. 128: p. 300-8.
187. Selman, T. J., Mann, C. H., Zamora, J., Khan, K. S., A systematic review of tests for lymph node status in primary endometrial cancer, BMC Womens Health, 2008. 8: p. 8., https://www.ncbi.nlm.nih.gov/pubmed/18457596
188. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22305013
189. Nougaret, S, Horta, M, Sala, E, Lakhman, Y, Thomassin-Naggara, I, Kido, A, et.al. Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology., Eur Radiol, 2019. 29 (2)(2): p. 792-805., https://pubmed.ncbi.nlm.nih.gov/29995239/
190. Luomaranta, A., Leminen, A., Loukovaara, M., Magnetic Resonance Imaging in the Assessment of High-Risk Features of Endometrial Carcinoma: A Meta-Analysis, Int J Gynecol Cancer, 2014., https://www.ncbi.nlm.nih.gov/pubmed/25010040
191. Radiologic staging in patients with endometrial cancer: a meta-analysis., 1999., https://www.ncbi.nlm.nih.gov/pubmed/10478237
192. Andreano, A., Rechichi, G., Rebora, P., Sironi, S., Valsecchi, M. G., Galimberti, S., MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis, Eur Radiol, 2014. 24: p. 1327-38., https://www.ncbi.nlm.nih.gov/pubmed/24668009
193. Das, S. K., Niu, X. K., Wang, J. L., Zeng, L. C., Wang, W. X., Bhetuwal, A., et.al. Usefulness of DWI in preoperative assessment of deep myometrial invasion in patients with endometrial carcinoma: a systematic review and meta-analysis, Cancer Imaging, 2015. 14: p. 32., https://www.ncbi.nlm.nih.gov/pubmed/25608571
194. Tsili, A. C., Tsampoulas, C., Dalkalitsis, N., Stefanou, D., Paraskevaidis, E., Efremidis, S. C., Local staging of endometrial carcinoma: role of multidetector CT, Eur Radiol, 2008. 18: p. 1043-8., https://www.ncbi.nlm.nih.gov/pubmed/18175120
195. Kitajima, K., Suenaga, Y., Ueno, Y., Kanda, T., Maeda, T., Takahashi, S., et.al. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with (1)(8)F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI, Eur J Radiol, 2013. 82: p. 1672-6., https://www.ncbi.nlm.nih.gov/pubmed/23727380
196. National Comprehensive Cancer Network (NCCN, Clinical Practice Guidelines in Oncology: Uterine NeoplasmsNational Comprehensive Cancer Network, 2015. 2016:
197. Chang, M. C., Chen, J. H., Liang, J. A., Yang, K. T., Cheng, K. Y., Kao, C. H., 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis, Eur J Radiol, 2012. 81: p. 3511-7.
198. Hu, J, Zhang, K, Yan, Y, Zang, Y, Wang, Y, Xue, F, Diagnostic accuracy of preoperative , Arch Gynecol Obstet, 2019. 300 (3)(3): p. 519-529., https://pubmed.ncbi.nlm.nih.gov/31165242/
199. Kakhki, V. R., Shahriari, S., Treglia, G., Hasanzadeh, M., Zakavi, S. R., Yousefi, Z., et.al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature, Int J Gynecol Cancer, 2013. 23: p. 1536-43., https://www.ncbi.nlm.nih.gov/pubmed/24172090
200. Bokhman, JV, Two pathogenetic types of endometrial carcinoma., Gynecol Oncol, 1983. 15 (1)(1): p. 10-7., https://pubmed.ncbi.nlm.nih.gov/6822361/
201. Board, WHO Classification of Tumours Editorial, Female Genital Tumours, 2020. 4:
202. Luchini, C, Bibeau, F, Ligtenberg, MJL, Singh, N, Nottegar, A, Bosse, T, et.al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach., Ann Oncol, 2019. 30 (8)(8): p. 1232-1243., https://pubmed.ncbi.nlm.nih.gov/31056702/
203. Concin, N, Matias-Guiu, X, Vergote, I, Cibula, D, Mirza, MR, Marnitz, S, et.al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma., Int J Gynecol Cancer, 2021. 31 (1)(1): p. 12-39., https://pubmed.ncbi.nlm.nih.gov/33397713/
204. Vermij, L, Smit, V, Nout, R, Bosse, T, Incorporation of molecular characteristics into endometrial cancer management., Histopathology, 2020. 76 (1)(1): p. 52-63., https://pubmed.ncbi.nlm.nih.gov/31846532/
205. Soslow, RA, Tornos, C, Park, KJ, Malpica, A, Matias-Guiu, X, Oliva, E, et.al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S64-S74., https://pubmed.ncbi.nlm.nih.gov/30550484/
206. Lax, SF, Kurman, RJ, A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses., Verh Dtsch Ges Pathol, 1997. 81 (): p. 228-32., https://pubmed.ncbi.nlm.nih.gov/9474874/
207. Lax, SF, Kurman, RJ, Pizer, ES, Wu, L, Ronnett, BM, A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis., Am J Surg Pathol, 2000. 24 (9)(9): p. 1201-8., https://pubmed.ncbi.nlm.nih.gov/10976693/
208. Lax, SF, Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification., Virchows Arch, 2004. 444 (3)(3): p. 213-23., https://pubmed.ncbi.nlm.nih.gov/14747944/
209. Horn, L. C., Schnurrbusch, U., Bilek, K., Hentschel, B., Einenkel, J., Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment, Int J Gynecol Cancer, 2004. 14: p. 348-53., https://www.ncbi.nlm.nih.gov/pubmed/15086736
210. Semere, LG, Ko, E, Johnson, NR, Vitonis, AF, Phang, LJ, Cramer, DW, et.al. Endometrial intraepithelial neoplasia: clinical correlates and outcomes., Obstet Gynecol, 2011. 118 (1)(1): p. 21-28., https://pubmed.ncbi.nlm.nih.gov/21691159/
211. Yuan, L, Biscotti, CV, Zhu, H, Booth, CN, Abdul-Karim, FW, Zhang, Y, Significance of atypical endometrial cells in women younger than 40 years of age., J Am Soc Cytopathol 9 (1)(1): p. 33-37., https://pubmed.ncbi.nlm.nih.gov/PMID:, 31353256/
212. Vetter, MH, Smith, B, Benedict, J, Hade, EM, Bixel, K, Copeland, LJ, et.al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia., Am J Obstet Gynecol, 2020. 222 (1)(1): p. 60.e1-60.e7., https://pubmed.ncbi.nlm.nih.gov/31401259/
213. Bourdel, N, Chauvet, P, Tognazza, E, Pereira, B, Botchorishvili, R, Canis, M, Sampling in Atypical Endometrial Hyperplasia: Which Method Results in the Lowest Underestimation of Endometrial Cancer? A Systematic Review and Meta-analysis., J Minim Invasive Gynecol 23 (5)(5): p. 692-701., https://pubmed.ncbi.nlm.nih.gov/27058769/
214. Smith, BQ, Boone, JD, Thomas, ED, Turner, TB, McGwin, G, Stisher, AM, et.al. The Reliability of Intraoperative Assessment on Predicting Tumor Size, Myometrial Invasion, and Cervical Involvement in Patients With a Preoperative Diagnosis of Complex Atypical Hyperplasia or (Clinical Stage I) Endometrial Cancer: A Prospective Cohort Study., Am J Clin Oncol, 2020. 43 (2)(2): p. 122-127., https://pubmed.ncbi.nlm.nih.gov/31764025/
215. Wheeler, DT, Bell, KA, Kurman, RJ, Sherman, ME, Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation., Am J Surg Pathol, 2000. 24 (6)(6): p. 797-806., https://pubmed.ncbi.nlm.nih.gov/10843281/
216. Trinh, VQ, Pelletier, MP, Echelard, P, Warkus, T, Sauthier, P, Gougeon, F, et.al. Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps., Int J Gynecol Pathol, 2020. 39 (2)(2): p. 128-135., https://pubmed.ncbi.nlm.nih.gov/30789501/
217. Mayr, Doris, Schmoeckel, Elisa, Höhn, Anne Kathrin, Hiller, Grit Gesine Ruth, Horn, Lars-Christian, Aktuelle WHO-Klassifikation des weiblichen Genitale, 2021. 42(3): p. 259 - 269., https://doi.org/10.1007/s00292-021-00933-w
218. Soslow, RA, High-grade endometrial carcinomas - strategies for typing., Histopathology, 2013. 62 (1)(1): p. 89-110., https://pubmed.ncbi.nlm.nih.gov/23240672/
219. Malpica, A, How to approach the many faces of endometrioid carcinoma., Mod Pathol, 2016. 29 Suppl 1 (): p. S29-44., https://pubmed.ncbi.nlm.nih.gov/26715172/
220. Murali, R, Davidson, B, Fadare, O, Carlson, JA, Crum, CP, Gilks, CB, et.al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S40-S63., https://pubmed.ncbi.nlm.nih.gov/30550483/
221. Hu, S, Hinson, JL, Matnani, R, Cibull, ML, Karabakhtsian, RG, Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma., Mod Pathol, 2018. 31 (2)(2): p. 358-364., https://pubmed.ncbi.nlm.nih.gov/28984301/
222. Chen, W, Husain, A, Nelson, GS, Rambau, PF, Liu, S, Lee, CH, et.al. Immunohistochemical Profiling of Endometrial Serous Carcinoma., Int J Gynecol Pathol, 2017. 36 (2)(2): p. 128-139., https://pubmed.ncbi.nlm.nih.gov/27167671/
223. Stewart, CJR, Crum, CP, McCluggage, WG, Park, KJ, Rutgers, JK, Oliva, E, et.al. Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S75-S92., https://pubmed.ncbi.nlm.nih.gov/30550485/
224. Rabban, JT, Gilks, CB, Malpica, A, Matias-Guiu, X, Mittal, K, Mutter, GL, et.al. Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S25-S39., https://pubmed.ncbi.nlm.nih.gov/30550482/
225. Lax, SF, Pathology of Endometrial Carcinoma., Adv Exp Med Biol, 2017. 943 (): p. 75-96., https://pubmed.ncbi.nlm.nih.gov/PMID:, 27910065/
226. Bell, DW, Ellenson, LH, Molecular Genetics of Endometrial Carcinoma., Annu Rev Pathol, 2019. 14 (): p. 339-367., https://pubmed.ncbi.nlm.nih.gov/30332563/
227. Horn, LC, Höhn, AK, Krücken, I, Stiller, M, Obeck, U, Brambs, CE, Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma., J Cancer Res Clin Oncol, 2020. 146 (4)(4): p. 971-983., https://pubmed.ncbi.nlm.nih.gov/31927619/
228. Euscher, ED, Bassett, R, Duose, DY, Lan, C, Wistuba, I, Ramondetta, L, et.al. Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma With an Aggressive Behavior., Am J Surg Pathol, 2020. 44 (4)(4): p. 429-443., https://pubmed.ncbi.nlm.nih.gov/31725471/
229. Horn, L. C., Dallacker, M., Bilek, K., [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors], Pathologe, 2009. 30: p. 292-301., https://www.ncbi.nlm.nih.gov/pubmed/19495763
230. Artioli, G, Wabersich, J, Ludwig, K, Gardiman, MP, Borgato, L, Garbin, F, Rare uterine cancer: carcinosarcomas. Review from histology to treatment., Crit Rev Oncol Hematol, 2015. 94 (1)(1): p. 98-104., https://pubmed.ncbi.nlm.nih.gov/25468677/
231. Zhao, S, Bellone, S, Lopez, S, Thakral, D, Schwab, C, English, DP, et.al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition., Proc Natl Acad Sci U S A, 2016. 113 (43)(43): p. 12238-12243., https://pubmed.ncbi.nlm.nih.gov/27791010/
232. Lopez-Garcia, M. A., Palacios, J., Pathologic and molecular features of uterine carcinosarcomas, Semin Diagn Pathol, 2011. 27: p. 274-86., https://www.ncbi.nlm.nih.gov/pubmed/21309261
233. Denschlag, D., Thiel, F. C., Ackermann, S., Harter, P., Juhasz-Boess, I., Mallmann, P., et.al. Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015), Geburtshilfe Frauenheilkd, 2015. 75: p. 1028-1042., https://www.ncbi.nlm.nih.gov/pubmed/26640293
234. Plotkin, A, Kuzeljevic, B, De Villa, V, Thompson, EF, Gilks, CB, Clarke, BA, et.al. Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens., Int J Gynecol Pathol, 2020. 39 (6)(6): p. 537-545., https://pubmed.ncbi.nlm.nih.gov/32281774/
235. Casey, L, Singh, N, POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting., Int J Gynecol Pathol, 2021. 40 (1)(1): p. 5-16., https://pubmed.ncbi.nlm.nih.gov/33290350/
236. Guerra, E, Matias-Guiu, X, Relevance of pathologic features in risk stratification for early-stage endometrial cancer., J Gynecol Oncol, 2021. 32 (4)(4): p. e67., https://pubmed.ncbi.nlm.nih.gov/34085800/
237. Hirschowitz, L, Nucci, M, Zaino, RJ, Problematic issues in the staging of endometrial, cervical and vulval carcinomas., Histopathology, 2013. 62 (1)(1): p. 176-202., https://pubmed.ncbi.nlm.nih.gov/PMID:, 23240675/
238. Horn, LC, Hoehn, AK, Processing and Histopathological Workup of Hysterectomy Specimens. In: Alkatout I, Mettler L (Hrsg) Hysterectomy. A Comprehensive Surgical Approach. Springer International Publishing, Cham, 2018. p. 259 - 295.
239. Argani, P., Cimino-Mathews, A., Intraoperative Frozen Sections. Diagnostic PitfallsDemos Medical Publishing, Consultant Pathology, 2014. 5:
240. Williams, J. W., Hirschowitz, L., Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas, Int J Gynecol Pathol, 2005. 25: p. 59-64., https://www.ncbi.nlm.nih.gov/pubmed/16306786
241. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H., Albo, D., Perineural invasion in cancer: a review of the literature, Cancer, 2009. 115: p. 3379-91., https://www.ncbi.nlm.nih.gov/pubmed/19484787
242. Wittekind, C., Brierley, JD., Lee, A., van Eycken, E., TNM Supplement: A Commentary on Uniform Use, 5th Edition, 2019., https://www.wiley.com/en-us/TNM+Supplement%3A+A+Commentary+on+Uniform+Use%2C+5th+Edition-p-9781119263920
243. Singh, N, Hirschowitz, L, Zaino, R, Alvarado-Cabrero, I, Duggan, MA, Ali-Fehmi, R, et.al. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S93-S113., https://pubmed.ncbi.nlm.nih.gov/30550486/
244. Folkins, AK, Nevadunsky, NS, Saleemuddin, A, Jarboe, EA, Muto, MG, Feltmate, CM, et.al. Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies., Mod Pathol, 2010. 23 (8)(8): p. 1073-9., https://pubmed.ncbi.nlm.nih.gov/20473276/
245. Wittekind, C, [Lymph nodes, tumour deposits, and TNM: are we getting better? 7th edition of UICC 2010 TNM classification of malignant tumors]., Strahlenther Onkol, 2012. 188 (2)(2): p. 191-2., https://pubmed.ncbi.nlm.nih.gov/22231635/
246. Peters, EEM, Bartosch, C, McCluggage, WG, Genestie, C, Lax, SF, Nout, R, et.al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer., Histopathology, 2019. 75 (1)(1): p. 128-136., https://pubmed.ncbi.nlm.nih.gov/31155736/
247. Qian, Y, Pollom, EL, Nwachukwu, C, Seiger, K, von Eyben, R, Folkins, AK, et.al. Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma., Gynecol Oncol, 2017. 147 (1)(1): p. 24-29., https://pubmed.ncbi.nlm.nih.gov/PMID:, 28709703/
248. Matsuo, K, Garcia-Sayre, J, Medeiros, F, Casabar, JK, Machida, H, Moeini, A, et.al. Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer., J Surg Oncol, 2015. 112 (6)(6): p. 669-76., https://pubmed.ncbi.nlm.nih.gov/26391212/
249. Barnes, EA, Martell, K, Parra-Herran, C, Taggar, AS, Donovan, E, Leung, E, Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer., Brachytherapy 20 (3)(3): p. 527-535., https://pubmed.ncbi.nlm.nih.gov/33485810/
250. Pifer, PM, Bhargava, R, Patel, AK, Ling, DC, Vargo, JA, Orr, BC, et.al. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study., Gynecol Oncol, 2020. 159 (1)(1): p. 23-29., https://pubmed.ncbi.nlm.nih.gov/32718729/
251. Winer, I, Ahmed, QF, Mert, I, Bandyopadhyay, S, Cote, M, Munkarah, AR, et.al. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?, Int J Gynecol Pathol, 2015. 34 (1)(1): p. 47-56., https://pubmed.ncbi.nlm.nih.gov/PMID:, 25473753/
252. Fader, AN, Roque, DM, Siegel, E, Buza, N, Hui, P, Abdelghany, O, et.al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis., Clin Cancer Res, 2020. 26 (15)(15): p. 3928-3935., https://pubmed.ncbi.nlm.nih.gov/32601075/
253. Buza, N, English, DP, Santin, AD, Hui, P, Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice., Mod Pathol, 2013. 26 (12)(12): p. 1605-12., https://pubmed.ncbi.nlm.nih.gov/23765245/
254. Quddus, MR, Hansen, K, Tantravahi, U, Sung, CJ, Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression., Gynecol Oncol Rep, 2020. 32 (): p. 100561., https://pubmed.ncbi.nlm.nih.gov/32258332/
255. Buza, N, HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting., Int J Gynecol Pathol, 2021. 40 (1)(1): p. 17-23., https://pubmed.ncbi.nlm.nih.gov/33290351/
256. Rottmann, D, Assem, H, Matsumoto, N, Wong, S, Hui, P, Buza, N, Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity., Int J Gynecol Pathol, 2021. 40 (3)(3): p. 263-271., https://pubmed.ncbi.nlm.nih.gov/PMID:, 32897955/
257. Jamieson, A, Thompson, EF, Huvila, J, Gilks, CB, McAlpine, JN, p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification., Int J Gynecol Cancer, 2021. 31 (6)(6): p. 907-913., https://pubmed.ncbi.nlm.nih.gov/33589443/
258. Jönsson, JM, Bååth, M, Björnheden, I, Sahin, ID, Måsbäck, A, Hedenfalk, I, Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer., Cancers (Basel), 2021. 13 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/33445465/
259. Ashley, CW, Da Cruz Paula, A, Kumar, R, Mandelker, D, Pei, X, Riaz, N, et.al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression., Gynecol Oncol, 2019. 152 (1)(1): p. 11-19., https://pubmed.ncbi.nlm.nih.gov/30415991/
260. Stephan, J. M., Hansen, J., Samuelson, M., McDonald, M., Chin, Y., Bender, D., et.al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer, Gynecol Oncol, 2014. 133: p. 499-505., https://www.ncbi.nlm.nih.gov/pubmed/24699308
261. Parkash, V, Matias-Guiu, X, Oliva, E, Malpica, A, McCluggage, WG, Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma: Results of a Web-based Survey by the International Society of Gynecological Pathologists (ISGyP)., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S3-S8., https://pubmed.ncbi.nlm.nih.gov/30550480/
262. Malpica, A, Euscher, ED, Hecht, JL, Ali-Fehmi, R, Quick, CM, Singh, N, et.al. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S9-S24., https://pubmed.ncbi.nlm.nih.gov/30550481/
263. Orezzoli, J. P., Sioletic, S., Olawaiye, A., Oliva, E., del Carmen, M. G., Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion, Gynecol Oncol, 2009. 113: p. 316-23., https://www.ncbi.nlm.nih.gov/pubmed/19345400
264. Zaino, R. J., Abendroth, C., Yemelyanova, A., Oliva, E., Lim, D., Soslow, R., et.al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible, Gynecol Oncol, 2012. 128: p. 83-7., https://www.ncbi.nlm.nih.gov/pubmed/23063759
265. Blakely, M, Liu, Y, Rahaman, J, Prasad-Hayes, M, Tismenetsky, M, Wang, X, et.al. Sentinel Lymph Node Ultra-staging as a Supplement for Endometrial Cancer Intraoperative Frozen Section Deficiencies., Int J Gynecol Pathol, 2019. 38 (1)(1): p. 52-58., https://pubmed.ncbi.nlm.nih.gov/28968296/
266. Strickland, SV, Rendi, MH, Garcia, RL, Norquist, BS, Pennington, KP, Kilgore, MR, Evaluation of Intraoperative Assessments in the Management of Endometrial Carcinoma: A Retrospective Quality Assurance Review., Int J Gynecol Pathol, 2018. 37 (5)(5): p. 414-420., https://pubmed.ncbi.nlm.nih.gov/30102260/
267. Euscher, E., Fox, P., Bassett, R., Al-Ghawi, H., Ali-Fehmi, R., Barbuto, D., et.al. The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma, Am J Surg Pathol, 2013. 37: p. 1728-36., https://www.ncbi.nlm.nih.gov/pubmed/24061515
268. Nakao, Y., Yamasaki, F., Yokoyama, M., Aihara, S., Yasunaga, M., Iwasaka, T., Minimal deviation endometrioid adenocarcinoma of the endometrium and its MRI findings, Eur J Gynaecol Oncol, 2014. 35: p. 185-7., https://www.ncbi.nlm.nih.gov/pubmed/24772926
269. Bartosch, C., Manuel Lopes, J., Oliva, E., Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features, Adv Anat Pathol, 2011. 18: p. 415-37., https://www.ncbi.nlm.nih.gov/pubmed/21993268
270. Şenol, T, Polat, M, Özkaya, E, Karateke, A, Misinterpretation of Frozen Section in Endometrial Cancer Cases: Does It Have Any Effect on Disease-free and Overall Survival?, Int J Gynecol Pathol, 2017. 36 (6)(6): p. 550-554., https://pubmed.ncbi.nlm.nih.gov/28134667/
271. Fotiou, S, Vlahos, N, Kondi-Pafiti, A, Zarganis, P, Papakonstantinou, K, Creatsas, G, Intraoperative gross assessment of myometrial invasion and cervical involvement in endometrial cancer: Role of tumor grade and size., Gynecol Oncol, 2009. 112 (3)(3): p. 517-20., https://pubmed.ncbi.nlm.nih.gov/19117598/
272. Kumar, S, Bandyopadhyay, S, Semaan, A, Shah, JP, Mahdi, H, Morris, R, et.al. The role of frozen section in surgical staging of low risk endometrial cancer., PLoS One, 2011. 6 (9)(9): p. e21912., https://pubmed.ncbi.nlm.nih.gov/PMID:, 21912633/
273. Takano, M., Ochi, H., Takei, Y., Miyamoto, M., Hasumi, Y., Kaneta, Y., et.al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?, Br J Cancer, 2013. 109: p. 1760-5., https://www.ncbi.nlm.nih.gov/pubmed/24002604
274. McCluggage, W. G., My approach to and thoughts on the typing of ovarian carcinomas, J Clin Pathol, 2008. 61: p. 152-63.
275. McCluggage, W. G., Hirschowitz, L., Wilson, G. E., Oliva, E., Soslow, R. A., Zaino, R. J., Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study, Am J Surg Pathol, 2011. 35: p. 289-94., https://www.ncbi.nlm.nih.gov/pubmed/21263250
276. Horn, L. C., Trost, M., Bilek, K., Staging of endometrial carcinoma: aspects of ovarian and cervical involvement, Int J Gynecol Pathol, 2009. 29: p. 63-6., https://www.ncbi.nlm.nih.gov/pubmed/19952935
277. Morotti, M, Menada, MV, Moioli, M, Sala, P, Maffeo, I, Abete, L, et.al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia., Gynecol Oncol, 2012. 125 (3)(3): p. 536-40., https://pubmed.ncbi.nlm.nih.gov/PMID:, 22361087/
278. Rakha, E, Wong, SC, Soomro, I, Chaudry, Z, Sharma, A, Deen, S, et.al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature., Am J Surg Pathol, 2012. 36 (11)(11): p. 1683-90., https://pubmed.ncbi.nlm.nih.gov/PMID:, 23073327/
279. Torres, M. L., Weaver, A. L., Kumar, S., Uccella, S., Famuyide, A. O., Cliby, W. A., et.al. Risk factors for developing endometrial cancer after benign endometrial sampling, Obstet Gynecol, 2012. 120: p. 998-1004., https://www.ncbi.nlm.nih.gov/pubmed/23090515
280. Vidal, F., Rafii, A., Lymph node assessment in endometrial cancer: towards personalized medicine, Obstet Gynecol Int, 2013. 2013: p. 892465., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804440/
281. Wittekind C., H.J., Meyer, TNM Klassifikation maligner TumorenWiley-VCH, 2010., http://www.wiley-vch.de/publish/dt/books/bySubjectMD00/ISBN3-527-32759-2/
282. Correction to "FIGO staging of endometrial cancer"., Int J Gynaecol Obstet, 2024. 166 (3)(3): p. 1374., https://pubmed.ncbi.nlm.nih.gov/37803501/
283. Taraboanta, C, Britton, H, Plotkin, A, Azordegan, N, Clement, PB, Gilks, CB, Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma., Int J Gynecol Pathol, 2020. 39 (1)(1): p. 19-25., https://pubmed.ncbi.nlm.nih.gov/31815891/
284. Emons, G, Beckmann, MW, Schmidt, D, Mallmann, P, New WHO Classification of Endometrial Hyperplasias., Geburtshilfe Frauenheilkd, 2015. 75 (2)(2): p. 135-136., https://pubmed.ncbi.nlm.nih.gov/25797956/
285. Singh, S, Best, C, Dunn, S, Leyland, N, Wolfman, WL, Abnormal uterine bleeding in pre-menopausal women., J Obstet Gynaecol Can, 2013. 35 (5)(5): p. 473-475., https://pubmed.ncbi.nlm.nih.gov/23756279/
286. Sakhdari, A, Moghaddam, PA, Liu, Y, Endometrial Samples From Postmenopausal Women: A Proposal for Adequacy Criteria., Int J Gynecol Pathol, 2016. 35 (6)(6): p. 525-530., https://pubmed.ncbi.nlm.nih.gov/26990506/
287. Juhasz-Böss,Ingolf, Ströder,Russalina, Schmidt,Gilda, Solomayer,Erich, Horn,Lars Christian, Herr,Daniel, Diagnostik und Therapie benigner und prämaligner Veränderungen des Endometriums, 2019///. 13(06): p. 511-529.
288. Phillips, V, McCluggage, WG, Results of a questionnaire regarding criteria for adequacy of endometrial biopsies., J Clin Pathol, 2005. 58 (4)(4): p. 417-9., https://pubmed.ncbi.nlm.nih.gov/15790709/
289. Zaino, RJ, FIGO staging of endometrial adenocarcinoma: a critical review and proposal., Int J Gynecol Pathol, 2009. 28 (1)(1): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/19047915/
290. Movahedi-Lankarani, S., Gilks, C. B., Soslow, R., Oliva, E., Protocol for the Examination of Specimens from Patients with Carcinoma of the Endometrium, 2011.
291. Robboy Sj, , Mutter G. L. , Shako-Levy R. , Bean S. M. , Prat J. , Bentley Russel P, Cutup – gross description and processing of specimens, in Robboy´s Pathology of the Female Reproductive Tract, 2009, Elsevier: Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto.
292. Ahmed, QF, Gattoc, L, Al-Wahab, Z, Abdulfatah, E, Ruterbusch, JJ, Cote, M, et.al. Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact., Am J Surg Pathol, 2015. 39 (2)(2): p. 221-6., https://pubmed.ncbi.nlm.nih.gov/25517962/
293. Kalyanasundaram, K, Ganesan, R, Perunovic, B, McCluggage, WG, Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis., Int J Surg Pathol, 2010. 18 (2)(2): p. 138-43., https://pubmed.ncbi.nlm.nih.gov/PMID:, 19117974/
294. Murray, SK, Young, RH, Scully, RE, Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance., Int J Gynecol Pathol, 2003. 22 (4)(4): p. 324-33., https://pubmed.ncbi.nlm.nih.gov/PMID:, 14501811/
295. Zaino, R., Carinelli, S. G., Ellenson, L. H., Tumours of the uterine Corpus: epithelial Tumours and Precursors, in WHO Classification of Tumours of Female Reproductive Tract, Kurman Rj, Carcangiu M. L. Herrington C. S. Young R. H.2014, IARC Press: Lyon. p. 125-126.
296. Han, G, Lim, D, Leitao, MM, Abu-Rustum, NR, Soslow, RA, Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma., Histopathology, 2014. 64 (3)(3): p. 389-98., https://pubmed.ncbi.nlm.nih.gov/PMID:, 24215212/
297. Jorge, S., Hou, J. Y., Tergas, A. I., Burke, W. M., Huang, Y., Hu, J. C., et.al. Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer, Gynecol Oncol, 2016. 140: p. 387-93., https://www.ncbi.nlm.nih.gov/pubmed/26768835
298. Wortman, BG, Creutzberg, CL, Putter, H, Jürgenliemk-Schulz, IM, Jobsen, JJ, Lutgens, LCHW, et.al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy., Br J Cancer, 2018. 119 (9)(9): p. 1067-1074., https://pubmed.ncbi.nlm.nih.gov/30356126/
299. Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., et.al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome, Am J Surg Pathol, 2006. 30: p. 230-6., https://www.ncbi.nlm.nih.gov/pubmed/16434898
300. Höhn, AK, Brambs, CE, Erber, R, Hiller, GGR, Mayr, D, Schmidt, D, et.al. [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes]., Pathologe, 2021. 42 (3)(3): p. 319-327., https://pubmed.ncbi.nlm.nih.gov/32700061/
301. Krizova, A, Clarke, BA, Bernardini, MQ, James, S, Kalloger, SE, Boerner, SL, et.al. Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review., Am J Surg Pathol, 2011. 35 (1)(1): p. 115-26., https://pubmed.ncbi.nlm.nih.gov/21164295/
302. Delair, D, Soslow, RA, Gardner, GJ, Barakat, RR, Leitao, MM, Tumoral displacement into fallopian tubes in patients undergoing robotically assisted hysterectomy for newly diagnosed endometrial cancer., Int J Gynecol Pathol, 2013. 32 (2)(2): p. 188-92., https://pubmed.ncbi.nlm.nih.gov/23370655/
303. Stewart, CJ, Doherty, DA, Havlat, M, Koay, MH, Leung, YC, Naran, A, et.al. Transtubal spread of endometrial carcinoma: correlation of intra-luminal tumour cells with tumour grade, peritoneal fluid cytology, and extra-uterine metastasis., Pathology, 2013. 45 (4)(4): p. 382-7., https://pubmed.ncbi.nlm.nih.gov/23635815/
304. Singh, R, Cho, KR, Serous Tubal Intraepithelial Carcinoma or Not? Metastases to Fallopian Tube Mucosa Can Masquerade as In Situ Lesions., Arch Pathol Lab Med, 2017. 141 (10)(10): p. 1313-1315., https://pubmed.ncbi.nlm.nih.gov/28968160/
305. Albright, BB, Black, JD, Passarelli, R, Gysler, S, Whicker, M, Altwerger, G, et.al. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer., Gynecol Oncol Rep, 2018. 23 (): p. 28-33., https://pubmed.ncbi.nlm.nih.gov/29387776/
306. Fedda, FA, Euscher, ED, Ramalingam, P, Malpica, A, Prophylactic Risk-reducing Hysterectomies and Bilateral Salpingo-oophorectomies in Patients With Lynch Syndrome: A Clinicopathologic Study of 29 Cases and Review of the Literature., Int J Gynecol Pathol, 2020. 39 (4)(4): p. 313-320., https://pubmed.ncbi.nlm.nih.gov/31851061/
307. Downes, MR, Allo, G, McCluggage, WG, Sy, K, Ferguson, SE, Aronson, M, et.al. Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing., Histopathology, 2014. 65 (2)(2): p. 228-39., https://pubmed.ncbi.nlm.nih.gov/24495259/
308. Lachiewicz, MP, Kravochuck, SE, O'Malley, MM, Heald, B, Church, JM, Kalady, MF, et.al. Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome., Gynecol Oncol, 2014. 132 (2)(2): p. 434-7., https://pubmed.ncbi.nlm.nih.gov/24211399/
309. Karamurzin, Y, Soslow, RA, Garg, K, Histologic evaluation of prophylactic hysterectomy and oophorectomy in Lynch syndrome., Am J Surg Pathol, 2013. 37 (4)(4): p. 579-85., https://pubmed.ncbi.nlm.nih.gov/23426126/
310. Lucas, E, Chen, H, Molberg, K, Castrillon, DH, Rivera Colon, G, Li, L, et.al. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?, Int J Gynecol Pathol, 2019. 38 (6)(6): p. 533-542., https://pubmed.ncbi.nlm.nih.gov/30383610/
311. de Leeuw, WJ, Dierssen, J, Vasen, HF, Wijnen, JT, Kenter, GG, Meijers-Heijboer, H, et.al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients., J Pathol, 2000. 192 (3)(3): p. 328-35., https://pubmed.ncbi.nlm.nih.gov/11054716/
312. Nieminen, TT, Gylling, A, Abdel-Rahman, WM, Nuorva, K, Aarnio, M, Renkonen-Sinisalo, L, et.al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia., Clin Cancer Res, 2009. 15 (18)(18): p. 5772-83., https://pubmed.ncbi.nlm.nih.gov/19723644/
313. Ichikawa, Y, Tsunoda, H, Takano, K, Oki, A, Yoshikawa, H, Microsatellite instability and immunohistochemical analysis of MLH1 and MSH2 in normal endometrium, endometrial hyperplasia and endometrial cancer from a hereditary nonpolyposis colorectal cancer patient., Jpn J Clin Oncol, 2002. 32 (3)(3): p. 110-2., https://pubmed.ncbi.nlm.nih.gov/11956307/
314. Vierkoetter, KR, Kagami, LA, Ahn, HJ, Shimizu, DM, Terada, KY, Loss of Mismatch Repair Protein Expression in Unselected Endometrial Adenocarcinoma Precursor Lesions., Int J Gynecol Cancer, 2016. 26 (2)(2): p. 228-32., https://pubmed.ncbi.nlm.nih.gov/26807560/
315. León-Castillo, A, de Boer, SM, Powell, ME, Mileshkin, LR, Mackay, HJ, Leary, A, et.al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy., J Clin Oncol, 2020. 38 (29)(29): p. 3388-3397., https://pubmed.ncbi.nlm.nih.gov/32749941/
316. Mills, AM, Longacre, TA, Lynch Syndrome Screening in the Gynecologic Tract: Current State of the Art., Am J Surg Pathol, 2016. 40 (4)(4): p. e35-44., https://pubmed.ncbi.nlm.nih.gov/26872009/
317. Cho, KR, Cooper, K, Croce, S, Djordevic, B, Herrington, S, Howitt, B, et.al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S114-S122., https://pubmed.ncbi.nlm.nih.gov/29521846/
318. Eggink, FA, Van Gool, IC, Leary, A, Pollock, PM, Crosbie, EJ, Mileshkin, L, et.al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies , Oncoimmunology 6 (2)(2): p. e1264565., https://pubmed.ncbi.nlm.nih.gov/28344870/
319. Green, A. K., Feinberg, J., Makker, V., A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer, Am Soc Clin Oncol Educ Book, 2020. 40: p. 1-7., https://pubmed.ncbi.nlm.nih.gov/32213091/
320. Reijnen, C, Küsters-Vandevelde, HVN, Prinsen, CF, Massuger, LFAG, Snijders, MPML, Kommoss, S, et.al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer., Gynecol Oncol, 2019. 154 (1)(1): p. 124-130., https://pubmed.ncbi.nlm.nih.gov/31103324/
321. Zakhour, M, Cohen, JG, Gibson, A, Walts, AE, Karimian, B, Baltayan, A, et.al. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series., BJOG, 2017. 124 (10)(10): p. 1576-1583., https://pubmed.ncbi.nlm.nih.gov/28128512/
322. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Kolorektales Karzinom, Version 2.1, Januar 2019, AWMF-Registernummer: 021/007OL, 2019., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Kolorektales_Karzinom/Version_2/LL_KRK_Langversion_2.1.pdf
323. Ryan, NAJ, McMahon, R, Tobi, S, Snowsill, T, Esquibel, S, Wallace, AJ, et.al. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study., PLoS Med, 2020. 17 (9)(9): p. e1003263., https://pubmed.ncbi.nlm.nih.gov/32941469/
324. Stelloo, E, Jansen, AML, Osse, EM, Nout, RA, Creutzberg, CL, Ruano, D, et.al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer., Ann Oncol, 2017. 28 (1)(1): p. 96-102., https://pubmed.ncbi.nlm.nih.gov/27742654/
325. Niu, BT, Hammond, RFL, Leen, SLS, Gilks, CB, Singh, N, Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma., Histopathology, 2019. 75 (3)(3): p. 442-445., https://pubmed.ncbi.nlm.nih.gov/31077605/
326. Josef Rüschoff, Gustavo Baretton, Hendrik Bläker et al., MSI-Testung. Was ist neu? Was ist zu beachten?, Der Pathologe, 2021. 42: p. 414–423.
327. Raffone, A, Travaglino, A, Cerbone, M, Gencarelli, A, Mollo, A, Insabato, L, et.al. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer., Pathol Oncol Res, 2020. 26 (3)(3): p. 1417-1427., https://pubmed.ncbi.nlm.nih.gov/32377987/
328. Amirkaveh Mojtahed, Iris Schrijver, James M Ford et al., A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas, Modern Pathology, 2011. 24: p. 1004–1014.
329. Sari, A, Pollett, A, Eiriksson, LR, Lumsden-Johanson, B, Van de Laar, E, Kazerouni, H, et.al. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas., Am J Surg Pathol, 2019. 43 (5)(5): p. 591-600., https://pubmed.ncbi.nlm.nih.gov/30864976/
330. Stinton, C, Fraser, H, Al-Khudairy, L, Court, R, Jordan, M, Grammatopoulos, D, et.al. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy., Gynecol Oncol, 2021. 160 (1)(1): p. 148-160., https://pubmed.ncbi.nlm.nih.gov/33190932/
331. Timmerman, S, Van Rompuy, AS, Van Gorp, T, Vanden Bempt, I, Brems, H, Van Nieuwenhuysen, E, et.al. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D., Gynecol Oncol, 2020. 157 (1)(1): p. 245-251., https://pubmed.ncbi.nlm.nih.gov/31980219/
332. Bruegl, AS, Kernberg, A, Broaddus, RR, Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer., Adv Anat Pathol, 2017. 24 (6)(6): p. 372-378., https://pubmed.ncbi.nlm.nih.gov/28820751/
333. Engel, KB, Moore, HM, Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue., Arch Pathol Lab Med, 2011. 135 (5)(5): p. 537-43., https://pubmed.ncbi.nlm.nih.gov/21526952/
334. Bass, BP, Engel, KB, Greytak, SR, Moore, HM, A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen?, Arch Pathol Lab Med, 2014. 138 (11)(11): p. 1520-30., https://pubmed.ncbi.nlm.nih.gov/25357115/
335. Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., et.al. Mutational landscape and significance across 12 major cancer types, Nature, 2013. 502: p. 333-9., https://www.ncbi.nlm.nih.gov/pubmed/24132290
336. Stelloo, E, Nout, RA, Osse, EM, Jürgenliemk-Schulz, IJ, Jobsen, JJ, Lutgens, LC, et.al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts., Clin Cancer Res, 2016. 22 (16)(16): p. 4215-24., https://pubmed.ncbi.nlm.nih.gov/27006490/
337. Burleigh, A., Talhouk, A., Gilks, C. B., McAlpine, J. N., Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors, Gynecol Oncol, 2015. 138: p. 141-6., https://www.ncbi.nlm.nih.gov/pubmed/25870916
338. Pilarski, R, None, Cancers (Basel), 2019. 11 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/31216739/
339. de Jonge, MM, Ritterhouse, LL, de Kroon, CD, Vreeswijk, MPG, Segal, JP, Puranik, R, et.al. Germline , Clin Cancer Res, 2019. 25 (24)(24): p. 7517-7526., https://pubmed.ncbi.nlm.nih.gov/31492746/
340. Vietri, MT, D'Elia, G, Caliendo, G, Casamassimi, A, Federico, A, Passariello, L, et.al. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer., Med Oncol, 2021. 38 (2)(2): p. 13., https://pubmed.ncbi.nlm.nih.gov/33484353/
341. Lawrence, J, Richer, L, Arseneau, J, Zeng, X, Chong, G, Weber, E, et.al. Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort., Curr Oncol, 2021. 28 (1)(1): p. 509-522., https://pubmed.ncbi.nlm.nih.gov/33467402/
342. Kahn, RM, Gordhandas, S, Maddy, BP, Baltich Nelson, B, Askin, G, Christos, PJ, et.al. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?, Cancer, 2019. 125 (18)(18): p. 3172-3183., https://pubmed.ncbi.nlm.nih.gov/31150123/
343. Pasanen, A, Loukovaara, M, Bützow, R, Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma., Mod Pathol, 2020. 33 (7)(7): p. 1443-1452., https://pubmed.ncbi.nlm.nih.gov/32060377/
344. Dillon, JL, Gonzalez, JL, DeMars, L, Bloch, KJ, Tafe, LJ, Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome., Hum Pathol, 2017. 70 (): p. 121-128., https://pubmed.ncbi.nlm.nih.gov/29107668/
345. Spinosa, D, Acosta, T, Wong, J, Kurtovic, K, Mewshaw, J, Collins, S, et.al. Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative., Gynecol Oncol, 2021. 160 (1)(1): p. 169-174., https://pubmed.ncbi.nlm.nih.gov/33393478/
346. Weinstein, JN, Collisson, EA, Mills, GB, Shaw, KR, Ozenberger, BA, Ellrott, K, et.al. The Cancer Genome Atlas Pan-Cancer analysis project., Nat Genet, 2013. 45 (10)(10): p. 1113-20., https://pubmed.ncbi.nlm.nih.gov/24071849/
347. Talhouk, A, McConechy, MK, Leung, S, Li-Chang, HH, Kwon, JS, Melnyk, N, et.al. A clinically applicable molecular-based classification for endometrial cancers., Br J Cancer, 2015. 113 (2)(2): p. 299-310., https://pubmed.ncbi.nlm.nih.gov/26172027/
348. Carlson, J, McCluggage, WG, Reclassifying endometrial carcinomas with a combined morphological and molecular approach., Curr Opin Oncol, 2019. 31 (5)(5): p. 411-419., https://pubmed.ncbi.nlm.nih.gov/31261170/
349. DeLair, DF, Burke, KA, Selenica, P, Lim, RS, Scott, SN, Middha, S, et.al. The genetic landscape of endometrial clear cell carcinomas., J Pathol, 2017. 243 (2)(2): p. 230-241., https://pubmed.ncbi.nlm.nih.gov/28718916/
350. Lax, Sigurd F., Pathology of Endometrial Carcinoma, in Molecular Genetics of Endometrial Carcinoma, Hedrick Ellenson, Lora , Editor. 2017, Springer International Publishing: Cham. p. 75-96., https://doi.org/10.1007/978-3-319-43139-0_3
351. Talhouk, A., Hoang, L. N., McConechy, M. K., Nakonechny, Q., Leo, J., Cheng, A., et.al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment, Gynecol Oncol, 2016. 143: p. 46-53., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421949/
352. Kommoss, S, McConechy, MK, Kommoss, F, Leung, S, Bunz, A, Magrill, J, et.al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series., Ann Oncol, 2018. 29 (5)(5): p. 1180-1188., https://pubmed.ncbi.nlm.nih.gov/29432521/
353. Brett, MA, Atenafu, EG, Singh, N, Ghatage, P, Clarke, BA, Nelson, GS, et.al. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma., Int J Gynecol Pathol, 2021. 40 (2)(2): p. 116-123., https://pubmed.ncbi.nlm.nih.gov/32265358/
354. Wortman, B. G., Bosse, T., Nout, R. A., Lutgens, Lchw, van der Steen-Banasik, E. M., Westerveld, H., et.al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial, Gynecol Oncol, 2018. 151(1): p. 69-75.
355. Marnitz, S, Walter, T, Schömig-Markiefka, B, Engler, T, Kommoss, S, Brucker, SY, A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?, Cancers (Basel), 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32927671/
356. Van Gool, IC, Rayner, E, Osse, EM, Nout, RA, Creutzberg, CL, Tomlinson, IPM, et.al. Adjuvant Treatment for , Clin Cancer Res, 2018. 24 (13)(13): p. 3197-3203., https://pubmed.ncbi.nlm.nih.gov/29559562/
357. Kim, SR, Cloutier, BT, Leung, S, Cochrane, D, Britton, H, Pina, A, et.al. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification., Gynecol Oncol, 2020. 158 (1)(1): p. 3-11., https://pubmed.ncbi.nlm.nih.gov/32331700/
358. Travaglino, A, Raffone, A, Gencarelli, A, Mollo, A, Guida, M, Insabato, L, et.al. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma., Pathol Oncol Res, 2020. 26 (4)(4): p. 2067-2073., https://pubmed.ncbi.nlm.nih.gov/32472441/
359. Travaglino, A, Raffone, A, Mollo, A, Borrelli, G, Alfano, P, Zannoni, GF, et.al. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma., Arch Gynecol Obstet, 2020. 301 (5)(5): p. 1117-1125., https://pubmed.ncbi.nlm.nih.gov/32253551/
360. Coll-de la Rubia, E, Martinez-Garcia, E, Dittmar, G, Gil-Moreno, A, Cabrera, S, Colas, E, Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis., J Clin Med, 2020. 9 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/32560580/
361. Bosse, T, Nout, RA, McAlpine, JN, McConechy, MK, Britton, H, Hussein, YR, et.al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups., Am J Surg Pathol, 2018. 42 (5)(5): p. 561-568., https://pubmed.ncbi.nlm.nih.gov/29505428/
362. Van Gool, IC, Ubachs, JEH, Stelloo, E, de Kroon, CD, Goeman, JJ, Smit, VTHBM, et.al. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing., Histopathology, 2018. 72 (2)(2): p. 248-258., https://pubmed.ncbi.nlm.nih.gov/28795426/
363. Devereaux, K., Steiner, D., Ho, C., A multiplex ANaPshot assay is a rapid and cost-effective method for detecting POLE mutations in endometrial carcinoma, Mod Pathol, 2020. 33 (Suppl2): p. 1040.
364. Köbel, M, Kang, EY, The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting., Int J Gynecol Pathol, 2021. 40 (1)(1): p. 32-40., https://pubmed.ncbi.nlm.nih.gov/33290354/
365. Singh, N, Piskorz, AM, Bosse, T, Jimenez-Linan, M, Rous, B, Brenton, JD, et.al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies., J Pathol, 2020. 250 (3)(3): p. 336-345., https://pubmed.ncbi.nlm.nih.gov/31829441/
366. Raffone, A, Travaglino, A, Cerbone, M, De Luca, C, Russo, D, Di Maio, A, et.al. Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer., Pathol Res Pract, 2020. 216 (8)(8): p. 153025., https://pubmed.ncbi.nlm.nih.gov/32703491/
367. Tashiro, K, Nakano, T, Honjo, T, Signal sequence trap. Expression cloning method for secreted proteins and type 1 membrane proteins., Methods Mol Biol, 1997. 69 (): p. 203-19., https://pubmed.ncbi.nlm.nih.gov/9116854/
368. Köbel, M, Ronnett, BM, Singh, N, Soslow, RA, Gilks, CB, McCluggage, WG, Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S123-S131., https://pubmed.ncbi.nlm.nih.gov/29517499/
369. Nastic, D, Shanwell, E, Wallin, KL, Valla, M, Måsbäck, A, Mateoiu, C, et.al. A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis., Int J Gynecol Pathol, 2017. 36 (4)(4): p. 339-347., https://pubmed.ncbi.nlm.nih.gov/28244894/
370. van Esterik, M, Van Gool, IC, de Kroon, CD, Nout, RA, Creutzberg, CL, Smit, VTHBM, et.al. Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer., Oncotarget, 2017. 8 (15)(15): p. 25542-25551., https://pubmed.ncbi.nlm.nih.gov/28424422/
371. Moroney, MR, Davies, KD, Wilberger, AC, Sheeder, J, Post, MD, Berning, AA, et.al. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers., Gynecol Oncol, 2019. 153 (3)(3): p. 517-520., https://pubmed.ncbi.nlm.nih.gov/30910249/
372. Costigan, DC, Dong, F, Nucci, MR, Howitt, BE, Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma., Int J Gynecol Pathol, 2020. 39 (2)(2): p. 119-127., https://pubmed.ncbi.nlm.nih.gov/30702464/
373. van den Heerik, ASVM, Horeweg, N, Nout, RA, Lutgens, LCHW, van der Steen-Banasik, EM, Westerveld, GH, et.al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer., Int J Gynecol Cancer, 2020. 30 (12)(12): p. 2002-2007., https://pubmed.ncbi.nlm.nih.gov/33046573/
374. De Leo, A, de Biase, D, Lenzi, J, Barbero, G, Turchetti, D, Grillini, M, et.al. None, Cancers (Basel), 2021. 13 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/33668727/
375. Kommoss, FK, Karnezis, AN, Kommoss, F, Talhouk, A, Taran, FA, Staebler, A, et.al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile., Br J Cancer, 2018. 119 (4)(4): p. 480-486., https://pubmed.ncbi.nlm.nih.gov/30050154/
376. Berek, JS, Matias-Guiu, X, Creutzberg, C, Fotopoulou, C, Gaffney, D, Kehoe, S, et.al. FIGO staging of endometrial cancer: 2023., Int J Gynaecol Obstet, 2023. 162 (2)(2): p. 383-394., https://pubmed.ncbi.nlm.nih.gov/37337978/
377. Jumaah, AS, Al-Haddad, HS, McAllister, KA, Yasseen, AA, The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis., PLoS One, 2022. 17 (2)(2): p. e0263585., https://pubmed.ncbi.nlm.nih.gov/35139130/
378. León-Castillo, A, Britton, H, McConechy, MK, McAlpine, JN, Nout, R, Kommoss, S, et.al. Interpretation of somatic POLE mutations in endometrial carcinoma., J Pathol, 2020. 250 (3)(3): p. 323-335., https://pubmed.ncbi.nlm.nih.gov/31829442/
379. Dorca, E, Velasco, A, Varela, M, Gatius, S, Villatoro, S, Fullana, N, et.al. Validation of Modaplex POLE mutation assay in endometrial carcinoma., Virchows Arch, 2023. 483 (6)(6): p. 787-794., https://pubmed.ncbi.nlm.nih.gov/37874375/
380. Talhouk, A, Jamieson, A, Crosbie, EJ, Taylor, A, Chiu, D, Leung, S, et.al. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol., Int J Gynecol Pathol, 2023. 42 (4)(4): p. 353-363., https://pubmed.ncbi.nlm.nih.gov/36731023/
381. Hammer, PM, Momeni-Boroujeni, A, Kolin, DL, Kingsley, L, Folkins, A, Geisick, RLP, et.al. POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases., Mod Pathol, 2025. 38 (3)(3): p. 100676., https://pubmed.ncbi.nlm.nih.gov/39615841/
382. Stelloo, E, Nout, RA, Naves, LC, Ter Haar, NT, Creutzberg, CL, Smit, VT, et.al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma., Gynecol Oncol, 2014. 133 (2)(2): p. 197-204., https://pubmed.ncbi.nlm.nih.gov/24556061/
383. Fumet, JD, Limagne, E, Thibaudin, M, Truntzer, C, Bertaut, A, Rederstorff, E, et.al. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment., BMC Cancer, 2020. 20 (1)(1): p. 748., https://pubmed.ncbi.nlm.nih.gov/32778095/
384. Sloan, EA, Ring, KL, Willis, BC, Modesitt, SC, Mills, AM, PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors., Am J Surg Pathol, 2017. 41 (3)(3): p. 326-333., https://pubmed.ncbi.nlm.nih.gov/27984238/
385. Kir, G, Olgun, ZC, Soylemez, T, Aydin, A, Demircan, B, Kaya, IA, et.al. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups., Int J Gynecol Pathol, 2020. Publish Ahead of Print ():, https://pubmed.ncbi.nlm.nih.gov/33332859/
386. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR), 2015., https://www.ncbi.nlm.nih.gov/pubmed/26089092
387. Skala, S. L., Hagemann, I. S., Optimal sampling of grossly normal omentum in staging of gynecologic malignancies, Int J Gynecol Pathol, 2015. 34: p. 281-7., https://www.ncbi.nlm.nih.gov/pubmed/25760907
388. Gilks, C. B., Movahedi-Lankarani, S., Baker, P. M., Otis, C. N., Protocol for the Examination of Specimens From Patients With Primary Tumors of the Ovary or Fallopian Tube, 2016.
389. McCluggage, WG, Judge, MJ, Clarke, BA, Davidson, B, Gilks, CB, Hollema, H, et.al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)., Mod Pathol, 2015. 28 (8)(8): p. 1101-22., https://pubmed.ncbi.nlm.nih.gov/26089092/
390. Ulker, V, Tunca, A, Numanoglu, C, Akbayir, O, Akyol, A, Erim, A, et.al. Should omentectomy be a part of surgical staging in patients with endometrioid adenocarcinoma of the uterine corpus?, Gynecol Obstet Invest, 2014. 77 (1)(1): p. 58-63., https://pubmed.ncbi.nlm.nih.gov/24356379/
391. Sakai, K., Yamagami, W., Susumu, N., Nomura, H., Kataoka, F., Banno, K., et.al. Pathological factors associated with omental metastases in endometrial cancer, Eur J Gynaecol Oncol, 2015. 36: p. 397-401., https://www.ncbi.nlm.nih.gov/pubmed/26390690
392. Horn, LC, Beckmann, MW, Follmann, M, Koch, MC, Mallmann, P, Marnitz, S, et.al. [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology]., Pathologe, 2015. 36 (6)(6): p. 585-93., https://pubmed.ncbi.nlm.nih.gov/26483249/
393. Multinu, F, Casarin, J, Cappuccio, S, Keeney, GL, Glaser, GE, Cliby, WA, et.al. Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer., Gynecol Oncol, 2019. 154 (1)(1): p. 60-64., https://pubmed.ncbi.nlm.nih.gov/31126637/
394. Ignatov, A, Lebius, C, Ignatov, T, Ivros, S, Knueppel, R, Papathemelis, T, et.al. Lymph node micrometastases and outcome of endometrial cancer., Gynecol Oncol, 2019. 154 (3)(3): p. 475-479., https://pubmed.ncbi.nlm.nih.gov/31345606/
395. Plante, M, Stanleigh, J, Renaud, MC, Sebastianelli, A, Grondin, K, Grégoire, J, Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?, Gynecol Oncol, 2017. 146 (2)(2): p. 240-246., https://pubmed.ncbi.nlm.nih.gov/28577885/
396. García Pineda, V, Hernández Gutiérrez, A, Gracia Segovia, M, Siegrist Ridruejo, J, Diestro Tejeda, MD, Zapardiel, I, Low-Volume Nodal Metastasis in Endometrial Cancer: Risk Factors and Prognostic Significance., J Clin Med, 2020. 9 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/32630498/
397. Rossi, EC, Kowalski, LD, Scalici, J, Cantrell, L, Schuler, K, Hanna, RK, et.al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study., Lancet Oncol, 2017. 18 (3)(3): p. 384-392., https://pubmed.ncbi.nlm.nih.gov/28159465/
398. Bogani, G, Murgia, F, Ditto, A, Raspagliesi, F, Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis., Gynecol Oncol, 2019. 153 (3)(3): p. 676-683., https://pubmed.ncbi.nlm.nih.gov/30952370/
399. Gómez-Hidalgo, NR, Ramirez, PT, Ngo, B, Pérez-Hoyos, S, Coreas, N, Sanchez-Iglesias, JL, et.al. Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis., Clin Transl Oncol, 2020. 22 (8)(8): p. 1272-1279., https://pubmed.ncbi.nlm.nih.gov/31863354/
400. Zanfagnin, V, Huang, Y, Mc Gree, ME, Weaver, AL, Casarin, J, Multinu, F, et.al. Predictors of extensive lymphatic dissemination and recurrences in node-positive endometrial cancer., Gynecol Oncol, 2019. 154 (3)(3): p. 480-486., https://pubmed.ncbi.nlm.nih.gov/31324453/
401. McCluggage, W. G., Colgan, T., Duggan, M., Hacker, N. F., Mulvany, N., Otis, C., et.al. Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia, Int J Gynecol Pathol, 2012. 32: p. 45-65., https://www.ncbi.nlm.nih.gov/pubmed/23202790
402. Euscher, ED, Malpica, A, Gynaecological malignancies and sentinel lymph node mapping: an update., Histopathology, 2020. 76 (1)(1): p. 139-150., https://pubmed.ncbi.nlm.nih.gov/31846525/
403. Abu-Rustum, NR, Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging., J Natl Compr Canc Netw, 2014. 12 (2)(2): p. 288-97., https://pubmed.ncbi.nlm.nih.gov/24586087/
404. Euscher, E, Sui, D, Soliman, P, Westin, S, Ramalingam, P, Bassett, R, et.al. Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods., Int J Gynecol Pathol, 2018. 37 (3)(3): p. 242-251., https://pubmed.ncbi.nlm.nih.gov/28700425/
405. Burg, LC, Hengeveld, EM, In 't Hout, J, Bulten, J, Bult, P, Zusterzeel, PLM, Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review., Int J Gynecol Cancer, 2021. 31 (5)(5): p. 744-753., https://pubmed.ncbi.nlm.nih.gov/33187974/
406. Holloway, RW, Abu-Rustum, NR, Backes, FJ, Boggess, JF, Gotlieb, WH, Jeffrey Lowery, W, et.al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations., Gynecol Oncol, 2017. 146 (2)(2): p. 405-415., https://pubmed.ncbi.nlm.nih.gov/28566221/
407. Tu, H, Gu, HF, Huang, H, Liu, KJ, Yun, JP, Chen, JP, et.al. Sectioning protocol determines accuracy of intraoperative pathological examination of sentinel lymph node in cervical cancer: A systematic review and meta-analysis., Gynecol Oncol, 2020. 158 (2)(2): p. 489-497., https://pubmed.ncbi.nlm.nih.gov/32507651/
408. Abu-Rustum, NR, Yashar, CM, Bradley, K, Campos, SM, Chino, J, Chon, HS, et.al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021., J Natl Compr Canc Netw, 2021. 19 (8)(8): p. 888-895., https://pubmed.ncbi.nlm.nih.gov/34416706/
409. Pacaut, C, Bourmaud, A, Rivoirard, R, Moriceau, G, Guy, JB, Collard, O, et.al. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy., Am J Clin Oncol, 2015. 38 (3)(3): p. 272-7., https://pubmed.ncbi.nlm.nih.gov/23751320/
410. Oz, M, Korkmaz, V, Meydanli, MM, Sari, ME, Cuylan, ZF, Gungor, T, Is Tumor Size Really Important for Prediction of Lymphatic Dissemination in Grade 1 Endometrial Carcinoma With Superficial Myometrial Invasion?, Int J Gynecol Cancer, 2017. 27 (7)(7): p. 1393-1398., https://pubmed.ncbi.nlm.nih.gov/28604451/
411. Tejerizo-Garcia, A., Jimenez-Lopez, J. S., Munoz-Gonzalez, J. L., Bartolome-Sotillos, S., Marqueta-Marques, L., Lopez-Gonzalez, G., et.al. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients, Onco Targets Ther, 2013. 9: p. 1305-13., https://www.ncbi.nlm.nih.gov/pubmed/24092993
412. Morice, P, Leary, A, Creutzberg, C, Abu-Rustum, N, Darai, E, Endometrial cancer., Lancet, 2016. 387 (10023)(10023): p. 1094-1108., https://pubmed.ncbi.nlm.nih.gov/26354523/
413. Kihara, A, Yoshida, H, Watanabe, R, Takahashi, K, Kato, T, Ino, Y, et.al. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma., Am J Surg Pathol, 2017. 41 (7)(7): p. 896-905., https://pubmed.ncbi.nlm.nih.gov/28418994/
414. Joehlin-Price, AS, McHugh, KE, Stephens, JA, Li, Z, Backes, FJ, Cohn, DE, et.al. The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas., Am J Surg Pathol, 2017. 41 (1)(1): p. 49-55., https://pubmed.ncbi.nlm.nih.gov/27740968/
415. Rau, TT, Bettschen, E, Büchi, C, Christe, L, Rohner, A, Müller, MD, et.al. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups., Mod Pathol, 2021. 34 (1)(1): p. 222-232., https://pubmed.ncbi.nlm.nih.gov/32728223/
416. Steiner, E., Einenkel, J., Schmidt, D., Horn, L. C., Prädiktive und prognostische Marker beim Endometriumkarzinom, Der Onkologe, 2012., https://www.researchgate.net/publication/257455370_Pradiktive_und_prognostische_Marker_beim_Endometriumkarzinom
417. Zhang, Y, Zhao, D, Gong, C, Zhang, F, He, J, Zhang, W, et.al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis., World J Surg Oncol, 2015. 13 (): p. 208., https://pubmed.ncbi.nlm.nih.gov/26108802/
418. Creutzberg, C. L., van Stiphout, R. G., Nout, R. A., Lutgens, L. C., Jurgenliemk-Schulz, I. M., Jobsen, J. J., et.al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials, Int J Radiat Oncol Biol Phys, 2015. 91: p. 530-9., https://www.ncbi.nlm.nih.gov/pubmed/25680597
419. Miller, MD, Salinas, EA, Newtson, AM, Sharma, D, Keeney, ME, Warrier, A, et.al. An integrated prediction model of recurrence in endometrial endometrioid cancers., Cancer Manag Res, 2019. 11 (): p. 5301-5315., https://pubmed.ncbi.nlm.nih.gov/31239780/
420. Salinas, EA, Miller, MD, Newtson, AM, Sharma, D, McDonald, ME, Keeney, ME, et.al. A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables., Int J Mol Sci, 2019. 20 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/30857319/
421. Travaglino, A, Raffone, A, Saccone, G, D'Alessandro, P, Arduino, B, de Placido, G, et.al. Significant risk of occult cancer in complex non-atypical endometrial hyperplasia., Arch Gynecol Obstet, 2019. 300 (5)(5): p. 1147-1154., https://pubmed.ncbi.nlm.nih.gov/31531779/
422. Trimble, C. L., Method, M., Leitao, M., Lu, K., Ioffe, O., Hampton, M., et.al. Management of endometrial precancers, Obstet Gynecol, 2012. 120: p. 1160-75., https://www.ncbi.nlm.nih.gov/pubmed/23090535
423. Chan, J. K., Wu, H., Cheung, M. K., Shin, J. Y., Osann, K., Kapp, D. S., The outcomes of 27,063 women with unstaged endometrioid uterine cancer, Gynecol Oncol, 2007. 106: p. 282-8., https://www.ncbi.nlm.nih.gov/pubmed/17662377
424. Antonsen, S. L., Ulrich, L., Hogdall, C., Patients with atypical hyperplasia of the endometrium should be treated in oncological centers, Gynecol Oncol, 2011. 125: p. 124-8., https://www.ncbi.nlm.nih.gov/pubmed/22198048
425. S3-Leitlinie Indikation und Methodik der Hysterektomie bei benignen Erkrankungen, Langversion 1.2, 2015., https://www.awmf.org/leitlinien/detail/ll/015-070.html
426. Wang, YQ, Kang, N, Li, LW, Wang, ZQ, Zhou, R, Shen, DH, et.al. [Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia]., Zhonghua Fu Chan Ke Za Zhi, 2022. 57 (9)(9): p. 692-700., https://pubmed.ncbi.nlm.nih.gov/36177581/
427. Zhang, X, Chen, D, Zhao, X, Wang, C, He, Y, Chen, Y, et.al. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia., Pathol Res Pract, 2023. 241 (): p. 154278., https://pubmed.ncbi.nlm.nih.gov/36580798/
428. Matsuo, K, Ciesielski, KM, Mandelbaum, RS, Lee, MW, Jooya, ND, Roman, LD, et.al. Lymph node evaluation for endometrial hyperplasia: a nationwide analysis of minimally invasive hysterectomy in the ambulatory setting., Surg Endosc, 2023. 37 (8)(8): p. 6163-6171., https://pubmed.ncbi.nlm.nih.gov/37157034/
429. Capozzi, VA, Sozzi, G, Butera, D, Chiantera, V, Ghi, T, Berretta, R, Nodal Assessment in Endometrial Atypical Hyperplasia., Gynecol Obstet Invest, 2022. 87 (3-4)(3-4): p. 226-231., https://pubmed.ncbi.nlm.nih.gov/35793641/
430. Sullivan, MW, Philp, L, Kanbergs, AN, Safdar, N, Oliva, E, Bregar, A, et.al. Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions., Gynecol Oncol, 2021. 162 (3)(3): p. 613-618., https://pubmed.ncbi.nlm.nih.gov/34247769/
431. Touhami, O, Grégoire, J, Renaud, MC, Sebastianelli, A, Grondin, K, Plante, M, The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia., Gynecol Oncol, 2018. 148 (3)(3): p. 485-490., https://pubmed.ncbi.nlm.nih.gov/29290489/
432. Polcher, M., Hauptmann, S., Fotopoulou, C., Schmalfeldt, B., Meinhold-Heerlein, I., Mustea, A., et.al. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO, Arch Gynecol Obstet, 2015. 292: p. 231-4., https://www.ncbi.nlm.nih.gov/pubmed/25914073
433. Sun, C., Chen, G., Yang, Z., Jiang, J., Yang, X., Li, N., et.al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis, Fertil Steril, 2013. 100: p. 782-7., https://www.ncbi.nlm.nih.gov/pubmed/23830105
434. Gu, Y., Zhou, X., Zhang, S. L., Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk, Genet Mol Res, 2011. 10: p. 3609-19.
435. Taşkın, S, Kan, Ö, Dai, Ö, Taşkın, EA, Koyuncu, K, Alkılıç, A, et.al. Lymph node dissection in atypical endometrial hyperplasia., J Turk Ger Gynecol Assoc, 2017. 18 (3)(3): p. 127-132., https://pubmed.ncbi.nlm.nih.gov/28890426/
436. Mueller, JJ, Rios-Doria, E, Park, KJ, Broach, VA, Alektiar, KM, Jewell, EL, et.al. Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?, Gynecol Oncol, 2023. 168 (): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/36334496/
437. Matanes, E, Amajoud, Z, Kogan, L, Mitric, C, Ismail, S, Raban, O, et.al. Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?, Gynecol Oncol, 2023. 168 (): p. 107-113., https://pubmed.ncbi.nlm.nih.gov/36423445/
438. Mandelbaum, RS, Ciccone, MA, Nusbaum, DJ, Khoshchehreh, M, Purswani, H, Morocco, EB, et.al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy., Am J Obstet Gynecol, 2020. 223 (1)(1): p. 103.e1-103.e13., https://pubmed.ncbi.nlm.nih.gov/31978437/
439. Mittermeier, T, Farrant, C, Wise, MR, Levonorgestrel-releasing intrauterine system for endometrial hyperplasia., Cochrane Database Syst Rev, 2020. 9 (9)(9): p. CD012658., https://pubmed.ncbi.nlm.nih.gov/32909630/
440. Luo, L., Luo, B., Zheng, Y., Zhang, H., Li, J., Sidell, N., Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia, Cochrane Database Syst Rev, 2013. 6: p. CD009458., https://www.ncbi.nlm.nih.gov/pubmed/23737032
441. Gunderson, C. C., Fader, A. N., Carson, K. A., Bristow, R. E., Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review, Gynecol Oncol, 2012. 125: p. 477-82., https://www.ncbi.nlm.nih.gov/pubmed/22245711
442. Gallos, I. D., Yap, J., Rajkhowa, M., Luesley, D. M., Coomarasamy, A., Gupta, J. K., Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis, Am J Obstet Gynecol, 2012. 207: p. 266.e1-12., https://www.ncbi.nlm.nih.gov/pubmed/23021687
443. Baker, J., Obermair, A., Gebski, V., Janda, M., Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature, Gynecol Oncol, 2012. 125: p. 263-70., https://www.ncbi.nlm.nih.gov/pubmed/22196499
444. Koskas, M., Uzan, J., Luton, D., Rouzier, R., Darai, E., Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis, Fertil Steril, 2014. 101: p. 785-94., https://www.ncbi.nlm.nih.gov/pubmed/24388202
445. Clement, NS, Oliver, TR, Shiwani, H, Sanner, JR, Mulvaney, CA, Atiomo, W, Metformin for endometrial hyperplasia., Cochrane Database Syst Rev, 2017. 10 (): p. CD012214., https://pubmed.ncbi.nlm.nih.gov/29077194/
446. Tehranian, A, Ghahghaei-Nezamabadi, A, Arab, M, Khalagi, K, Aghajani, R, Sadeghi, S, The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial., J Gynecol Obstet Hum Reprod, 2021. 50 (6)(6): p. 101863., https://pubmed.ncbi.nlm.nih.gov/32652300/
447. Matsuo, K, Mandelbaum, RS, Ciccone, M, Khoshchehreh, M, Pursuwani, H, Morocco, EB, et.al. Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia., Int J Gynecol Cancer, 2020. 30 (9)(9): p. 1331-1339., https://pubmed.ncbi.nlm.nih.gov/32376736/
448. Yang, BY, Gulinazi, Y, Du, Y, Ning, CC, Cheng, YL, Shan, WW, et.al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial., BJOG, 2020. 127 (7)(7): p. 848-857., https://pubmed.ncbi.nlm.nih.gov/31961463/
449. Walsh, C., Holschneider, C., Hoang, Y., Tieu, K., Karlan, B., Cass, I., Coexisting ovarian malignancy in young women with endometrial cancer, Obstet Gynecol, 2005. 106: p. 693-9., https://www.ncbi.nlm.nih.gov/pubmed/16199623
450. Williams, M. G., Bandera, E. V., Demissie, K., Rodriguez-Rodriguez, L., Synchronous primary ovarian and endometrial cancers: a population-based assessment of survival, Obstet Gynecol, 2009. 113: p. 783-9., https://www.ncbi.nlm.nih.gov/pubmed/19305320
451. Oranratanaphan, S., Manchana, T., Sirisabya, N., Clinicopathologic variables and survival comparison of patients with synchronous endometrial and ovarian cancers versus primary endometrial cancer with ovarian metastasis, Asian Pac J Cancer Prev, 2008. 9: p. 403-7., https://www.ncbi.nlm.nih.gov/pubmed/18990010
452. Akbayir, O., Kuru, O., Goksedef, P., Numanoglu, C., Corbacioglu, A., Cetin, A., Coexisting ovarian malignancy in patients with clinical stage I endometrial carcinoma, Arch Gynecol Obstet, 2012. 286: p. 1241-5., https://www.ncbi.nlm.nih.gov/pubmed/22688443
453. Duska, L. R., Garrett, A., Rueda, B. R., Haas, J., Chang, Y., Fuller, A. F., Endometrial cancer in women 40 years old or younger, Gynecol Oncol, 2001. 83: p. 388-93., https://www.ncbi.nlm.nih.gov/pubmed/11606102
454. Dogan, A., Schultheis, B., Rezniczek, G. A., Hilal, Z., Cetin, C., Hausler, G., et.al. Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature, Anticancer Res, 2017. 37: p. 969-978., https://www.ncbi.nlm.nih.gov/pubmed/28314254
455. Anglesio, M. S., Wang, Y. K., Maassen, M., Horlings, H. M., Bashashati, A., Senz, J., et.al. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality, J Natl Cancer Inst, 2016. 108: p. djv428., https://www.ncbi.nlm.nih.gov/pubmed/26832771
456. Goyal, A., Masand, R. P., Roma, A. A., Value of PAX-8 and SF-1 Immunohistochemistry in the Distinction Between Female Adnexal Tumor of Probable Wolffian Origin and its Mimics, Int J Gynecol Pathol, 2015. 35: p. 167-75., https://www.ncbi.nlm.nih.gov/pubmed/26352548
457. Batte, B. A., Bruegl, A. S., Daniels, M. S., Ring, K. L., Dempsey, K. M., Djordjevic, B., et.al. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome, Gynecol Oncol, 2014. 134: p. 319-25., https://www.ncbi.nlm.nih.gov/pubmed/24933100
458. Ruiz, MP, Huang, Y, Hou, JY, Tergas, AI, Burke, WM, Ananth, CV, et.al. All-cause mortality in young women with endometrial cancer receiving progesterone therapy., Am J Obstet Gynecol, 2017. 217 (6)(6): p. 669.e1-669.e13., https://pubmed.ncbi.nlm.nih.gov/28844824/
459. Gonthier, C, Trefoux-Bourdet, A, Koskas, M, Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium., Int J Gynecol Cancer, 2017. 27 (3)(3): p. 493-499., https://pubmed.ncbi.nlm.nih.gov/28187090/
460. Greenwald, ZR, Huang, LN, Wissing, MD, Franco, EL, Gotlieb, WH, Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?, Cancer, 2017. 123 (9)(9): p. 1545-1554., https://pubmed.ncbi.nlm.nih.gov/28026855/
461. Guillon, S, Popescu, N, Phelippeau, J, Koskas, M, A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma., Int J Gynaecol Obstet, 2019. 146 (3)(3): p. 277-288., https://pubmed.ncbi.nlm.nih.gov/31197826/
462. Raffone, A, Travaglino, A, Saccone, G, Insabato, L, Mollo, A, De Placido, G, et.al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis., Arch Gynecol Obstet, 2019. 299 (5)(5): p. 1233-1242., https://pubmed.ncbi.nlm.nih.gov/30810881/
463. Thigpen, J. T., Brady, M. F., Alvarez, R. D., Adelson, M. D., Homesley, H. D., Manetta, A., et.al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group, J Clin Oncol, 1999. 17: p. 1736-44., https://www.ncbi.nlm.nih.gov/pubmed/10561210
464. Lentz, S. S., Brady, M. F., Major, F. J., Reid, G. C., Soper, J. T., High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, 1996. 14: p. 357-61., https://www.ncbi.nlm.nih.gov/pubmed/8636744
465. Liu, T, Tu, H, Li, Y, Liu, Z, Liu, G, Gu, H, Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis., Ann Surg Oncol, 2019. 26 (9)(9): p. 2933-2942., https://pubmed.ncbi.nlm.nih.gov/31147990/
466. Cohn, D. E., Woeste, E. M., Cacchio, S., Zanagnolo, V. L., Havrilesky, L. J., Mariani, A., et.al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma, Obstet Gynecol, 2007. 109: p. 1062-7., https://www.ncbi.nlm.nih.gov/pubmed/17470583
467. Tamussino, K. F., Reich, O., Gucer, F., Moser, F., Zivkovic, F., Lang, P. F., et.al. Parametrial spread in patients with endometrial carcinoma undergoing radical hysterectomy, Int J Gynecol Cancer, 2001. 10: p. 313-317., https://www.ncbi.nlm.nih.gov/pubmed/11240692
468. Body, N, Grégoire, J, Renaud, MC, Sebastianelli, A, Grondin, K, Plante, M, Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer., Gynecol Oncol, 2018. 150 (2)(2): p. 267-273., https://pubmed.ncbi.nlm.nih.gov/29909967/
469. Lambrou, N. C., Gomez-Marin, O., Mirhashemi, R., Beach, H., Salom, E., Almeida-Parra, Z., et.al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival, Gynecol Oncol, 2004. 93: p. 653-8., https://www.ncbi.nlm.nih.gov/pubmed/15196860
470. Shih, K. K., Yun, E., Gardner, G. J., Barakat, R. R., Chi, D. S., Leitao, M. M., Jr., Surgical cytoreduction in stage IV endometrioid endometrial carcinoma, Gynecol Oncol, 2011. 122: p. 608-11., https://www.ncbi.nlm.nih.gov/pubmed/21664663
471. Todo, Y., Kato, H., Kaneuchi, M., Watari, H., Takeda, M., Sakuragi, N., Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis, Lancet, 2010. 375: p. 1165-72., https://www.ncbi.nlm.nih.gov/pubmed/20188410
472. Odagiri, T., Watari, H., Kato, T., Mitamura, T., Hosaka, M., Sudo, S., et.al. Distribution of lymph node metastasis sites in endometrial cancer undergoing systematic pelvic and para-aortic lymphadenectomy: a proposal of optimal lymphadenectomy for future clinical trials, Ann Surg Oncol, 2014. 21: p. 2755-61., https://www.ncbi.nlm.nih.gov/pubmed/24705578
473. Alay, I., Turan, T., Ureyen, I., Karalok, A., Tasci, T., Ozfuttu, A., et.al. Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer, Pathol Oncol Res, 2015. 21: p. 803-10., https://www.ncbi.nlm.nih.gov/pubmed/25564000
474. Guo, W, Cai, J, Li, M, Wang, H, Shen, Y, Survival benefits of pelvic lymphadenectomy versus pelvic and para-aortic lymphadenectomy in patients with endometrial cancer: A meta-analysis., Medicine (Baltimore), 2018. 97 (1)(1): p. e9520., https://pubmed.ncbi.nlm.nih.gov/29505525/
475. Cosgrove, CM, Cohn, DE, Rhoades, J, Felix, AS, The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment., Gynecol Oncol, 2019. 153 (3)(3): p. 505-510., https://pubmed.ncbi.nlm.nih.gov/30935714/
476. Nemani, D., Mitra, N., Guo, M., Lin, L., Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis, Gynecol Oncol, 2008. 111: p. 82-8., https://www.ncbi.nlm.nih.gov/pubmed/18674808
477. Bodurtha Smith, AJ, Fader, AN, Tanner, EJ, Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis., Am J Obstet Gynecol, 2017. 216 (5)(5): p. 459-476.e10., https://pubmed.ncbi.nlm.nih.gov/27871836/
478. Bogani, G, Casarin, J, Leone Roberti Maggiore, U, Ditto, A, Pinelli, C, Dell'acqua, A, et.al. Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis., Gynecol Oncol, 2020. 158 (1)(1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/32389376/
479. Kogan, L, Matanes, E, Wissing, M, Mitric, C, How, J, Amajoud, Z, et.al. The added value of sentinel node mapping in endometrial cancer., Gynecol Oncol, 2020. 158 (1)(1): p. 84-91., https://pubmed.ncbi.nlm.nih.gov/32349874/
480. Benedetti Panici, P., Basile, S., Maneschi, F., Alberto Lissoni, A., Signorelli, M., Scambia, G., et.al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial, J Natl Cancer Inst, 2008. 100: p. 1707-16., https://www.ncbi.nlm.nih.gov/pubmed/19033573
481. Yerramilli, D, Chen, YH, Venkatachalam, V, Alban, GM, Buscariollo, DL, Cheng, T, et.al. Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer., Pract Radiat Oncol, 2021. 11 (5)(5): p. 394-403., https://pubmed.ncbi.nlm.nih.gov/34015544/
482. Yoon, MS, Park, W, Huh, SJ, Kim, HJ, Kim, YS, Kim, YB, et.al. A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17)., Gynecol Oncol, 2015. 138 (3)(3): p. 519-25., https://pubmed.ncbi.nlm.nih.gov/26115977/
483. Holloway, CL, Alexander, C, Walter, C, Aquino-Parsons, C, Truong, PT, Stage IIIC Endometrial Cancer: Relapse and Survival Outcomes in Women Treated With Pelvic or Extended Field Para-Aortic Nodal Radiation Therapy., Am J Clin Oncol, 2017. 40 (5)(5): p. 458-463., https://pubmed.ncbi.nlm.nih.gov/25844822/
484. Onal, C, Yuce Sari, S, Akkus Yildirim, B, Gultekin, M, Guler, OC, Yildiz, F, Is there any benefit of paraaortic field irradiation in pelvic lymph node positive endometrial cancer patients? A propensity match analysis., J Obstet Gynaecol, 2020. 40 (7)(7): p. 1012-1019., https://pubmed.ncbi.nlm.nih.gov/31793400/
485. Sueoka, K., Umayahara, K., Abe, A., Usami, T., Yamamoto, A., Nomura, H., et.al. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy, Int J Gynecol Cancer, 2014. 25: p. 81-6., https://www.ncbi.nlm.nih.gov/pubmed/25347094
486. Sirisabya, N., Manchana, T., Worasethsin, P., Khemapech, N., Lertkhachonsuk, R., Sittisomwong, T., et.al. Is complete surgical staging necessary in clinically early-stage endometrial carcinoma?, Int J Gynecol Cancer, 2009. 19: p. 1057-61., https://www.ncbi.nlm.nih.gov/pubmed/19820368
487. Garg, G., Morris, R. T., Solomon, L., Toy, E. P., Kruger, M., Clary, K., et.al. Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIC endometrial cancer, Gynecol Oncol, 2011. 123: p. 208-13., https://www.ncbi.nlm.nih.gov/pubmed/21821278
488. Kapp, D. S., Kiet, T. K., Chan, J. K., Prognostic discrimination of subgrouping node-positive endometrioid uterine cancer: location vs nodal extent, Br J Cancer, 2011. 105: p. 1137-43., https://www.ncbi.nlm.nih.gov/pubmed/21915131
489. Creasman, W. T., Morrow, C. P., Bundy, B. N., Homesley, H. D., Graham, J. E., Heller, P. B., Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study, Cancer, 1987. 60: p. 2035-41., https://www.ncbi.nlm.nih.gov/pubmed/3652025
490. Mariani, A., Dowdy, S. C., Cliby, W. A., Gostout, B. S., Jones, M. B., Wilson, T. O., et.al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging, Gynecol Oncol, 2008. 109: p. 11-8., https://www.ncbi.nlm.nih.gov/pubmed/18304622
491. Kim, H. S., Suh, D. H., Kim, M. K., Chung, H. H., Park, N. H., Song, Y. S., Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis, Jpn J Clin Oncol, 2012. 42: p. 405-12., https://www.ncbi.nlm.nih.gov/pubmed/22396619
492. Setiawan, V. W., Yang, H. P., Pike, M. C., McCann, S. E., Yu, H., Xiang, Y. B., et.al. Type I and II endometrial cancers: have they different risk factors?, J Clin Oncol, 2013. 31: p. 2607-18., https://www.ncbi.nlm.nih.gov/pubmed/23733771
493. Petousis, S, Christidis, P, Margioula-Siarkou, C, Papanikolaou, A, Dinas, K, Mavromatidis, G, et.al. Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis., Arch Gynecol Obstet, 2020. 302 (1)(1): p. 249-263., https://pubmed.ncbi.nlm.nih.gov/32468162/
494. Cantrell, L. A., Blank, S. V., Duska, L. R., Uterine carcinosarcoma: A review of the literature, Gynecol Oncol, 2015. 137: p. 581-8., https://www.ncbi.nlm.nih.gov/pubmed/25805398
495. Versluis, MAC, Pielsticker, C, van der Aa, MA, de Bruyn, M, Hollema, H, Nijman, HW, Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study., Oncology, 2018. 95 (2)(2): p. 100-108., https://pubmed.ncbi.nlm.nih.gov/29791913/
496. Torne, A., Pahisa, J., Vidal-Sicart, S., Martinez-Roman, S., Paredes, P., Puerto, B., et.al. Transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR): a new method for sentinel lymph node detection in endometrial cancer, Gynecol Oncol, 2013. 128: p. 88-94., https://www.ncbi.nlm.nih.gov/pubmed/23085461
497. Lopez-De la Manzanara Cano, C., Cordero Garcia, J. M., Martin-Francisco, C., Pascual-Ramirez, J., Parra, C. P., Cespedes Casas, C., Sentinel lymph node detection using 99mTc combined with methylene blue cervical injection for endometrial cancer surgical management: a prospective study, Int J Gynecol Cancer, 2014. 24: p. 1048-53., https://www.ncbi.nlm.nih.gov/pubmed/24927249
498. Ballester, M., Dubernard, G., Lecuru, F., Heitz, D., Mathevet, P., Marret, H., et.al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO), Lancet Oncol, 2011. 12: p. 469-76., https://www.ncbi.nlm.nih.gov/pubmed/21489874
499. Ballester, M., Naoura, I., Chereau, E., Seror, J., Bats, A. S., Bricou, A., et.al. Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study, Ann Surg Oncol, 2012. 20: p. 407-12., https://www.ncbi.nlm.nih.gov/pubmed/23054119
500. Koskas, M., Chereau, E., Ballester, M., Dubernard, G., Lecuru, F., Heitz, D., et.al. Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer, Br J Cancer, 2013. 108: p. 1267-72., https://www.ncbi.nlm.nih.gov/pubmed/23481184
501. Darai, E., Dubernard, G., Bats, A. S., Heitz, D., Mathevet, P., Marret, H., et.al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study, Gynecol Oncol, 2014. 136: p. 54-9., https://www.ncbi.nlm.nih.gov/pubmed/25450151
502. Cormier, B., Rozenholc, A. T., Gotlieb, W., Plante, M., Giede, C., Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research, Gynecol Oncol, 2015. 138: p. 478-85., https://www.ncbi.nlm.nih.gov/pubmed/26047592
503. Mueller, JJ, Pedra Nobre, S, Braxton, K, Alektiar, KM, Leitao, MM, Aghajanian, C, et.al. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma., Gynecol Oncol, 2020. 157 (3)(3): p. 619-623., https://pubmed.ncbi.nlm.nih.gov/32247604/
504. Imboden, S, Mereu, L, Siegenthaler, F, Pellegrini, A, Papadia, A, Tateo, S, et.al. Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection., Eur J Surg Oncol, 2019. 45 (9)(9): p. 1638-1643., https://pubmed.ncbi.nlm.nih.gov/31229377/
505. Zheng, Y, Yang, X, Liang, Y, Zhang, T, Chen, J, Li, Y, et.al. Effects of lymphadenectomy among women with stage IA endometrial cancer: a SEER database analysis., Future Oncol, 2019. 15 (19)(19): p. 2251-2266., https://pubmed.ncbi.nlm.nih.gov/31094582/
506. Nahshon, C, Kadan, Y, Lavie, O, Ostrovsky, L, Segev, Y, Sentinel lymph node sampling versus full lymphadenectomy in endometrial cancer: a SEER database analysis., Int J Gynecol Cancer, 2023. 33 (10)(10): p. 1557-1563., https://pubmed.ncbi.nlm.nih.gov/37487660)/
507. Matsuo, K, Klar, M, Khetan, VU, Violette, CJ, Youssefzadeh, AC, Yessaian, AA, et.al. Association between sentinel lymph node biopsy and micrometastasis in endometrial cancer., Eur J Obstet Gynecol Reprod Biol, 2022. 275 (): p. 91-96., https://pubmed.ncbi.nlm.nih.gov/35763967/
508. Ouldamer, L, Bendifallah, S, Body, G, Canlorbe, G, Touboul, C, Graesslin, O, et.al. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group., Ann Surg Oncol, 2017. 24 (6)(6): p. 1660-1666., https://pubmed.ncbi.nlm.nih.gov/28058558/
509. Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., et.al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up, Int J Gynecol Cancer, 2015. 26: p. 2-30., https://www.ncbi.nlm.nih.gov/pubmed/26634381
510. Bogani, G, Dowdy, SC, Cliby, WA, Ghezzi, F, Rossetti, D, Mariani, A, Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence., J Obstet Gynaecol Res, 2014. 40 (2)(2): p. 301-11., https://pubmed.ncbi.nlm.nih.gov/24472047/
511. Papadia, A, Gasparri, ML, Buda, A, Mueller, MD, Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue., J Cancer Res Clin Oncol, 2017. 143 (10)(10): p. 2039-2048., https://pubmed.ncbi.nlm.nih.gov/28828528/
512. Sinno, AK, Peijnenburg, E, Fader, AN, Temkin, SM, Stone, R, Levinson, K, et.al. Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer., Gynecol Oncol, 2016. 143 (2)(2): p. 281-286., https://pubmed.ncbi.nlm.nih.gov/27568279/
513. Cusimano, MC, Vicus, D, Pulman, K, Maganti, M, Bernardini, MQ, Bouchard-Fortier, G, et.al. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging., JAMA Surg, 2021. 156 (2)(2): p. 157-164., https://pubmed.ncbi.nlm.nih.gov/33175109/
514. Schlappe, BA, Weaver, AL, McGree, ME, Ducie, J, Zahl Eriksson, AG, Dowdy, SC, et.al. Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma., Gynecol Oncol, 2020. 156 (1)(1): p. 62-69., https://pubmed.ncbi.nlm.nih.gov/31776037/
515. Gu, Y, Cheng, H, Zong, L, Kong, Y, Xiang, Y, Operative and Oncological Outcomes Comparing Sentinel Node Mapping and Systematic Lymphadenectomy in Endometrial Cancer Staging: Meta-Analysis With Trial Sequential Analysis., Front Oncol, 2020. 10 (): p. 580128., https://pubmed.ncbi.nlm.nih.gov/33520696/
516. Marchocki, Z, Cusimano, MC, Clarfield, L, Kim, SR, Fazelzad, R, Espin-Garcia, O, et.al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics., Am J Obstet Gynecol, 2021. 225 (4)(4): p. 367.e1-367.e39., https://pubmed.ncbi.nlm.nih.gov/34058168/
517. Nagar, H, Wietek, N, Goodall, RJ, Hughes, W, Schmidt-Hansen, M, Morrison, J, Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer., Cochrane Database Syst Rev, 2021. 6 (6)(6): p. CD013021., https://pubmed.ncbi.nlm.nih.gov/34106467/
518. Ditto, A, Casarin, J, Pinelli, C, Perrone, AM, Scollo, P, Martinelli, F, et.al. Corrigendum to "Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group" [European Journal of Cancer. Volume 140, November 2020, Pages 1-10]., Eur J Cancer, 2021. 144 (): p. 399., https://pubmed.ncbi.nlm.nih.gov/33342624/
519. Persson, J, Salehi, S, Bollino, M, Lönnerfors, C, Falconer, H, Geppert, B, Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging., Eur J Cancer, 2019. 116 (): p. 77-85., https://pubmed.ncbi.nlm.nih.gov/31181536/
520. Asher, R, Obermair, A, Janda, M, Gebski, V, Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis., Int J Gynecol Cancer, 2018. 28 (3)(3): p. 529-538., https://pubmed.ncbi.nlm.nih.gov/29369119/
521. Galaal, K., Bryant, A., Fisher, A. D., Al-Khaduri, M., Kew, F., Lopes, A. D., Laparoscopy versus laparotomy for the management of early stage endometrial cancer, Cochrane Database Syst Rev, 2012. 9: p. Cd006655., https://www.ncbi.nlm.nih.gov/pubmed/22972096
522. Galaal, K, Donkers, H, Bryant, A, Lopes, AD, Laparoscopy versus laparotomy for the management of early stage endometrial cancer., Cochrane Database Syst Rev, 2018. 10 (): p. CD006655., https://pubmed.ncbi.nlm.nih.gov/30379327/
523. Scaletta, G, Dinoi, G, Capozzi, V, Cianci, S, Pelligra, S, Ergasti, R, et.al. Comparison of minimally invasive surgery with laparotomic approach in the treatment of high risk endometrial cancer: A systematic review., Eur J Surg Oncol, 2020. 46 (5)(5): p. 782-788., https://pubmed.ncbi.nlm.nih.gov/31818527/
524. Kim, NR, Lee, AJ, Yang, EJ, So, KA, Lee, SJ, Kim, TJ, et.al. Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis., Gynecol Oncol, 2022. 166 (2)(2): p. 236-244., https://pubmed.ncbi.nlm.nih.gov/35725657/
525. Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., et.al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2, J Clin Oncol, 2009. 27: p. 5331-6., https://www.ncbi.nlm.nih.gov/pubmed/19805679
526. Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., et.al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study, J Clin Oncol, 2012. 30: p. 695-700., https://www.ncbi.nlm.nih.gov/pubmed/22291074
527. Bartels, HC, Rogers, AC, Janda, M, Obermair, A, Brennan, DJ, Quality of life following minimally invasive hysterectomy compared to abdominal hysterectomy: A metanalysis., Eur J Obstet Gynecol Reprod Biol, 2020. 252 (): p. 206-212., https://pubmed.ncbi.nlm.nih.gov/32623252/
528. Zullo, F., Falbo, A., Palomba, S., Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials, Am J Obstet Gynecol, 2012. 207: p. 94-100., https://www.ncbi.nlm.nih.gov/pubmed/22340944
529. Philp, L, Tannenbaum, S, Haber, H, Saini, A, Laurent, JS, James, K, et.al. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer., Gynecol Oncol, 2021. 160 (2)(2): p. 389-395., https://pubmed.ncbi.nlm.nih.gov/33358198/
530. Meng, Y, Liu, Y, Lin, S, Cao, C, Wu, P, Gao, P, et.al. The effects of uterine manipulators in minimally invasive hysterectomy for endometrial cancer: A systematic review and meta-analysis., Eur J Surg Oncol, 2020. 46 (7)(7): p. 1225-1232., https://pubmed.ncbi.nlm.nih.gov/32360066/
531. Padilla-Iserte, P., Lago, V., Tauste, C., Díaz-Feijoo, B., Gil-Moreno, A., Oliver, R., et.al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery, Am J Obstet Gynecol, 2021. 224(1): p. 65.e1-65.e11.
532. Cusimano, MC, Simpson, AN, Dossa, F, Liani, V, Kaur, Y, Acuna, SA, et.al. Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications., Am J Obstet Gynecol, 2019. 221 (5)(5): p. 410-428.e19., https://pubmed.ncbi.nlm.nih.gov/31082383/
533. Wang, L, Liu, F, Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer., Arch Gynecol Obstet, 2018. 298 (3)(3): p. 505-510., https://pubmed.ncbi.nlm.nih.gov/30008031/
534. Ind, T, Laios, A, Hacking, M, Nobbenhuis, M, A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis., Int J Med Robot, 2017. 13 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/28762635/
535. Lindfors, A, Heshar, H, Adok, C, Sundfeldt, K, Dahm-Kähler, P, Long-term survival in obese patients after robotic or open surgery for endometrial cancer., Gynecol Oncol, 2020. 158 (3)(3): p. 673-680., https://pubmed.ncbi.nlm.nih.gov/32527569/
536. Wright, J. D., Burke, W. M., Wilde, E. T., Lewin, S. N., Charles, A. S., Kim, J. H., et.al. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer, J Clin Oncol, 2012. 30: p. 783-91., https://www.ncbi.nlm.nih.gov/pubmed/22291073
537. Ran, L., Jin, J., Xu, Y., Bu, Y., Song, F., Comparison of robotic surgery with laparoscopy and laparotomy for treatment of endometrial cancer: a meta-analysis, PLoS One, 2014. 9: p. e108361., https://www.ncbi.nlm.nih.gov/pubmed/25259856
538. Chan, J. K., Gardner, A. B., Taylor, K., Thompson, C. A., Blansit, K., Yu, X., et.al. Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates, Gynecol Oncol, 2015. 139: p. 300-5., https://www.ncbi.nlm.nih.gov/pubmed/26363212
539. O'Malley, D. M., Smith, B., Fowler, J. M., The role of robotic surgery in endometrial cancer, J Surg Oncol, 2015. 112: p. 761-8., https://www.ncbi.nlm.nih.gov/pubmed/26385835
540. Muaddi, H, Hafid, ME, Choi, WJ, Lillie, E, de Mestral, C, Nathens, A, et.al. Clinical Outcomes of Robotic Surgery Compared to Conventional Surgical Approaches (Laparoscopic or Open): A Systematic Overview of Reviews., Ann Surg, 2021. 273 (3)(3): p. 467-473., https://pubmed.ncbi.nlm.nih.gov/32398482/
541. Tanner, E. J., Leitao, M. M., Jr., Garg, K., Chi, D. S., Sonoda, Y., Gardner, G. J., et.al. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma, Gynecol Oncol, 2011. 123: p. 548-52., https://www.ncbi.nlm.nih.gov/pubmed/21945551
542. Barlin, J. N., Puri, I., Bristow, R. E., Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis, Gynecol Oncol, 2010. 118: p. 14-8., https://www.ncbi.nlm.nih.gov/pubmed/20434198
543. de Lange, NM, Ezendam, NPM, Kwon, JS, Vandenput, I, Mirchandani, D, Amant, F, et.al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer., Curr Oncol, 2019. 26 (2)(2): p. e226-e232., https://pubmed.ncbi.nlm.nih.gov/31043831/
544. Zhang, Y, Hao, Z, Yang, S, Survival benefit of surgical treatment for patients with stage IVB endometrial cancer: a propensity score-matched SEER database analysis., J Obstet Gynaecol, 2023. 43 (1)(1): p. 2204937., https://pubmed.ncbi.nlm.nih.gov/37170930/
545. Martin-Hirsch, P. P. L., Bryant, Andrew, Keep Sarah, L., Kitchener Henry, C., Lilford, Richard, Adjuvant progestagens for endometrial cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2011., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238061/
546. Matei, D, Filiaci, V, Randall, ME, Mutch, D, Steinhoff, MM, DiSilvestro, PA, et.al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer., N Engl J Med, 2019. 380 (24)(24): p. 2317-2326., https://pubmed.ncbi.nlm.nih.gov/31189035/
547. Nomura, H, Aoki, D, Michimae, H, Mizuno, M, Nakai, H, Arai, M, et.al. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial., JAMA Oncol, 2019. 5 (6)(6): p. 833-840., https://pubmed.ncbi.nlm.nih.gov/30896757/
548. Miller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., et.al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209), J Clin Oncol, 2020. 38(33): p. 3841-3850., https://pubmed.ncbi.nlm.nih.gov/33078978/
549. de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, et.al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018. 19 (3)(3): p. 295-309., https://pubmed.ncbi.nlm.nih.gov/29449189/
550. Mirza, MR, Chase, DM, Slomovitz, BM, dePont Christensen, R, Novák, Z, Black, D, et.al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer., N Engl J Med, 2023. 388 (23)(23): p. 2145-2158., https://pubmed.ncbi.nlm.nih.gov/36972026/
551. Eskander, RN, Sill, MW, Beffa, L, Moore, RG, Hope, JM, Musa, FB, et.al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer., N Engl J Med, 2023. 388 (23)(23): p. 2159-2170., https://pubmed.ncbi.nlm.nih.gov/36972022/
552. Colombo, N, Biagioli, E, Harano, K, Galli, F, Hudson, E, Antill, Y, et.al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2024. 25 (9)(9): p. 1135-1146., https://pubmed.ncbi.nlm.nih.gov/39102832/
553. Westin, SN, Moore, K, Chon, HS, Lee, JY, Thomes Pepin, J, Sundborg, M, et.al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial., J Clin Oncol, 2024. 42 (3)(3): p. 283-299., https://pubmed.ncbi.nlm.nih.gov/37864337/
554. de Boer, P., Adam, J. A., Buist, M. R., van de Vijver, M. J., Rasch, C. R., Stoker, J., et.al. Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy, Eur J Radiol, 2013. 82: p. e422-8.
555. Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., et.al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, 2005. 24: p. 36-44., https://www.ncbi.nlm.nih.gov/pubmed/16330675
556. Nomura, H., Aoki, D., Susumu, N., Mizuno, M., Nakai, H., Arai, M., et.al. Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial, Gynecol Oncol, 2019. 155(3): p. 413-419., https://pubmed.ncbi.nlm.nih.gov/31601493/
557. Kong, A., Johnson, N., Kitchener, H. C., Lawrie, T. A., Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis, J Natl Cancer Inst, 2012. 104: p. 1625-34., https://www.ncbi.nlm.nih.gov/pubmed/22962693
558. Creutzberg, C. L., Nout, R. A., Lybeert, M. L., Warlam-Rodenhuis, C. C., Jobsen, J. J., Mens, J. W., et.al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma, Int J Radiat Oncol Biol Phys, 2011. 81: p. e631-8., https://www.ncbi.nlm.nih.gov/pubmed/21640520
559. Nout, R. A., Smit, V. T., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., et.al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet, 2010. 375: p. 816-23., https://www.ncbi.nlm.nih.gov/pubmed/20206777
560. AlHilli, M, Amarnath, S, Elson, P, Rybicki, L, Dowdy, S, Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma., Int J Gynecol Cancer, 2020. 30 (6)(6): p. 789-796., https://pubmed.ncbi.nlm.nih.gov/32184268/
561. Rydzewski, NR, Strohl, AE, Donnelly, ED, Kanis, MJ, Lurain, JR, Nieves-Neira, W, et.al. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study., Cancer, 2016. 122 (23)(23): p. 3724-3731., https://pubmed.ncbi.nlm.nih.gov/27509082/
562. Bertelsen, K., Ortoft, G., Hansen, E. S., Survival of Danish patients with endometrial cancer in the intermediate-risk group not given postoperative radiotherapy: the Danish Endometrial Cancer Study (DEMCA), Int J Gynecol Cancer, 2011. 21: p. 1191-9., https://www.ncbi.nlm.nih.gov/pubmed/21885985
563. Ortoft, G., Hansen, E. S., Bertelsen, K., Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study, Int J Gynecol Cancer, 2013. 23: p. 1429-37., https://www.ncbi.nlm.nih.gov/pubmed/24257557
564. Maggi, R., Lissoni, A., Spina, F., Melpignano, M., Zola, P., Favalli, G., et.al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial, Br J Cancer, 2006. 95: p. 266-71., https://www.ncbi.nlm.nih.gov/pubmed/16868539
565. Hogberg, T., Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A. A., Sorbe, B., et.al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies, Eur J Cancer, 2010. 46: p. 2422-31., https://www.ncbi.nlm.nih.gov/pubmed/20619634
566. de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, et.al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial., Lancet Oncol, 2019. 20 (9)(9): p. 1273-1285., https://pubmed.ncbi.nlm.nih.gov/31345626/
567. Xiang, M, English, DP, Kidd, EA, Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma., Gynecol Oncol, 2019. 154 (3)(3): p. 487-494., https://pubmed.ncbi.nlm.nih.gov/31257010/
568. Goodman, CR, Hatoum, S, Seagle, BL, Donnelly, ED, Barber, EL, Shahabi, S, et.al. Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer., Gynecol Oncol, 2019. 153 (1)(1): p. 41-48., https://pubmed.ncbi.nlm.nih.gov/30660345/
569. Kurnit, KC, Nobre, SP, Fellman, BM, Iglesias, DA, Lindemann, K, Jhingran, A, et.al. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study., Gynecol Oncol, 2022. 167 (3)(3): p. 452-457., https://pubmed.ncbi.nlm.nih.gov/36243601/
570. Ao, M, Ding, T, Tang, D, Xi, M, Efficacy and Toxicity of Adjuvant Therapies for High-Risk Endometrial Cancer in Stage I-III: A Systematic Review and Network Meta-Analysis., Med Sci Monit, 2020. 26 (): p. e925595., https://pubmed.ncbi.nlm.nih.gov/32950998/
571. Mitra, D., Klopp, A. H., Viswanathan, A. N., Pros and cons of vaginal brachytherapy after external beam radiation therapy in endometrial cancer, Gynecol Oncol, 2015. 140: p. 167-75., https://www.ncbi.nlm.nih.gov/pubmed/26432041
572. Cantrell, L. A., Havrilesky, L., Moore, D. T., O'Malley, D., Liotta, M., Secord, A. A., et.al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma, Gynecol Oncol, 2012. 127: p. 22-6., https://www.ncbi.nlm.nih.gov/pubmed/22727985
573. Galaal, K., van der Heijden, E., Godfrey, K., Naik, R., Kucukmetin, A., Bryant, A., et.al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma, Cochrane Database Syst Rev, 2013. 2: p. Cd006812., https://www.ncbi.nlm.nih.gov/pubmed/23450572
574. Powell, MA, Filiaci, VL, Hensley, ML, Huang, HQ, Moore, KN, Tewari, KS, et.al. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial., J Clin Oncol, 2022. 40 (9)(9): p. 968-977., https://pubmed.ncbi.nlm.nih.gov/35007153/
575. Wagner, P, Kommoss, FKF, Kommoss, S, Hartkopf, AD, Pasternak, I, Oberlechner, E, et.al. Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease., Gynecol Oncol, 2019. 153 (1)(1): p. 49-54., https://pubmed.ncbi.nlm.nih.gov/30635214/
576. Wright, JD, Tergas, AI, Cui, R, Burke, WM, Hou, JY, Ananth, CV, et.al. Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy., JAMA Oncol, 2015. 1 (1)(1): p. 69-77., https://pubmed.ncbi.nlm.nih.gov/26182307/
577. Xu, X, Lin, H, Wright, JD, Gross, CP, Boscoe, FP, Hutchison, LM, et.al. Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy., J Clin Oncol, 2019. 37 (35)(35): p. 3412-3424., https://pubmed.ncbi.nlm.nih.gov/31518176/
578. Von Bargen, EC, Grimes, CL, Mishra, K, Wang, R, Haviland, MJ, Hacker, MR, et.al. Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease., Int J Gynaecol Obstet, 2017. 137 (2)(2): p. 123-128., https://pubmed.ncbi.nlm.nih.gov/28170091/
579. Cabrera, S, Gómez-Hidalgo, NR, García-Pineda, V, Bebia, V, Fernández-González, S, Alonso, P, et.al. Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer., Ann Surg Oncol, 2023. 30 (12)(12): p. 7653-7662., https://pubmed.ncbi.nlm.nih.gov/37633852/
580. Matsuo, K, Chen, L, Neuman, MK, Klar, M, Carlson, JW, Roman, LD, et.al. Lymph Node Isolated Tumor Cells in Patients With Endometrial Cancer., JAMA Netw Open, 2024. 7 (3)(3): p. e240988., https://pubmed.ncbi.nlm.nih.gov/38497964/
581. van der Steen-Banasik, E., Christiaens, M., Shash, E., Coens, C., Casado, A., Herrera, F. G., et.al. Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma, Eur J Cancer, 2016. 65: p. 172-81., https://www.ncbi.nlm.nih.gov/pubmed/27501506
582. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen, Langversion 1.1 – April 2017, AWMF-Registernummer: 032/054OL, 2017., https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/
583. European Medicines Agency (EMA), Public summary of positive opinion for orphan designation of sodium butyrate (rectal use) for the prevention of radiation proctitis, 2005., https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/05/284-public-summary-positive-opinion-orphan-designation-sodium-butyrate-rectal-use-prevention_en.pdf
584. Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., et.al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants, J Clin Oncol, 2008. 27: p. 127-45., https://www.ncbi.nlm.nih.gov/pubmed/19018081
585. Bristow, R. E., Purinton, S. C., Santillan, A., Diaz-Montes, T. P., Gardner, G. J., Giuntoli, R. L., Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance, Gynecologic Oncology, 2006. 103: p. 709-713., https://www.ncbi.nlm.nih.gov/pubmed/16797686
586. Gadducci, A., Cosio, S., Fanucchi, A., Cristofani, R., Genazzani, A. R., An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer, Anticancer Res, 2000. 20: p. 1977-84., https://www.ncbi.nlm.nih.gov/pubmed/10928137
587. Reddoch, J. M., Burke, T. W., Morris, M., Tornos, C., Levenback, C., Gershenson, D. M., Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme, Gynecol Oncol, 1995. 59: p. 221-5., https://www.ncbi.nlm.nih.gov/pubmed/7590477
588. Salani, R., Nagel, C. I., Drennen, E., Bristow, R. E., Recurrence patterns and surveillance for patients with early stage endometrial cancer, Gynecol Oncol, 2011. 123: p. 205-7., https://www.ncbi.nlm.nih.gov/pubmed/21820709
589. Sartori, E., Pasinetti, B., Carrara, L., Gambino, A., Odicino, F., Pecorelli, S., Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients, Gynecol Oncol, 2007. 107: p. S241-7., https://www.ncbi.nlm.nih.gov/pubmed/17826824
590. Smith, C. J., Heeren, M., Nicklin, J. L., Perrin, L. C., Land, R., Crandon, A. J., et.al. Efficacy of routine follow-up in patients with recurrent uterine cancer, Gynecol Oncol, 2007. 107: p. 124-9., https://www.ncbi.nlm.nih.gov/pubmed/17655917
591. Zola, P, Ciccone, G, Piovano, E, Fuso, L, Di Cuonzo, D, Castiglione, A, et.al. Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial., J Clin Oncol, 2022. 40 (33)(33): p. 3817-3827., https://pubmed.ncbi.nlm.nih.gov/35858170/
592. Fung-Kee-Fung, M., Dodge, J., Elit, L., Lukka, H., Chambers, A., Oliver, T., Follow-up after primary therapy for endometrial cancer: a systematic review, Gynecol Oncol, 2006. 101: p. 520-9., https://www.ncbi.nlm.nih.gov/pubmed/16556457
593. Carrara, L., Gadducci, A., Landoni, F., Maggino, T., Scambia, G., Galletto, L., et.al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis, Int J Gynecol Cancer, 2012. 22: p. 1013-9., https://www.ncbi.nlm.nih.gov/pubmed/22706226
594. Yalamanchi, P., Shabason, J. E., Zhang, X., Ko, E. M., Lin, L. L., Use of Aggressive Surveillance for Locoregional Endometrial Cancer After Local Therapy, Int J Gynecol Cancer, 2018. 28(7): p. 1264-1270., https://pubmed.ncbi.nlm.nih.gov/30036223/
595. Testa, A. C., Fruscella, E., Ludovisi, M., De Vincenzo, R., Malaggese, M., Corrado, G., et.al. The role of sonographic examination in the follow-up of gynecological neoplasms, Gynecol Oncol, 2005. 99: p. 696-703., https://www.ncbi.nlm.nih.gov/pubmed/16140365
596. Beaver, K, Williamson, S, Sutton, C, Hollingworth, W, Gardner, A, Allton, B, et.al. Comparing hospital and telephone follow-up for patients treated for stage-I endometrial cancer (ENDCAT trial): a randomised, multicentre, non-inferiority trial., BJOG, 2017. 124 (1)(1): p. 150-160., https://pubmed.ncbi.nlm.nih.gov/27062690/
597. Jeppesen, MM, Jensen, PT, Hansen, DG, Christensen, RD, Mogensen, O, Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer., BJOG, 2018. 125 (13)(13): p. 1705-1714., https://pubmed.ncbi.nlm.nih.gov/29978593/
598. Morrison, V, Spencer, LH, Totton, N, Pye, K, Yeo, ST, Butterworth, C, et.al. Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial., Int J Gynecol Cancer, 2018. 28 (2)(2): p. 401-411., https://pubmed.ncbi.nlm.nih.gov/29324539/
599. Høeg, B. L., Bidstrup, P. E., Karlsen, R. V., Friberg, A. S., Albieri, V., Dalton, S. O., et.al. Follow-up strategies following completion of primary cancer treatment in adult cancer survivors, Cochrane Database Syst Rev, 2019. 2019(11):, https://pubmed.ncbi.nlm.nih.gov/31750936/
600. Nicolaije, KA, Ezendam, NP, Vos, MC, Pijnenborg, JM, Boll, D, Boss, EA, et.al. Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial., J Clin Oncol, 2015. 33 (31)(31): p. 3550-9., https://pubmed.ncbi.nlm.nih.gov/26304900/
601. Kadkhodayan, S., Shahriari, S., Treglia, G., Yousefi, Z., Sadeghi, R., Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature, Gynecol Oncol, 2013. 128: p. 397-404., https://www.ncbi.nlm.nih.gov/pubmed/23107613
602. Bollineni, V. R., Ytre-Hauge, S., Bollineni-Balabay, O., Salvesen, H. B., Haldorsen, I. S., High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature, J Nucl Med, 2016. 57(6): p. 879-85., https://pubmed.ncbi.nlm.nih.gov/26823564/
603. Wright, J. D., Seshan, V. E., Shah, M., Schiff, P. B., Burke, W. M., Cohen, C. J., et.al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma, Am J Obstet Gynecol, 2008. 199: p. 536 e1-8., https://www.ncbi.nlm.nih.gov/pubmed/18511017
604. Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Warlam-Rodenhuis, C. C., et.al. Survival after relapse in patients with endometrial cancer: results from a randomized trial, Gynecol Oncol, 2003. 89: p. 201-9., https://www.ncbi.nlm.nih.gov/pubmed/12713981
605. Vargo, J. A., Kim, H., Houser, C. J., Berhane, H., Sukumvanich, P., Olawaiye, A. B., et.al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification, Radiother Oncol, 2014. 113: p. 126-31., https://www.ncbi.nlm.nih.gov/pubmed/25241996
606. Hardarson, H. A., Heidemann, L. N., dePont Christensen, R., Mogensen, O., Jochumsen, K. M., Vaginal vault recurrences of endometrial cancer in non-irradiated patients - Radiotherapy or surgery, Gynecol Oncol Rep, 2015. 11: p. 26-30., https://www.ncbi.nlm.nih.gov/pubmed/26076091
607. Jereczek-Fossa, B., Badzio, A., Jassem, J., Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy, Int J Radiat Oncol Biol Phys, 2000. 48: p. 405-13., https://www.ncbi.nlm.nih.gov/pubmed/10974454
608. Ng, T. Y., Perrin, L. C., Nicklin, J. L., Cheuk, R., Crandon, A. J., Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy, Gynecol Oncol, 2000. 79: p. 490-4., https://www.ncbi.nlm.nih.gov/pubmed/11104626
609. Chapman, C. H., Maghsoudi, K., Littell, R. D., Chen, L. M., Hsu, I. C., Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy, Brachytherapy, 2017. 16(6): p. 1152-1158., https://pubmed.ncbi.nlm.nih.gov/28802913/
610. Moukarzel, LA, Braxton, KF, Zhou, QC, Pedra Nobre, S, Iasonos, A, Alektiar, KM, et.al. Non-exenterative surgical management of recurrent endometrial carcinoma., Gynecol Oncol, 2021. 162 (2)(2): p. 268-276., https://pubmed.ncbi.nlm.nih.gov/34090704/
611. Barlin, JN, Ueda, SM, Bristow, RE, Cytoreductive surgery for advanced and recurrent endometrial cancer: a review of the literature., Womens Health (Lond), 2009. 5 (4)(4): p. 403-11., https://pubmed.ncbi.nlm.nih.gov/19586432/
612. Dhanis, J, Blake, D, Rundle, S, Pijnenborg, JMA, Smits, A, Cytoreductive surgery in recurrent endometrial cancer: A new paradigm for surgical management?, Surg Oncol, 2022. 43 (): p. 101811., https://pubmed.ncbi.nlm.nih.gov/35849994/
613. Kurra, V, Krajewski, KM, Jagannathan, J, Giardino, A, Berlin, S, Ramaiya, N, Typical and atypical metastatic sites of recurrent endometrial carcinoma., Cancer Imaging, 2013. 13 (1)(1): p. 113-22., https://pubmed.ncbi.nlm.nih.gov/23545091/
614. Guo, J, Cui, X, Zhang, X, Qian, H, Duan, H, Zhang, Y, The Clinical Characteristics of Endometrial Cancer With Extraperitoneal Metastasis and the Value of Surgery in Treatment., Technol Cancer Res Treat, 2020. 19 (): p. 1533033820945784., https://pubmed.ncbi.nlm.nih.gov/32721274/
615. Ozturk Basarir, Z, Karaca, MO, Balaban, K, Basarir, K, Yildiz, HY, Prognostic factors in endometrial cancer patients with bone metastasis., Jt Dis Relat Surg, 2023. 34 (1)(1): p. 207-214., https://pubmed.ncbi.nlm.nih.gov/36700284/
616. Tangjitgamol, S, Levenback, CF, Beller, U, Kavanagh, JJ, Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review., Int J Gynecol Cancer, 2004. 14 (3)(3): p. 399-422., https://pubmed.ncbi.nlm.nih.gov/15228413/
617. Makker, V, Colombo, N, Casado Herráez, A, Monk, BJ, Mackay, H, Santin, AD, et.al. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775., J Clin Oncol, 2023. 41 (16)(16): p. 2904-2910., https://pubmed.ncbi.nlm.nih.gov/37058687/
618. Colombo, N, Lorusso, D, Monk, BJ, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, et.al. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab., Oncologist, 2024. 29 (1)(1): p. 25-35., https://pubmed.ncbi.nlm.nih.gov/37523661/
619. O'Malley, DM, Bariani, GM, Cassier, PA, Marabelle, A, Hansen, AR, De Jesus Acosta, A, et.al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study., J Clin Oncol, 2022. 40 (7)(7): p. 752-761., https://pubmed.ncbi.nlm.nih.gov/34990208/
620. Oaknin, A, Gilbert, L, Tinker, AV, Brown, J, Mathews, C, Press, J, et.al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study., J Immunother Cancer, 2022. 10 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/35064011/
621. Ethier, JL, Desautels, DN, Amir, E, MacKay, H, Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis., Gynecol Oncol, 2017. 147 (1)(1): p. 158-166., https://pubmed.ncbi.nlm.nih.gov/28689667/
622. Jerzak, KJ, Duska, L, MacKay, HJ, Endocrine therapy in endometrial cancer: An old dog with new tricks., Gynecol Oncol, 2019. 153 (1)(1): p. 175-183., https://pubmed.ncbi.nlm.nih.gov/30616900/
623. Kokka, F., Brockbank, E., Oram, D., Gallagher, C., Bryant, A., Hormonal therapy in advanced or recurrent endometrial cancer, Cochrane Database Syst Rev, 2010. p. Cd007926., https://www.ncbi.nlm.nih.gov/pubmed/21154390
624. Covens, A. L., Filiaci, V., Gersell, D., Lutman, C. V., Bonebrake, A., Lee, Y. C., Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 2010. 120: p. 185-8., https://www.ncbi.nlm.nih.gov/pubmed/21075433
625. Le, DT, Durham, JN, Smith, KN, Wang, H, Bartlett, BR, Aulakh, LK, et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade., Science, 2017. 357 (6349)(6349): p. 409-413., https://pubmed.ncbi.nlm.nih.gov/28596308/
626. Marabelle, A, Le, DT, Ascierto, PA, Di Giacomo, AM, De Jesus-Acosta, A, Delord, JP, et.al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study., J Clin Oncol, 2020. 38 (1)(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/31682550/
627. Oaknin, A, Pothuri, B, Gilbert, L, Sabatier, R, Brown, J, Ghamande, S, et.al. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study., Clin Cancer Res, 2023. 29 (22)(22): p. 4564-4574., https://pubmed.ncbi.nlm.nih.gov/37363992/
628. Konstantinopoulos, PA, Luo, W, Liu, JF, Gulhan, DC, Krasner, C, Ishizuka, JJ, et.al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer., J Clin Oncol, 2019. 37 (30)(30): p. 2786-2794., https://pubmed.ncbi.nlm.nih.gov/31461377/
629. Makker, V, Taylor, MH, Aghajanian, C, Oaknin, A, Mier, J, Cohn, AL, et.al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer., J Clin Oncol, 2020. 38 (26)(26): p. 2981-2992., https://pubmed.ncbi.nlm.nih.gov/32167863/
630. Makker, V, Colombo, N, Casado Herráez, A, Santin, AD, Colomba, E, Miller, DS, et.al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer., N Engl J Med, 2022. 386 (5)(5): p. 437-448., https://pubmed.ncbi.nlm.nih.gov/35045221/
631. Roncolato, F., Lindemann, K., Willson, M. L., Martyn, J., Mileshkin, L., PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer, Cochrane Database Syst Rev, 2019. 10(10): p. Cd012160., https://pubmed.ncbi.nlm.nih.gov/31588998/
632. Wierzbicka, A, Mańkowska-Wierzbicka, D, Cieślewicz, S, Stelmach-Mardas, M, Mardas, M, Interventions Preventing Vaginitis, Vaginal Atrophy after Brachytherapy or Radiotherapy Due to Malignant Tumors of the Female Reproductive Organs-A Systematic Review., Int J Environ Res Public Health, 2021. 18 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/33918070/
633. Morris, L., Do, V., Chard, J., Brand, A. H., Radiation-induced vaginal stenosis: current perspectives, Int J Womens Health, 2017. 9: p. 273-279., https://pubmed.ncbi.nlm.nih.gov/28496367/
634. Guidozzi, F, Estrogen therapy in gynecological cancer survivors, Climacteric, 2013. 16: p. 611-7., https://www.ncbi.nlm.nih.gov/pubmed/23952524
635. Shim, S. H., Lee, S. J., Kim, S. N., Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis, Eur J Cancer, 2014. 50(9): p. 1628-37., https://pubmed.ncbi.nlm.nih.gov/24685478/
636. Simon, J., Nachtigall, L., Ulrich, L. G., Eugster-Hausmann, M., Gut, R., Endometrial safety of ultra-low-dose estradiol vaginal tablets, Obstet Gynecol, 2010. 116(4): p. 876-883., https://pubmed.ncbi.nlm.nih.gov/20859151/
637. Lester, J., Pahouja, G., Andersen, B., Lustberg, M., Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue, J Pers Med, 2015. 5: p. 50-66., https://www.ncbi.nlm.nih.gov/pubmed/25815692
638. Lee, Y. K., Chung, H. H., Kim, J. W., Park, N. H., Song, Y. S., Kang, S. B., Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial, Obstet Gynecol, 2011. 117: p. 922-7., https://www.ncbi.nlm.nih.gov/pubmed/21422866
639. Quick, AM, Dockter, T, Le-Rademacher, J, Salani, R, Hudson, C, Hundley, A, et.al. Pilot study of fractional CO, Maturitas, 2021. 144 (): p. 37-44., https://pubmed.ncbi.nlm.nih.gov/33358206/
640. Pitkin, R. M., VanVoorhis, L. W., Postirradiation vaginitis. An evaluation of prophylaxis with topical estrogen, Radiology, 1971. 99: p. 417-21., https://www.ncbi.nlm.nih.gov/pubmed/5553582
641. Denton, A. S., Maher, E. J., Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy, Cochrane Database Syst Rev, 2003. p. CD003750., https://www.ncbi.nlm.nih.gov/pubmed/12535485
642. Hintz, B. L., Kagan, A. R., Gilbert, H. A., Rao, A. R., Chan, P., Nussbaum, H., Systemic absorption of conjugated estrogenic cream by the irradiated vagina, Gynecol Oncol, 1981. 12: p. 75-82., https://www.ncbi.nlm.nih.gov/pubmed/6268486
643. Bartl, W., Breitenecker, G., Kemeter, P., Tatra, G., [The absorption of conjugated oestrogens from the irradiated and non-irradiated vagina (author's transl)], Geburtshilfe Frauenheilkd, 1980. 40(4): p. 319-25., https://pubmed.ncbi.nlm.nih.gov/6247239/
644. Singh, P., Oehler, M. K., Hormone replacement after gynaecological cancer, Maturitas, 2009. 65: p. 190-7., https://www.ncbi.nlm.nih.gov/pubmed/20018467
645. Edey, K. A., Rundle, S., Hickey, M., Hormone replacement therapy for women previously treated for endometrial cancer, Cochrane Database Syst Rev, 2018. 5(5): p. Cd008830., https://pubmed.ncbi.nlm.nih.gov/29763969/
646. Nout, R. A., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., et.al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data, Eur J Cancer, 2011. 48: p. 1638-48., https://www.ncbi.nlm.nih.gov/pubmed/22176868
647. Miles, T., Johnson, N., Vaginal dilator therapy for women receiving pelvic radiotherapy, Cochrane Database Syst Rev, 2014. 9: p. CD007291., https://www.ncbi.nlm.nih.gov/pubmed/20824858
648. National Comprehensive Cancer Network (NCCN, NCCN Guideline - Uterine Neoplasms, 2020., https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1473
649. Akbaba, S., Oelmann-Avendano, J. T., Krug, D., Arians, N., Bostel, T., Hoerner-Rieber, J., et.al. The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer, Strahlenther Onkol, 2019. 195(10): p. 902-912., https://pubmed.ncbi.nlm.nih.gov/30997541/
650. Stahl, J. M., Qian, J. M., Tien, C. J., Carlson, D. J., Chen, Z., Ratner, E. S., et.al. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy, Support Care Cancer, 2019. 27(4): p. 1425-1433., https://pubmed.ncbi.nlm.nih.gov/30187220/
651. Cerentini, T. M., Schlöttgen, J., Viana da Rosa, P., La Rosa, V. L., Vitale, S. G., Giampaolino, P., et.al. Clinical and Psychological Outcomes of the Use of Vaginal Dilators After Gynaecological Brachytherapy: a Randomized Clinical Trial, Adv Ther, 2019. 36(8): p. 1936-1949., https://pubmed.ncbi.nlm.nih.gov/31209699/
652. Hanlon, A., Small, W., Jr., Strauss, J., Lin, L. L., Hanisch, L., Huang, L., et.al. Dilator Use After Vaginal Brachytherapy for Endometrial Cancer: A Randomized Feasibility and Adherence Study, Cancer Nurs, 2018. 41(3): p. 200-209., https://pubmed.ncbi.nlm.nih.gov/28437283/
653. Mension, E, Alonso, I, Tortajada, M, Matas, I, Gómez, S, Ribera, L, et.al. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review., Maturitas, 2022. 156 (): p. 37-59., https://pubmed.ncbi.nlm.nih.gov/34217581/
654. Knight, C, Logan, V, Fenlon, D, A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors., Ecancermedicalscience, 2019. 13 (): p. 988., https://pubmed.ncbi.nlm.nih.gov/32010212/
655. Li, FG, Fuchs, T, Deans, R, McCormack, L, Nesbitt-Hawes, E, Abbott, J, et.al. Vaginal epithelial histology before and after fractional CO, Am J Obstet Gynecol, 2023. 229 (3)(3): p. 278.e1-278.e9., https://pubmed.ncbi.nlm.nih.gov/37192705/
656. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer: 128/001OL, 2020., http://leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.html
657. Leenen, C. H., van Lier, M. G., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de Waard, J., et.al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years, Gynecol Oncol, 2012. 125: p. 414-20., https://www.ncbi.nlm.nih.gov/pubmed/22306203
658. ten Broeke, S. W., Brohet, R. M., Tops, C. M., van der Klift, H. M., Velthuizen, M. E., Bernstein, I., et.al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk, J Clin Oncol, 2014. 33: p. 319-25., https://www.ncbi.nlm.nih.gov/pubmed/25512458
659. Dowty, J. G., Win, A. K., Buchanan, D. D., Lindor, N. M., Macrae, F. A., Clendenning, M., et.al. Cancer risks for MLH1 and MSH2 mutation carriers, Hum Mutat, 2012. 34: p. 490-7., https://www.ncbi.nlm.nih.gov/pubmed/23255516
660. Westin, S. N., Lacour, R. A., Urbauer, D. L., Luthra, R., Bodurka, D. C., Lu, K. H., et.al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome, J Clin Oncol, 2008. 26: p. 5965-71., https://www.ncbi.nlm.nih.gov/pubmed/19001318
661. Hampel, H, de la Chapelle, A, The search for unaffected individuals with Lynch syndrome: do the ends justify the means?, Cancer Prev Res (Phila), 2011. 4 (1)(1): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/21205737/
662. Win, AK, Jenkins, MA, Dowty, JG, Antoniou, AC, Lee, A, Giles, GG, et.al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer., Cancer Epidemiol Biomarkers Prev, 2017. 26 (3)(3): p. 404-412., https://pubmed.ncbi.nlm.nih.gov/27799157/
663. Nelen, M. R., Kremer, H., Konings, I. B., Schoute, F., van Essen, A. J., Koch, R., et.al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations, Eur J Hum Genet, 1999. 7: p. 267-73., https://www.ncbi.nlm.nih.gov/pubmed/10234502
664. Ryan, NAJ, Glaire, MA, Blake, D, Cabrera-Dandy, M, Evans, DG, Crosbie, EJ, The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis., Genet Med, 2019. 21 (10)(10): p. 2167-2180., https://pubmed.ncbi.nlm.nih.gov/31086306/
665. Snowsill, TM, Ryan, NAJ, Crosbie, EJ, Frayling, IM, Evans, DG, Hyde, CJ, Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting., PLoS One, 2019. 14 (8)(8): p. e0221419., https://pubmed.ncbi.nlm.nih.gov/31469860/
666. Dominguez-Valentin, M, Sampson, JR, Seppälä, TT, Ten Broeke, SW, Plazzer, JP, Nakken, S, et.al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database., Genet Med, 2020. 22 (1)(1): p. 15-25., https://pubmed.ncbi.nlm.nih.gov/31337882/
667. Riegert-Johnson, D. L., Gleeson, F. C., Roberts, M., Tholen, K., Youngborg, L., Bullock, M., et.al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients, Hered Cancer Clin Pract, 2010. 8: p. 6., https://www.ncbi.nlm.nih.gov/pubmed/20565722
668. Tan, M. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., Eng, C., Lifetime cancer risks in individuals with germline PTEN mutations, Clin Cancer Res, 2012. 18: p. 400-7., https://www.ncbi.nlm.nih.gov/pubmed/22252256
669. Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et.al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients, Cancer Res, 2006. 66: p. 7810-7., https://www.ncbi.nlm.nih.gov/pubmed/16885385
670. Bubien, V., Bonnet, F., Brouste, V., Hoppe, S., Barouk-Simonet, E., David, A., et.al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome, J Med Genet, 2013. 50: p. 255-63., https://www.ncbi.nlm.nih.gov/pubmed/23335809
671. Clarke, B. A., Cooper, K., Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas, Adv Anat Pathol, 2012. 19: p. 231-8., https://www.ncbi.nlm.nih.gov/pubmed/22692286
672. Lamberti, C., Mangold, E., Pagenstecher, C., Jungck, M., Schwering, D., Bollmann, M., et.al. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany, Digestion, 2006. 74: p. 58-67., https://www.ncbi.nlm.nih.gov/pubmed/17095871
673. Chen, S., Wang, W., Lee, S., Nafa, K., Lee, J., Romans, K., et.al. Prediction of germline mutations and cancer risk in the Lynch syndrome, JAMA, 2006. 296: p. 1479-87., https://www.ncbi.nlm.nih.gov/pubmed/17003396
674. Hampel, Heather, Panescu, Jenny, Lockman, Janet, Sotamaa, Kaisa, Fix, Daniel, Comeras, Ilene, et.al. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients, Cancer Research, 2007. 67: p. 9603-9603., http://cancerres.aacrjournals.org/content/66/15/7810.short
675. Buchanan, D. D., Tan, Y. Y., Walsh, M. D., Clendenning, M., Metcalf, A. M., Ferguson, K., et.al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing, J Clin Oncol, 2013. 32: p. 90-100., https://www.ncbi.nlm.nih.gov/pubmed/24323032
676. Egoavil, C., Alenda, C., Castillejo, A., Paya, A., Peiro, G., Sanchez-Heras, A. B., et.al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers, PLoS One, 2013. 8: p. e79737., https://www.ncbi.nlm.nih.gov/pubmed/24244552
677. Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et.al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer, J Clin Oncol, 2007. 25: p. 5158-64., https://www.ncbi.nlm.nih.gov/pubmed/17925543
678. Barrow, E., Hill, J., Evans, D. G., Cancer risk in Lynch Syndrome, Fam Cancer, 2013. 12: p. 229-40., https://www.ncbi.nlm.nih.gov/pubmed/23604856
679. Lynch, H. T., Harris, R. E., Lynch, P. M., Guirgis, H. A., Lynch, J. F., Bardawil, W. A., Role of heredity in multiple primary cancer, Cancer, 1977. 40: p. 1849-54., https://www.ncbi.nlm.nih.gov/pubmed/907988
680. Mecklin, J. P., Jarvinen, H. J., Clinical features of colorectal carcinoma in cancer family syndrome, Dis Colon Rectum, 1986. 29: p. 160-4., https://www.ncbi.nlm.nih.gov/pubmed/3943429
681. Win, A. K., Lindor, N. M., Winship, I., Tucker, K. M., Buchanan, D. D., Young, J. P., et.al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome, J Natl Cancer Inst, 2013. 105: p. 274-9., https://www.ncbi.nlm.nih.gov/pubmed/23385444
682. Lu, K. H., Dinh, M., Kohlmann, W., Watson, P., Green, J., Syngal, S., et.al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome, Obstet Gynecol, 2005. 105: p. 569-74., https://www.ncbi.nlm.nih.gov/pubmed/15738026
683. Ferguson, S. E., Aronson, M., Pollett, A., Eiriksson, L. R., Oza, A. M., Gallinger, S., et.al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing, Cancer, 2014. 120: p. 3932-9., https://www.ncbi.nlm.nih.gov/pubmed/25081409
684. National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2016, 2016. 2:, https://www.genomeweb.com/sites/default/files/nccn_2017.pdf
685. National Comprehensive Cancer Network (NCCN, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2016, 2016.
686. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities., 1998., https://www.ncbi.nlm.nih.gov/pubmed/9809732
687. Tabor, A., Watt, H. C., Wald, N. J., Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding, Obstet Gynecol, 2002. 99: p. 663-70., https://www.ncbi.nlm.nih.gov/pubmed/12039131
688. Carcangiu, M. L., Radice, P., Casalini, P., Bertario, L., Merola, M., Sala, P., Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types, Int J Surg Pathol, 2009. 18: p. 21-6., https://www.ncbi.nlm.nih.gov/pubmed/19443869
689. Pagon, R. A., Adam, M. P., Ardinger, H. H., Wallace, S. E., Amemiya, A., Bean, L. J. H., et.al. GeneReviewsUniversity of Washington, Seattle, 1993.
690. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et.al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, 2004. 96: p. 261-8., https://www.ncbi.nlm.nih.gov/pubmed/14970275
691. Vasen, H. F., Mecklin, J. P., Khan, P. M., Lynch, H. T., The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC), Dis Colon Rectum, 1991. 34: p. 424-5., https://www.ncbi.nlm.nih.gov/pubmed/2022152
692. Steinke, V., Holzapfel, S., Loeffler, M., Holinski-Feder, E., Morak, M., Schackert, H. K., et.al. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families, Int J Cancer, 2014. 135: p. 69-77., https://www.ncbi.nlm.nih.gov/pubmed/24493211
693. Barrow, P., Khan, M., Lalloo, F., Evans, D. G., Hill, J., Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome, Br J Surg, 2013. 100: p. 1719-31., https://www.ncbi.nlm.nih.gov/pubmed/24227356
694. Barrow, P., Green, K., Clancy, T., Lalloo, F., Hill, J., Evans, D. G., Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey, Clin Genet, 2015. 87: p. 517-24., https://www.ncbi.nlm.nih.gov/pubmed/25652327
695. Backes, F. J., Mitchell, E., Hampel, H., Cohn, D. E., Endometrial cancer patients and compliance with genetic counseling: room for improvement, Gynecol Oncol, 2011. 123: p. 532-6., https://www.ncbi.nlm.nih.gov/pubmed/21968342
696. Aktan-Collan, K., Kaariainen, H., Jarvinen, H., Peltomaki, P., Pylvanainen, K., Mecklin, J. P., et.al. Psychosocial consequences of predictive genetic testing for Lynch syndrome and associations to surveillance behaviour in a 7-year follow-up study, Fam Cancer, 2013. 12: p. 639-46., https://www.ncbi.nlm.nih.gov/pubmed/23512527
697. Eliezer, D., Hadley, D. W., Koehly, L. M., Exploring psychological responses to genetic testing for Lynch Syndrome within the family context, Psychooncology, 2014. 23: p. 1292-9., https://www.ncbi.nlm.nih.gov/pubmed/24872228
698. Esplen, M. J., Wong, J., Aronson, M., Butler, K., Rothenmund, H., Semotiuk, K., et.al. Long-term psychosocial and behavioral adjustment in individuals receiving genetic test results in Lynch syndrome, Clin Genet, 2014. 87: p. 525-32., https://www.ncbi.nlm.nih.gov/pubmed/25297893
699. Galiatsatos, P., Rothenmund, H., Aubin, S., Foulkes, W. D., Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families, Dig Dis Sci, 2015. 60: p. 2246-50., https://www.ncbi.nlm.nih.gov/pubmed/25786861
700. Hirschberg, A. M., Chan-Smutko, G., Pirl, W. F., Psychiatric implications of cancer genetic testing, Cancer, 2014. 121: p. 341-60., https://www.ncbi.nlm.nih.gov/pubmed/25234846
701. Holthausen-Markou S, Steiner, P, Psychische Aspekte im Zusammenhang mit tumorgenetischer Beratung, PSYCH up2date, 2014. 8: p. 225-240., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0034-1370167
702. Keller, M., Erbliche Tumorerkrankungen - psychosoziale und familiäre Aspekte, Psychotherapie im Dialog, 2010. p. 151-154., https://eref.thieme.de/ejournals/1439-913X_2010_02#/10.1055-s-0030-1248465
703. Landsbergen, K. M., Prins, J. B., Brunner, H. G., Kraaimaat, F. W., Hoogerbrugge, N., Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact, Fam Cancer, 2009. 8: p. 325-37., https://www.ncbi.nlm.nih.gov/pubmed/19330464
704. Landsbergen, K. M., Prins, J. B., Brunner, H. G., van Duijvendijk, P., Nagengast, F. M., van Krieken, J. H., et.al. Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative, Fam Cancer, 2012. 11: p. 259-67., https://www.ncbi.nlm.nih.gov/pubmed/22311584
705. Gesetz über genetische Untersuchungen bei Menschen (Gendiagnostikgesetz - GenDG), 2010., http://www.gesetze-im-internet.de/gendg/
706. Robert-Koch-Institut, Richtlinien der Gendiagnostik-Kommission (GEKO) zur genetischen Untersuchung bei nicht-einwilligungsfähigen Personen nach § 14 in Verbindung mit § 23 Abs. 2 Nr. 1c GenDG, Bundesgesundheitsbl, 2011. 54: p. 1248–1256., https://www.rki.de/DE/Content/Kommissionen/GendiagnostikKommission/Richtlinien/Richtlinien_node.html
707. Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., Delatycki, M. B., The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis, Fam Cancer, 2009. 9: p. 27-35., https://www.ncbi.nlm.nih.gov/pubmed/19760114
708. Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., et.al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res, 1998. 58: p. 5248-57., https://www.ncbi.nlm.nih.gov/pubmed/9823339
709. Hegde, M., Ferber, M., Mao, R., Samowitz, W., Ganguly, A., ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis), Genet Med, 2013. 16: p. 101-16., https://www.ncbi.nlm.nih.gov/pubmed/24310308
710. Backes, F. J., Leon, M. E., Ivanov, I., Suarez, A., Frankel, W. L., Hampel, H., et.al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer, Gynecol Oncol, 2009. 114: p. 486-90., https://www.ncbi.nlm.nih.gov/pubmed/19515405
711. Moline, J., Mahdi, H., Yang, B., Biscotti, C., Roma, A. A., Heald, B., et.al. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center, Gynecol Oncol, 2013. 130: p. 121-6., https://www.ncbi.nlm.nih.gov/pubmed/23612316
712. Gausachs, M., Mur, P., Corral, J., Pineda, M., Gonzalez, S., Benito, L., et.al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study, Eur J Hum Genet, 2012. 20: p. 762-8., https://www.ncbi.nlm.nih.gov/pubmed/22274583
713. Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J. P., Allen, B. A., et.al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin Cancer Res, 2004. 10: p. 191-5., https://www.ncbi.nlm.nih.gov/pubmed/14734469
714. Kawaguchi, M., Yanokura, M., Banno, K., Kobayashi, Y., Kuwabara, Y., Kobayashi, M., et.al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer, Int J Oncol, 2009. 34: p. 1541-7., https://www.ncbi.nlm.nih.gov/pubmed/19424571
715. Post, CCB, de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, et.al. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial., Int J Radiat Oncol Biol Phys, 2021. 109 (4)(4): p. 975-986., https://pubmed.ncbi.nlm.nih.gov/33129910/
716. Bellido, F, Pineda, M, Aiza, G, Valdés-Mas, R, Navarro, M, Puente, DA, et.al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance., Genet Med, 2016. 18 (4)(4): p. 325-32., https://pubmed.ncbi.nlm.nih.gov/26133394/
717. Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H., Cooper, C., et.al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome, Health Technol Assess, 2014. 18: p. 1-406., https://www.ncbi.nlm.nih.gov/pubmed/25244061
718. Richtlinien zur prädiktiven genetischen Diagnostik, 2003., www.bundesaerztekammer.de/bericht2002-2003/pdf/130510.pdf
719. Zertifizierte medizinische Fortbildung: Indikationen zur molekulargenetischen Diagnostik bei erblichen Krankheiten, 2006., https://www.aerzteblatt.de/archiv/50438/Zertifizierte-medizinische-Fortbildung-Indikationen-zur-molekulargenetischen-Diagnostik-bei-erblichen-Krankheiten
720. Plon, SE, Eccles, DM, Easton, D, Foulkes, WD, Genuardi, M, Greenblatt, MS, et.al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results., Hum Mutat, 2008. 29 (11)(11): p. 1282-91., https://pubmed.ncbi.nlm.nih.gov/18951446/
721. S2k-Leitlinie Humangenetische Diagnostik und genetische Beratung, 2011., http://www.awmf.org/leitlinien/detail/ll/078-015.html
722. Burn, J, Sheth, H, Elliott, F, Reed, L, Macrae, F, Mecklin, JP, et.al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial., Lancet, 2020. 395 (10240)(10240): p. 1855-1863., https://pubmed.ncbi.nlm.nih.gov/32534647/
723. Dove-Edwin, I., Boks, D., Goff, S., Kenter, G. G., Carpenter, R., Vasen, H. F., et.al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma, Cancer, 2002. 94: p. 1708-12., https://www.ncbi.nlm.nih.gov/pubmed/11920532
724. Rijcken, F. E., Mourits, M. J., Kleibeuker, J. H., Hollema, H., van der Zee, A. G., Gynecologic screening in hereditary nonpolyposis colorectal cancer, Gynecol Oncol, 2003. 91: p. 74-80., https://www.ncbi.nlm.nih.gov/pubmed/14529665
725. Lecuru, F., Le Frere Belda, M. A., Bats, A. S., Tulpin, L., Metzger, U., Olschwang, S., et.al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study, Int J Gynecol Cancer, 2008. 18: p. 1326-31., https://www.ncbi.nlm.nih.gov/pubmed/18217965
726. Lu, K. H., Daniels, M., Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention, Fam Cancer, 2013. 12: p. 273-7., https://www.ncbi.nlm.nih.gov/pubmed/23765559
727. Auranen, A., Joutsiniemi, T., A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families, Acta Obstet Gynecol Scand, 2011. 90: p. 437-44., https://www.ncbi.nlm.nih.gov/pubmed/21306348
728. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome, 2006., https://www.ncbi.nlm.nih.gov/pubmed/17096354
729. Møller, P, Seppälä, T, Bernstein, I, Holinski-Feder, E, Sala, P, Evans, DG, et.al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database., Gut, 2017. 66 (3)(3): p. 464-472., https://pubmed.ncbi.nlm.nih.gov/26657901/
730. Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et.al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome, N Engl J Med, 2006. 354: p. 261-9., https://www.ncbi.nlm.nih.gov/pubmed/16421367
731. Helder-Woolderink, JM, Blok, EA, Vasen, HF, Hollema, H, Mourits, MJ, De Bock, GH, Ovarian cancer in Lynch syndrome; a systematic review., Eur J Cancer, 2016. 55 (): p. 65-73., https://pubmed.ncbi.nlm.nih.gov/26773421/
732. Seppälä, T, Pylvänäinen, K, Evans, DG, Järvinen, H, Renkonen-Sinisalo, L, Bernstein, I, et.al. Colorectal cancer incidence in , Hered Cancer Clin Pract, 2017. 15 (): p. 18., https://pubmed.ncbi.nlm.nih.gov/29046738/
733. Dominguez-Valentin, M, Crosbie, EJ, Engel, C, Aretz, S, Macrae, F, Winship, I, et.al. Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report., Genet Med, 2021. 23 (4)(4): p. 705-712., https://pubmed.ncbi.nlm.nih.gov/33257847/
734. Reuter, K., Raugust, S., Marschner, N., Harter, M., Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynaecological cancer, Eur J Cancer Care (Engl), 2007. 16: p. 222-30., https://www.ncbi.nlm.nih.gov/pubmed/17508941
735. Steele, R., Fitch, M. I., Supportive care needs of women with gynecologic cancer, Cancer Nurs, 2008. 31: p. 284-91., https://www.ncbi.nlm.nih.gov/pubmed/18600115
736. Mehnert, A., Brahler, E., Faller, H., Harter, M., Keller, M., Schulz, H., et.al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities, J Clin Oncol, 2014. 32: p. 3540-6., https://www.ncbi.nlm.nih.gov/pubmed/25287821
737. Roth, A. J.; Carter, J.; Nelson, C. J., Sexuality After Cancer, in Psycho-Oncology, Jimmie C. Holland, William S. Breitbart, Paul B. Jacobsen, Matthew J. Loscalzo, Ruth McCorkle, and Phyllis N. Butow , Editor. 2010, Oxford University Press: New York. p. 245-250.
738. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50: p. 440-7., https://www.ncbi.nlm.nih.gov/pubmed/19855028
739. Hodgkinson, K, Butow, P, Fuchs, A, Hunt, GE, Stenlake, A, Hobbs, KM, et.al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes., Gynecol Oncol, 2007. 104 (2)(2): p. 381-9., https://pubmed.ncbi.nlm.nih.gov/17027072/
740. Mehnert, A., Lehmann, C., Cao, P., Koch, U., Die Erfassung psychosozialer Belastungen und Ressourcen in der Onkologie - Ein Literaturüberblick zu Screeningmethoden und Entwicklungstrends [Assessment of psychosocial distress and resources in oncology - a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56: p. 462-79.
741. Singer, S., Schwarz, R., [Psychosocial aftercare of patients with endometrial or cervical cancer], Zentralbl Gynakol, 2002. 124: p. 64-70., https://www.ncbi.nlm.nih.gov/pubmed/11873318
742. Sporn, NJ, Smith, KB, Pirl, WF, Lennes, IT, Hyland, KA, Park, ER, Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred?, Psychooncology, 2015. 24 (9)(9): p. 1167-73., https://pubmed.ncbi.nlm.nih.gov/25534170/
743. Donovan, K. A., Boyington, A. R., Judson, P. L., Wyman, J. F., Bladder and bowel symptoms in cervical and endometrial cancer survivors, Psychooncology, 2014. 23: p. 672-8., https://www.ncbi.nlm.nih.gov/pubmed/24481859
744. Jeppesen, M. M., Mogensen, O., Dehn, P., Jensen, P. T., Needs and priorities of women with endometrial and cervical cancer, J Psychosom Obstet Gynaecol, 2015. 36: p. 122-32., https://www.ncbi.nlm.nih.gov/pubmed/26123123
745. Karabuga, H., Gultekin, M., Tulunay, G., Yuce, K., Ayhan, A., Yuce, D., et.al. Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy, Int J Gynecol Cancer, 2015. 25: p. 1526-33., https://www.ncbi.nlm.nih.gov/pubmed/26207785
746. Lee, W. L., Lee, F. K., Su, W. H., Tsui, K. H., Kuo, C. D., Hsieh, S. L., et.al. Hormone therapy for younger patients with endometrial cancer, Taiwan J Obstet Gynecol, 2013. 51: p. 495-505., https://www.ncbi.nlm.nih.gov/pubmed/23276551
747. Honerlaw, K. R., Rumble, M. E., Rose, S. L., Coe, C. L., Costanzo, E. S., Biopsychosocial predictors of pain among women recovering from surgery for endometrial cancer, Gynecol Oncol, 2015. 140: p. 301-6., https://www.ncbi.nlm.nih.gov/pubmed/26363211
748. Erekson, E. A., Sung, V. W., DiSilvestro, P. A., Myers, D. L., Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer, Int Urogynecol J Pelvic Floor Dysfunct, 2008. 20: p. 159-63., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887706/
749. Wiggins, D. L., Wood, R., Granai, C. O., Dizon, D. S., Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO), J Psychosoc Oncol, 2007. 25: p. 61-70., https://www.ncbi.nlm.nih.gov/pubmed/18032265
750. Klee, M., Thranov, I., Machin Prof, D., The patients' perspective on physical symptoms after radiotherapy for cervical cancer, Gynecol Oncol, 2000. 76: p. 14-23., https://www.ncbi.nlm.nih.gov/pubmed/10620435
751. Deutsches Institut für Medizinische Dokumentation und Information (DIMDI), ICD-10-GM 2018 Systematisches Verzeichnis : Internationale statistische Klassifikation der Krankheiten und verwandter GesundheitsproblemeDeutscher Ärzte-Verlag, 2017, im Druck.
752. Sanjida, Saira, Kissane, David, McPhail, Steven M., Obermair, Andreas, Janda, Monika, Anxiety and depression in patients with early stage endometrial cancer: A longitudinal analysis from before surgery to 6-month post-surgery, Journal of Psychosocial Oncology Research and Practice, 2019. 1(3):, https://journals.lww.com/jporp/Fulltext/2019/12000/Anxiety_and_depression_in_patients_with_early.1.aspx
753. Sanjida, S, Obermair, A, Gebski, V, Armfield, N, Janda, M, Long-term quality of life outcomes of women treated for early-stage endometrial cancer., Int J Gynecol Cancer, 2021. 31 (4)(4): p. 530-536., https://pubmed.ncbi.nlm.nih.gov/33361459/
754. Rowlands, I. J., Lee, C., Beesley, V. L., Webb, P. M., Predictors of sexual well-being after endometrial cancer: results of a national self-report survey, Support Care Cancer, 2014. 22: p. 2715-23., https://www.ncbi.nlm.nih.gov/pubmed/24798754
755. Rowlands, I. J., Lee, C., Janda, M., Nagle, C. M., Obermair, A., Webb, P. M., Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors, Psychooncology, 2012. 22: p. 1963-71., https://www.ncbi.nlm.nih.gov/pubmed/23239462
756. Nouri, K., Reinthaller, A., Fertilitätserhalt bei prämenopausalen Frauen mit Endometriumkarzinom im frühen, niedriggradigen Stadium, Speculum, 2015. 33: p. 12-16., https://www.kup.at/kup/pdf/12731.pdf
757. Hurria, A., Li, D., Hansen, K., Patil, S., Gupta, R., Nelson, C., et.al. Distress in older patients with cancer, J Clin Oncol, 2009. 27: p. 4346-51., https://www.ncbi.nlm.nih.gov/pubmed/19652074
758. Köhler, N, Götze, H, Mehnert, A, Psychische Belastung und psychosoziale Unterstützung älterer Krebspatienten, Der Onkologe, 2015. 21(6): p. 518-522., https://www.springermedizin.de/psychische-belastung-und-psychosoziale-unterstuetzung-aelterer-k/8665544
759. Kornblith, A. B., Powell, M., Regan, M. M., Bennett, S., Krasner, C., Moy, B., et.al. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer, Psychooncology, 2007. 16: p. 895-903., https://www.ncbi.nlm.nih.gov/pubmed/17245695
760. Rowlands, I. J., Janda, M., McKinnon, L., Webb, P. M., Beesley, V. L., Prevalence, predictors, and correlates of supportive care needs among women 3-5 years after a diagnosis of endometrial cancer, Support Care Cancer, 2014. 23: p. 1205-14., https://www.ncbi.nlm.nih.gov/pubmed/25304121
761. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Version 1.1, Januar 2014, AWMF-Registernummer: 032/051OL, 2014., http://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/
762. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Version 1.0, September 2014, AWMF-Registernummer: 032/033OL, 2014., http://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom/
763. de Rooij, BH, Ezendam, NPM, Vos, MC, Pijnenborg, JMA, Boll, D, Kruitwagen, RFPM, et.al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery., Cancer, 2019. 125 (5)(5): p. 788-797., https://pubmed.ncbi.nlm.nih.gov/30500067/
764. Geue, K., Sowa, E., Kuhnt, S., Körperliche Beschwerden und psychosoziale Folgen nach einer Zervixkarzinomerkrankung, Der Onkologe, 2016. 22: p. 780-784.
765. Weis, J, Giesler, J.M., Standards in der psychosozialen Versorgung von Krebspatienten, Der Onkologe, 2016. 22(3): p. 198-205., http://link.springer.com/article/10.1007/s00761-015-2938-9
766. Herschbach, P., Weis, J., Screeningverfahren in der PsychoonkologieDeutsche Krebsgesellschaft, 2010.
767. Beesley, V., Eakin, E., Steginga, S., Aitken, J., Dunn, J., Battistutta, D., Unmet needs of gynaecological cancer survivors: implications for developing community support services, Psychooncology, 2007. 17: p. 392-400., https://www.ncbi.nlm.nih.gov/pubmed/17680554
768. Chan, Y. M., Lee, P. W., Fong, D. Y., Fung, A. S., Wu, L. Y., Choi, A. Y., et.al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial, J Clin Oncol, 2005. 23: p. 4913-24., https://www.ncbi.nlm.nih.gov/pubmed/15939927
769. Faller, H, Schuler, M, Richard, M, Heckl, U, Weis, J, Küffner, R, Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis., J Clin Oncol, 2013. 31 (6)(6): p. 782-93., https://pubmed.ncbi.nlm.nih.gov/23319686/
770. Manne, SL, Virtue, SM, Ozga, M, Kashy, D, Heckman, C, Kissane, D, et.al. A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients., Gynecol Oncol, 2017. 144 (2)(2): p. 354-362., https://pubmed.ncbi.nlm.nih.gov/27887806/
771. Buchanan, A, Roddy, M, Badr, H, Patient-reported outcomes of non-pharmacological interventions for endometrial cancer survivors: a systematic review., J Cancer Surviv, 2021. 15 (4)(4): p. 526-535., https://pubmed.ncbi.nlm.nih.gov/33140266/
772. Gilbert, E., Ussher, J. M., Perz, J., Sexuality after gynaecological cancer: a review of the material, intrapsychic, and discursive aspects of treatment on women's sexual-wellbeing, Maturitas, 2011. 70: p. 42-57., https://www.ncbi.nlm.nih.gov/pubmed/15939927
773. Hasenburg A., Roxana Schwab R., Farthmann J., Sexualität nach gynäko-onkologischen ErkrankungenDe Gruyter, 2020.
774. Dadak, C, Sohlmann, S, Sexualität nach einer Krebserkrankung, Der Gynäkologe, 2014. 47(2): p. 99-103., https://www.springermedizin.de/sexualitaet-nach-einer-krebserkrankung/8105692
775. Faubion, SS, MacLaughlin, KL, Long, ME, Pruthi, S, Casey, PM, Surveillance and Care of the Gynecologic Cancer Survivor., J Womens Health (Larchmt), 2015. 24 (11)(11): p. 899-906., https://pubmed.ncbi.nlm.nih.gov/26208166/
776. White, ID, Sangha, A, Lucas, G, Wiseman, T, Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments., Gynecol Oncol, 2016. 143 (3)(3): p. 664-673., https://pubmed.ncbi.nlm.nih.gov/27671030/
777. Baser, RE, Li, Y, Carter, J, Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors., Cancer, 2012. 118 (18)(18): p. 4606-18., https://pubmed.ncbi.nlm.nih.gov/22359250/
778. Neijenhuijs, KI, Hooghiemstra, N, Holtmaat, K, Aaronson, NK, Groenvold, M, Holzner, B, et.al. The Female Sexual Function Index (FSFI)-A Systematic Review of Measurement Properties., J Sex Med, 2019. 16 (5)(5): p. 640-660., https://pubmed.ncbi.nlm.nih.gov/30956110/
779. M. M. Berner, L. Kriston, H.-P. Zahradnik , M. Härter, A. Rohde, Überprüfung der Gültigkeit und Zuverlässigkeit des deutschen Female Sexual Function Index (FSFI-d), Geburtshilfe Frauenheilkd, 2004. 64(3): p. 293-303.
780. S3-Leitlinie Mammakarzinom, Langversion 4.3, AWMF-Registernummer: 032 – 045OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
781. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0, Dezember 2016, AWMF-Registernummer: 043/022OL, 2016., http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
782. Gilligan, T, Coyle, N, Frankel, RM, Berry, DL, Bohlke, K, Epstein, RM, et.al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline., J Clin Oncol, 2017. 35 (31)(31): p. 3618-3632., https://pubmed.ncbi.nlm.nih.gov/28892432/
783. Gysels, M, Higginson, IJ, Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials., Support Care Cancer, 2007. 15 (1)(1): p. 7-20., https://pubmed.ncbi.nlm.nih.gov/17024500/
784. Nilsen, ES, Myrhaug, HT, Johansen, M, Oliver, S, Oxman, AD, Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material., Cochrane Database Syst Rev, 2006. (3)(3): p. CD004563., https://pubmed.ncbi.nlm.nih.gov/16856050/
785. Wofford, JL, Smith, ED, Miller, DP, The multimedia computer for office-based patient education: a systematic review., Patient Educ Couns, 2005. 59 (2)(2): p. 148-57., https://pubmed.ncbi.nlm.nih.gov/16257619/
786. Bundesgesundheitsblatt, 2013.
787. N, h, s, Effective Health Care: Informing, communicating and sharing decision with people who have cancerLatimer Trend & Company Ltd., 2000., https://www.ncbi.nlm.nih.gov/pubmed/11533427
788. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328: p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034
789. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23: p. 6623-30., https://www.ncbi.nlm.nih.gov/pubmed/16170169
790. Katz, S. J., Lantz, P. M., Janz, N. K., Fagerlin, A., Schwartz, K., Liu, L., et.al. Patient involvement in surgery treatment decisions for breast cancer, J Clin Oncol, 2005. 23: p. 5526-33., https://www.ncbi.nlm.nih.gov/pubmed/16110013
791. Wagner, K., Koller, M., Keil, A., Trott, D., Engenhart-Cabillic, R., Pfab, R., et.al. [Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment], Chirurg, 1998. 69: p. 252-8., https://www.ncbi.nlm.nih.gov/pubmed/9576035
792. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73: p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394
793. Albert, U. S., Schulz, K. D., Alt, D., Beck, V., Doherty, J., Holsteg, K., et.al. [A guideline for guidelines--methodological report and use of the guideline women's information], Zentralbl Gynakol, 2004. 125: p. 484-93., https://www.ncbi.nlm.nih.gov/pubmed/14755359
794. Klemperer, D., Lang, B., Koch, K., Bastian, H., Brunsmann, F., M, Burkhardt, et.al. Die Gute Praxis Gesundheitsinformation, ZEFQ, 2010. 104: p. 66-68., https://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf
795. O'Connor, A. M., Fiset, V., DeGrasse, C., Graham, I. D., Evans, W., Stacey, D., et.al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications, J Natl Cancer Inst Monogr, 2000. p. 67-80., https://www.ncbi.nlm.nih.gov/pubmed/10854460
796. Dissemination, NHS Centre for Reviews and, Effective Health Care: Informing, communicating and sharing decisions with people who have cancerLatimer Trend & Company Ltd, 2000. 6:
797. Bundesministerium für Justiz, Patientenrechtegesetz, Gesetz zur Verbesserung der Rechte von Patientinnen und PatientenDeutscher Bundestag, 20. Februar 2013. Jahrgang 2013: p. 277-282., https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl113s0277.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl113s0277.pdf%27%5D__1489429188064
798. Cherny, NI, Radbruch, L, European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care., Palliat Med, 2009. 23 (7)(7): p. 581-93., https://pubmed.ncbi.nlm.nih.gov/19858355/
799. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.0, 2015, AWMF-Registernummer: 128/001OL, 2015., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
800. G. J. Bauerschmitz, M. Hellriegel, G. Emons, Palliative Konzepte beim Endometrium‑, Zervix- und Vulvakarzinom, Der Gynäkologe, 2017. 12:
801. L, e, i, t, l, i, et.al. Komplementärmedizin in der Behandlung von onkologischen PatientInnen, Langversion, Registernummer: 032/055OL, 2021. Version 1.1:, https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/
802. Berger, AM, Abernethy, AP, Atkinson, A, Barsevick, AM, Breitbart, WS, Cella, D, et.al. NCCN Clinical Practice Guidelines Cancer-related fatigue., J Natl Compr Canc Netw, 2010. 8 (8)(8): p. 904-31., https://pubmed.ncbi.nlm.nih.gov/20870636/
803. Fabi, A, Bhargava, R, Fatigoni, S, Guglielmo, M, Horneber, M, Roila, F, et.al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment., Ann Oncol, 2020. 31 (6)(6): p. 713-723., https://pubmed.ncbi.nlm.nih.gov/32173483/
804. Greer, J. A., Smith, A. L., Arya, L. A., Pelvic floor muscle training for urgency urinary incontinence in women: a systematic review, Int Urogynecol J, 2012. 23: p. 687-97., https://www.ncbi.nlm.nih.gov/pubmed/22246576
805. Hartmann, K. E., McPheeters, M. L., Biller, D. H., Ward, R. M., McKoy, J. N., Jerome, R. N., et.al. Treatment of overactive bladder in women, Evid Rep Technol Assess (Full Rep), 2009. p. 1-120, v., https://www.ncbi.nlm.nih.gov/pubmed/19947666
806. Berghmans, B., van Waalwijk van Doorn, E., Nieman, F., de Bie, R., van den Brandt, P., Van Kerrebroeck, P., Efficacy of physical therapeutic modalities in women with proven bladder overactivity, Eur Urol, 2002. 41: p. 581-7., https://www.ncbi.nlm.nih.gov/pubmed/12074773
807. Wang, A. C., Wang, Y. Y., Chen, M. C., Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder, Urology, 2004. 63: p. 61-6., https://www.ncbi.nlm.nih.gov/pubmed/14751349
808. Dumoulin, C., Hay-Smith, J., Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women, Cochrane Database Syst Rev, 2010. p. CD005654., https://www.ncbi.nlm.nih.gov/pubmed/24823491
809. Hay-Smith, E. J., Herderschee, R., Dumoulin, C., Herbison, G. P., Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women, Cochrane Database Syst Rev, 2011. p. CD009508., https://www.ncbi.nlm.nih.gov/pubmed/22161451
810. Imamura, M., Abrams, P., Bain, C., Buckley, B., Cardozo, L., Cody, J., et.al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence, Health Technol Assess, 2010. 14: p. 1-188, iii-iv., https://www.ncbi.nlm.nih.gov/pubmed/20738930
811. Choi, H., Palmer, M. H., Park, J., Meta-analysis of pelvic floor muscle training: randomized controlled trials in incontinent women, Nurs Res, 2007. 56: p. 226-34., https://www.ncbi.nlm.nih.gov/pubmed/17625461
812. Lo, Sing Kai, Naidu, Jaya, Cao, Yuelong, Additive Effect of Interferential Therapy Over Pelvic Floor Exercise Alone in the Treatment of Female Urinary Stress and Urge Incontinence: A Randomized Controlled Trial, Hong Kong Physiotherapy Journal, 2003. 21: p. 37-42., https://www.sciencedirect.com/science/article/pii/S1013702509700387
813. Patil, S. P., Nagrale, A. V., Ganvir, S. D., Additive effect of interferential therapy over pelvic floor exercises, International Journal of Therapy & Rehabilitation, 2010. 17: p. 596-602., https://www.magonlinelibrary.com/doi/abs/10.12968/ijtr.2010.17.11.79540
814. Hosker, G., Cody, J. D., Norton, C. C., Electrical stimulation for faecal incontinence in adults, Cochrane Database Syst Rev, 2007. p. CD001310., https://www.cochrane.org/CD001310/INCONT_electrical-stimulation-for-faecal-incontinence-in-adults
815. Norton, C., Cody, J. D., Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults, Cochrane Database Syst Rev, 2012. p. CD002111., https://www.ncbi.nlm.nih.gov/pubmed/22786479
816. Le Borgne, G., Mercier, M., Woronoff, A. S., Guizard, A. V., Abeilard, E., Caravati-Jouvenceaux, A., et.al. Quality of life in long-term cervical cancer survivors: a population-based study, Gynecol Oncol, 2013. 129: p. 222-8., https://www.ncbi.nlm.nih.gov/pubmed/23280088
817. Devoogdt, N., Christiaens, M. R., Geraerts, I., Truijen, S., Smeets, A., Leunen, K., et.al. Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial, BMJ, 2011. 343: p. d5326., https://www.ncbi.nlm.nih.gov/pubmed/21885537
818. Hayes, S. C., Reul-Hirche, H., Turner, J., Exercise and secondary lymphedema: safety, potential benefits, and research issues, Med Sci Sports Exerc, 2009. 41: p. 483-9., https://www.ncbi.nlm.nih.gov/pubmed/19204604
819. Sagen, A., Karesen, R., Risberg, M. A., Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up, Acta Oncol, 2009. 48: p. 1102-10., https://www.ncbi.nlm.nih.gov/pubmed/19863217
820. Ahmed Omar, M. T., Abd-El-Gayed Ebid, A., El Morsy, A. M., Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study, J Surg Res, 2010. 165: p. 82-90., https://www.ncbi.nlm.nih.gov/pubmed/20538293
821. Kozanoglu, E., Basaran, S., Paydas, S., Sarpel, T., Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial, Clin Rehabil, 2009. 23: p. 117-24., https://www.ncbi.nlm.nih.gov/pubmed/19164399
822. Tsai, H. J., Hung, H. C., Yang, J. L., Huang, C. S., Tsauo, J. Y., Could Kinesio tape replace the bandage in decongestive lymphatic therapy for breast-cancer-related lymphedema? A pilot study, Support Care Cancer, 2009. 17: p. 1353-60., https://www.ncbi.nlm.nih.gov/pubmed/19199105
823. Mohile, SG, Dale, W, Somerfield, MR, Schonberg, MA, Boyd, CM, Burhenn, PS, et.al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology., J Clin Oncol, 2018. 36 (22)(22): p. 2326-2347., https://pubmed.ncbi.nlm.nih.gov/29782209/
824. Decoster, L, Van Puyvelde, K, Mohile, S, Wedding, U, Basso, U, Colloca, G, et.al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†., Ann Oncol, 2015. 26 (2)(2): p. 288-300., https://pubmed.ncbi.nlm.nih.gov/24936581/
825. Nadaraja, S, Jørgensen, TL, Matzen, LE, Herrstedt, J, Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study., Drugs Real World Outcomes, 2018. 5 (4)(4): p. 225-235., https://pubmed.ncbi.nlm.nih.gov/30460662/
826. Bourgin, C, Saidani, M, Poupon, C, Cauchois, A, Foucher, F, Leveque, J, et.al. Endometrial cancer in elderly women: Which disease, which surgical management? A systematic review of the literature., Eur J Surg Oncol, 2016. 42 (2)(2): p. 166-75., https://pubmed.ncbi.nlm.nih.gov/26647302/
827. Driver, JA, Viswanathan, AN, Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older., Gynecol Oncol, 2017. 145 (3)(3): p. 526-530., https://pubmed.ncbi.nlm.nih.gov/28359689/
828. Ahmed, A, Deng, W, Tew, W, Bender, D, Mannel, RS, Littell, RD, et.al. Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study., Gynecol Oncol, 2018. 150 (2)(2): p. 300-305., https://pubmed.ncbi.nlm.nih.gov/29807694/
829. Bauer, J, Denkinger, M , Freiberger, E., Frohnhofen, Geser, C, Goisser, S, Hofmann, W, et.al. S1-Leitlinie „Geriatrisches Assessment der Stufe 2, 2019., https://www.awmf.org/leitlinien/detail/ll/084-002.html
830. van Walree, IC, Hamaker, ME, de Rooij, BH, Boll, D, van Huis-Tanja, LH, Emmelot-Vonk, MH, et.al. Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?, J Geriatr Oncol, 2020. 11 (7)(7): p. 1078-1086., https://pubmed.ncbi.nlm.nih.gov/32169547/
831. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG), Methodische Grundlagen. Version 2.1, 2024., https://iqtig.org/veroeffentlichungen/methodische-grundlagen/
832. Donabedian, A, Evaluating the quality of medical care. 1966., Milbank Q, 2005. 83 (4)(4): p. 691-729., https://pubmed.ncbi.nlm.nih.gov/16279964/
833. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 4.1, 2025., http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/
834. Beckmann, M W, Jud S M, Gynäkologische Krebszentren – Kompetenzbündelung zur Qualitätsverbesserung, Frauenheilkunde up2date, 2009. 3: p. 71-74., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0028-1098885
835. Wesselmann, S., Beckmann, M. W., Winter, A., The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care, Arch Gynecol Obstet, 2013. 289: p. 7-12., https://www.ncbi.nlm.nih.gov/pubmed/24220845
836. Kowalski, C., Wesselmann, S., Ansmann, L., Kreienberg, R., Pfaff, H., Zertifizierte Brustkrebszentren aus Sicht der Zentrumsleitungen: Ergebnisse einer Schlüsselpersonenbefragung, Geburtsh Frauenheilk, 2012. 72: p. 235-242.
837. Huthmann, D., Seufferlein, T., Post, S., Benz, S., Stinner, B., Wesselmann, S., Zertifizierte Darmkrebszentren aus Sicht der Zentrumsleitungen: Ergebnisse einer Schlüsselpersonenbefragung, Gastroenterol, 2012. 50: p. 753-759.
838. Kowalski, C., Wesselmann, S., Ansmann, L., Kreienberg, R., Pfaff, H., Zertifizierte Brustkrebszentren aus Sicht der Patientinnen: Stärken und Verbesserungspotenziale, Geburtsh Frauenheilk, 2012. 71: p. 137-143.
839. Thiel, F. C., Scharl, A., Hildebrandt, T., Kotziabassis, E., Schrauder, M. G., Bani, M. R., et.al. Financing of certified centers: a willingness-to-pay analysis, Arch Gynecol Obstet, 2012. 287: p. 495-509., https://www.ncbi.nlm.nih.gov/pubmed/23080545
840. Lux, M. P., Fasching, P. A., Bani, M. R., Schrauder, M., Marketing von Brust- und Perinatalzentren – Sind Patientinnen mit dem Produkt „zertifiziertes Zentrum“ vertraut?, Geburtsh Frauenheilk, 2009. 69: p. 321-327.
841. Wesselmann, S., Winter, A., Ferencz, J., Seufferlein, T., Post, S., Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013, Int J Colorectal Dis, 2014. 29: p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/24584335
842. Beckmann, M. W., Adler, G., Albers, P., Bruns, J., Dreistufenmodell optimiert Behandlung unter Kostendeckung Wie die künftigen Strukturen der onkologischen Versorgung in Deutschland aussehen sollten, Dtsch Arztebl, 2007. 104: p. 3004-3009., https://www.aerzteblatt.de/archiv/57409/Onkologie-Dreistufenmodell-optimiert-Behandlung-unter-Kostendeckung-Wie-die-kuenftigen-Strukturen-der-onkologischen-Versorgung-in-Deutschland-aussehen-sollten
843. O, n, k, o, z, e, et.al. Kennzahlenauswertung 2020 - Jahresbericht der zertifizierten Gynäkologischen Krebszentren - Auditjahr 2019 / Kennzahlenjahr 2018, 2020., https://www.onkozert.de/wordpress/wp-content/uploads/2020/04/qualitaetsindikatoren_gynaekologische-krebserkrankungen_2020-A1_200402.pdf?v=44353574
844. Roland, P. Y., Kelly, F. J., Kulwicki, C. Y., Blitzer, P., Curcio, M., Orr, J. W., Jr., The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment, Gynecol Oncol, 2004. 93: p. 125-30., https://www.ncbi.nlm.nih.gov/pubmed/15047225
845. Macdonald, O. K., Sause, W. T., Lee, R. J., Dodson, M. K., Zempolich, K., Gaffney, D. K., Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium?, Gynecol Oncol, 2005. 99: p. 730-5., https://www.ncbi.nlm.nih.gov/pubmed/16139348
846. Chan, J. K., Sherman, A. E., Kapp, D. S., Zhang, R., Osann, K. E., Maxwell, L., et.al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer, J Clin Oncol, 2011. 29: p. 832-8., https://www.ncbi.nlm.nih.gov/pubmed/21263082
847. Beckmann, M. W., et al., Der neue Schwerpunkt Gynäkologische Onkologie: nationale und internationale Chance?, Geburtsh Frauenheilk, 2006. 66: p. 123-127.
848. Ioka, A., Tsukuma, H., Ajiki, W., Oshima, A., Influence of hospital procedure volume on uterine cancer survival in Osaka, Japan, Cancer Sci, 2005. 96: p. 689-94., https://www.ncbi.nlm.nih.gov/pubmed/16232201
849. Diaz-Montes, T. P., Zahurak, M. L., Giuntoli, R. L., 2nd, Gardner, G. J., Bristow, R. E., Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality, Gynecol Oncol, 2006. 103: p. 1043-7., https://www.ncbi.nlm.nih.gov/pubmed/16876234
850. Elit, L. M., O'Leary, E. M., Pond, G. R., Seow, H. Y., Impact of wait times on survival for women with uterine cancer, J Clin Oncol, 2013. 32: p. 27-33., https://www.ncbi.nlm.nih.gov/pubmed/24276779
851. Beckmann, M. W.,, Frauenarzt/-ärztin der Zukunft: müssen die Kliniken neu strukturiert werden?, Der Gynäkologe, 2010. 43: p. 748-756., https://www.springermedizin.de/frauenarzt-aerztin-der-zukunft-muessen-die-kliniken-neu-struktur/8104622
852. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft e.V.; Stiftung Deutsche Krebshilfe; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V.),, Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm OnkologieLeitlinienprogramm Onkologie, 2017. 2017:, https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_2017_Version_2.1.pdf